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Introduction
In January, 1957, in a medical ward 
in the Western Infirmary of Glasgow, I saw 
a patient with myeloproliferative disease.
This patient had neither typical chronic 
myeloid leukaemia nor typical myelofibrosis 
but had features of each disease. The interest 
of this 'intermediate* form of disease was 
pointed out to me by Dr. Abraham Goldberg who 
also encouraged me to investigate some of the 
clinical problems of myeloproliferative disease. 
This I did for over three years during which 
time more problems presented and consequently 
the scope of the study expanded until twenty 
seven patients had been investigated from 
various aspects.
The main theme of this thesis is concerned 
with the question of relationship of the 
myeloproliferative disorders. This problem 
was investigated by a comparison of firstly, 
the clinical features, secondly, the haematological 
findings and thirdly the mechanisms of blood
/production and destruction in the various
myeloproliferative disorders.
The results of studies of other points 
of interest, such as the occurrence of 
infection and hypogammaglobulinaemia, the 
problem of gout and uric acid metabolism and 
the causation of megaloblastic erythropoiesis, 
are reported. Lastly, the clinical and 
haematological response to therapy, in 
particular splenectomy and splenic irradiation, 
and the effect of treatment on the course of 
the disease are discussed. Conclusions are
then drawn as to the possible aetiology of
the myeloproliferative group of disorders.
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A3 E C H O  N  I
T H E B A C K G  R 0 U N D
HISTORICAL BACKGROUND OR 
MYELOPROLIFERATIVE DISEASE
3Historical
The obliteration of the bone marrow by 
an overgrowth of fibrous tissue and bone is 
known as myelosclerosis. This condition may 
be a primary disease or may be secondary 
to other diseases. There are many causes 
for secondary myelosclerosis e.g. metastatic 
carcinomatous deposits in the marrow from 
primary growths in lung, thyroid, breast, 
stomach, prostate and adrenal glands; the 
results of the action of toxic agents such as 
aniline, arsenic, benzine, fluorine, phosphorus 
and X-irradiation; and other diseases such as 
Hodgkin’s disease, myelomatosis, Gaucher’s 
disease, osteomalacia and syphilis. Crail,
Alt and Hadler (1948) considered that tuberculosis 
was aetiologically significant and reported 
several cases with this association. A complete 
review of conditions giving rise to diffuse 
or focal myelosclerosis has been made by 
Erf and Herbut (1944).
Myelosclerosis, however, also occurs in 
two forms as a primary disease. Both forms 
give rise to splenomegaly and a leucoerythroblastic
4/anaemia but they are clinically and 
aetiologically distinct diseases. The first 
is the rare and hereditary condition which 
occurs in children and young adults and is 
known as Osteopetrosis or the Marble-bone 
Disease of Albers-Schflnberg (1904). The second 
form of primary myelosclerosis is seen in adults; 
it is not hereditary and appears to bear no 
relation to Marble-bone disease. The aetiology 
of this condition is unknown and the disease 
is characterised by a slowly progressive 
splenomegaly, a leucoerythroblastic blood 
picture and overgrowth of the bone marrow by 
fibrous and osteoid tissue. Myelofibrosis is 
that same condition without proliferation of 
bone in the marrow cavity.
Wood (1871) discussed lfA Splenic Variety 
of Pseudo-Leukaemia” and described gelatinous 
degeneration of the bone marrow in association 
with splenomegaly. It is possible that his 
patients had primary myelosclerosis but the 
first report of the definite association of 
generalised osteosclerosis, hepatosplenomegaly
Zwei Falle von Leukamie mit eigenthfimlichem Blut- resp; 
Knockenmarksbefund.
Von Dr. G. H euck, klin. Assistenzarzt.
(Aus der medic. Klinik zu Heidelberg.)
Bekanntlich sind in den letzten Jahren beim Studium des in 
vieler Beziehung imraer noch dunklen Krankheitszustandes der Leu­
kamie die Untersuchungen des Blutes auf’s Neue, die des Rnochen- 
marks zuerst mit besonderem Eifer betrieben worden, und sehr 
wichtige, fflr das Verstiindniss dieser Affection hochst bedeutungs- 
volle Befunde sind dabei zu Tage getreten.
Was zunScbst die Blutuntersuchungen betrifft, so hat man sicb 
neuerdings vorzugsweise mit dem Verhalten der rothen Blutkdrper- 
chen beschSftigt, da es sich herausgestellt hat, dass dieselben nicht 
nur bei Leukamie, sondern auch bei einer ganzen Reihe anderer, 
zu Anamie ftlhrender Krankheitszustande unter Umstanden sehr auf- 
fallende Veranderungen erleiden, Veranderungen, die bei der erst- 
genannten Erkrankung frUher wohl deshalb (ibersehen worden sind, 
weil man wesentlich nur den weissen Blutkdrperchen Aufrnerksam- 
keit zugewendet batte.
So mannichfaltig nun aber auch die Beobachtungen von ab- 
normem Verhalten der rothen Blutkdrperchen sind und soviel man 
sich bisher mit der Erkiarung derselben abgemiiht hat, so wenig 
wissen wir doch im Ganzen iiber die Bedingungen, unter denen jene 
Veranderungen zu Stande kommen, und erst ein weiteres kliniscbes 
Studium, insbesondere eine genauere Beachtung dessen, ob diese 
eigentbtlmlichen Blutbefunde mit bestimmten anderen Krankheits-
1 The first report of the association 
of osteosclerosis, hepatosplenomegaly 
and a leukaemic blood picture.
3/and a leukaemia blood picture is generally- 
credited to Heuck (1879) (fig.l). He 
considered that this was a chance association 
of chronic myeloid leukaemia with osteosclerosis. 
In 1908, however, Donhauser suggested that a 
primary interference in the bone marrow 
caused secondary and compensatory erythropoiesis 
to appear in the liver and spleen and so led 
to enlargement of these organs. This explanation 
was accepted for many years while more cases were 
gradually reported under a variety of names 
such as megakaryocytic myelosis, (Hewer, 1937) 
aleukaemic megakaryocytic myelosis, (Favre et al, 
1934; Lindeboom, 1938) chronic non leukaemic 
myelosis, (Carpenter & Flory, 1941) agnogenic 
myeloid metaplasia (Jackson et al, 1940) and 
myeloid megakaryocytic hepatosplenomegaly 
(Downey and Hordland, 1939)* In 1939 however, 
Vaughan and Harrison challenged this view and 
pointed out that considerable enlargement of the 
spleen could occur at a time when the bone 
marrow was still cellular. They felt that 
splenic enlargement was due not simply to 
compensatory erythropoiesis but to the fundamental
7/megakaryocytic thrombocythaemia and erythraemic 
myelosis, were related disorders of 
development of the primitive mesenchyme cell. 
Dameshek (1951) considered them to he variable 
manifestations of a single myeloproliferative 
stimulus and in his opinion there was no fine 
dividing line between them and many transition 
forms existed. In the same year Wintrobe 
(1951) felt that there was no sound evidence 
for this suggested relationship between 
myelosclerosis and chronic myeloid leukaemia. 
More recently Leonard, Israels and Wilkinson 
(1957) in a study of 28 cases of myelosclerosis 
considered that these diseases were clinically, 
pathologically and perhaps even biochemically 
distinguishable and not simply different 
facets of a single disease. They went even 
further in relation to myelosclerosis and stated 
that their findings supported the previous 
conception that marrow failure caused blood 
formation to appear in the spleen and liver.
It is clear, then, that there has been 
considerable controversy about the relationship
a/or lack of relationship of what are now 
termed the myeloproliferative disorders.
This controversy has persisted up to the 
present and the recent study of Leonard et 
al in 1957 provides data supporting Donhauser's 
theory of almost fifty years earlier. In 
view of the conflicting opinions it would 
seem that any advancement in knowledge of this 
subject and any answer to the question of 
relationship must depend on the use of more 
dynamic methods of study which, in conjunction 
with detailed clinical, haematological and 
biochemical assessment would provide 
fundamental information about this interesting 
group of diseases.
9C h a p t e r  2
MATERIALS AND METHODS
THE PATIENTS
The twenty seven cases of myeloproliferative 
disease used in this study were patients 
admitted to either of two medical units in 
the Western Infirmary, Glasgow, during the 
period 1st. January 1957 to 1st. March I960.
All patients admitted to these two units 
and found to have myeloproliferative disease 
were included in the investigation with the
exception of a few who were too ill to justify 
delay in treatment.
PERIPHERAL BLOOD AND MARROW
The routine haematological investigations 
were carried out by the standard methods as 
described by Dacie (1956) and Whitby and 
Britton (1957). Bone marrow smears were 
prepared from marrow obtained by needle puncture 
of the sternum. No patient was considered to 
have a *dry tap1 until several punctures had 
been carried out at each of two or more sites. 
Iliac crest trephine was carried out by open 
operation under local anaesthesia.
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/SPLENIC PUNCTUKE
Splenic puncture was carried out under
local anaesthesia by the abdominal route as
described by Chatterjea et al (1952).
RADIOISOTOPE STUDIES
.59
The radioiron ( Ee) and radiochromium
R1
( Cr) used for these studies were obtained 
from the Radiochemical Centre, Amersham. 
Radioiron
z 5 9 \10 uc of radioactive iron ( Ee) in the 
form of ferric chloride was injected 
intravenously in a 10 ml solution. A 
directional scintillation counter was used to 
record the radioactivity over the heart, the 
spleen, the liver and the sacrum as described 
by Ledlie and Baxter (1954) and Wetherley-Mein 
et al (1956). The heart was used as a measure 
of whole blood activity, the sacrum as a measure 
of marrow activity and the liver and spleen 
as possible sites of erythropoiesis; the
counting sites are illustrated in fig.t_. Changes 
in activity over these areas were recorded at 
intervals over a period of 100 hours and
/were corrected for background radiation. The 
results are plotted with radioactivity on a 
linear ordinate scale against time on a log 
abscissa scale.
Samples of blood were withdrawn at 
intervals up to 14 days after the administration 
of radioiron to determine the utilisation 
of the injected radioiron for haemoglobin formation. 
In calculating the utilisation from the maximum 
blood radioactivity (usually about the tenth day)
correction was made for total body haematocrit,
background radiation and the natural decay of the 
radioiron. The result is expressed as a 
percentage of the dose of radioiron injected.
1
Radio chromium
51The radioactive chromium ( Cr) technique
was based on the method of Mollison and Veall
(1955) using heparin as the anticoagulant.
51A dose of 100 uc Or was used in the form of 
sodium chromate. A sample of 20 ml of the
patient^1 blood was incubated with the
radiochromium for 45 minutes and then having 
been washed 3 times in saline the cells were
/reinjected intravenously in normal saline.
Bed cell volume was calculated from the 
radioactivity in a sample of venous blood 
obtained 20 minutes after the injection of 
the labelled cells, by the dilution principle. 
Plasma volume was calculated from the red cell 
volume by use of the venous haematocrit
corrected for total body haematocrit and for 
trapped plasma (Chaplin and Mollison, 1952).
A measure of red cell survival was obtained 
by the examination for radioactivity of samples 
of blood taken off at intervals usually of 
1 - 2  days until the blood radioactivity was 
reduced to 50 per cent of that found in the 
first sample. The time taken for this to occur 
was expressed in days (Tig-). Por convenience 
the results are plotted with radioactivity as 
a percentage of the first sample on a log ordinat 
scale and time in days on a linear abscissa scale 
Corrections were made for haematocrit readings 
and for the natural decay of the isotope.
Sequestration studies were carried out by 
counting the radioactivity over praecordium,
/liver and spleen as described by Jandl et al
(1956) at intervals of a few days-after
injection of the labelled cells. A spleen/liver
ratio of 2.5/1 was considered the lower limit 
of significant sequestration (G-oldberg and
Seaton (I960).
Apparatus
Body counts were carried out with a
directional scintillation counter. The
radioactivity of the blood samples was
measured in a well counter using an Ecko
automatic scaler type B530A. All radioactive
counts were corrected for background radiation
which was taken as the mean of two readings,
one before and one after the sample counts.
All samples were counted for 300 seconds,
and body counts were taken for 100 seconds.
5bRadioactive Go vitamin absorption tests
Radioactive vitamin B-^ was obtained from 
the Radiochemical Centre, Amersham, and diluted 
to a working concentration of 0.5ug, specific 
activity 0.5 uc, in 5 ml. saline. The oral 
dose of 5 ml of this solution was given in
/200 ml. water, the patient having fasted 
overnight. When intrinsic factor was used
it was given in a dose of 30 mgm. suspended in 
the vitamin solution a few minutes before 
ingestion. 1000 ug vitamin B ^  was injected 
intramuscularly 2 hours later and the urine was 
then collected for 24 hours. The total 
radioactivity excreted in 24 hours in the urine 
was then estimated and expressed as a percentage 
of the dose given. In normal subjects over 
7 per cent of the dose given was excreted within 
24 hours. This urinary excretion test is
based on the method of Schilling (1953) and 
further details are as described by Adams and
Seaton (1961).
VITAMIN B12 ASSAY
Serum vitamin B^^ levels were estimated 
by microbiological assay using Euglena Gracilis, 
based on the method of Hutner et al (1956).
SERUM PROTEINS
Biochemical estimation of the total serum 
proteins was carried out by the biuret method 
as described by Gornall et al (1949). Serum
/protein filter paper electrophoresis was 
performed using the horizontal paper strip method, 
and after staining, quantitative estimation of 
the various fractions was carried out using 
the EEL scanner.
URIC ACID ESTIMATIONS 
Serum uric acid
Estimation of serum uric acid was carried 
out by the method of Caraway (1955).
Urinary uric acid
The urine was first diluted 1 in 200 and 
then uric acid content was estimated by the 
method of Caraway (1955).
FAECAL UROBILINOGEN
The urobilinogen content of faeces was 
estimated by the method of Maclagan (1946)
MS E C T I O N  II
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C h a p t e r  3
THE CLINICAL PICTUBES OP
CHBONIC MYELOID LEUKAEMIA 
AND
MYELOEIBBOSIS
Although chronic myeloid leukaemia has 
been reported in a baby of only three months 
of age (Keith, 1945) this is quite exceptional 
and the disease is essentially one of middle 
or later life and occurs usually between the 
ages of thirty and sixty years (Scott, 1957).
In myelofibrosis the incidence is, if anything, 
rather later and the disease is found mostly 
in patients over forty five years of age 
(Mulcahy, 1957). In this series the age of 
the patients with chronic myeloid leukaemia 
ranged from thirty three to fifty nine years 
(mean 51.8 years) and of those with 
myelofibrosis from forty two to sixty four 
years (mean 56.9 years) at the time of diagnosis. 
The sex incidence is about equal in both diseases 
although in the patients described here there 
was a preponderance of females in each disease; 
four out of five patients with chronic myeloid 
leukaemia were females and seven out of nine 
patients with myelofibrosis were females. The 
age and sex incidence is seen in table 1.
The discrepancy is attributable to the relatively
Case Sex Diagnosis
J.C female Mf
female Mf
M.G.B female Mf
female Mf
M.C female Mf
S.H female Mf
R.C female Mf
male Mf
J.G male Mf
C.L female C.M.L
E.W female C.M.L
J.L male C.M.L
female C.M.L
female C.M.L
Table I Age and sex incidence of the patients with 
chronic myeloid leukaemia and myelofibrosis. 
(C.M.L. * chronic myeloid leukaemia; Mf.=
myelofibrosis)•
20
/small number of cases of each disease included 
in the investigation,,
The onset of symptoms in either disease 
is usually insidious and estimates of time of 
onset, duration of the disease and length of 
survival of the patients are rendered of 
doubtful value. Furthermore, changes may take 
place in the blood, even before the onset of 
symptoms. The chance finding of an unexplained 
leucocytosis up to nearly four years before 
any further evidence of chronic myeloid 
leukaemia has come to light has allowed the 
development of the disease to be observed. 
(Wintrobe and Hashenbush, 1939). Thus, 
chronic myeloid leukaemia may exist for some 
time, and possibly a long time, before the 
onset of symptoms. This slow progression of 
the disease sometimes results in the patient 
paying little attention to symptoms until, 
after a considerable time, they have become 
troublesome. This insidious nature of these 
disorders is confirmed by the incidental finding 
of splenomegaly in patient S.H. with 
myelofibrosis during the investigation of true
Number of 
patients affected
C *M *L. Mf.
abdominal swelling 
or discomfort
3 6
symptoms of anaemia 4 6
asthenia 3 5
ankle swelling 2 3
pallor 2 6
loss of weight 4 6
bleeding tendency 2 1
thrombotic tendency 1 1
bone pain 0 1
gout 0 1
Table 2 Main symptoms in the five patients with
chronic myeloid leukaemia and the nine
patients with myelofibrosiso
(C.M.L. = chronic myeloid leukaemia*
Mf. = myelofibrosis).
21
/peripheral vascular disease. This patient 
had had anorexia, weight loss, tiredness and 
dyspnoea on exertion for approximately three 
years and had not sought medical advice until 
her activity was severely limited by 
intermittent claudication. Patient E.C. with 
myelofibrosis had symptoms of anaemia, anorexia, 
weight loss, dyspepsia and angina of effort 
for three years and patient M.M. with chronic 
myeloid leukaemia had symptoms for two years 
before the first attendance at hospital.
The main symptoms of the patients with 
chronic myeloid leukaemia and myelofibrosis are 
demonstrated in Table 2.
The initial symptoms in chronic myeloid 
leukaemia are commonly those of anaemia, 
asthenia, loss of weight and abdominal swelling 
or discomfort; bone pain, a bleeding tendency 
and ankle oedema occur less commonly. Of the 
five patients with chronic myeloid leukaemia, 
four had weight loss, four had symptoms of 
anaemia and three complained of abdominal 
swelling or discomfort and weakness or tiredness.
22
/Of the more unusual symptoms, spontaneous 
bruising and ankle oedema were each noted 
in two patients and another two patients were 
aware of increasing pallor. In the male 
an early symptom may be priapism (Whitby 
and Britton, 1957) and this occurred in the one 
male patient.
In myelofibrosis the presenting symptoms 
are very similar, namely, asthenia, symptoms of 
anaemia, weight loss and abdominal swelling 
or discomfort and occasionally bleeding tenuency, 
bone pain and ankle swelling. Abdominal discomfort 
or swelling, symptoms of anaemia, loss of weight 
and pallor were each present in six of the nine 
patients with myelofibrosis, asthenia occurred 
in five and ankle swelling in three cases.
A bleeding tendency and bone pain each were 
noted once. These features are in agreement 
with these found by Korst et al (1956) in a 
series of 23 cases of myelofibrosis.
Although these symptoms appear to give a 
classical picture the diagnosis cannot always 
be made with certainty on the history alone
23
/and several interesting points emerge from 
this. One patient, J.L., a male of thirty three 
years of age, complained of loss of over one 
stone in weight during the preceding three 
months. He maintained that his appetite was 
good and his only other complaint was of breath- 
:lessness on exertion. As a result, he was 
referred to an Endocrine Clinic as a case of 
suspected thyrotoxicosis. This, on consideration 
of the brief history alone, is understandable 
but on physical examination the error was 
apparent. The mistake in initial diagnosis 
was due to the occurrence of marked loss of 
weight in the presence of a good appetite.
Weight loss occurred in six of the nine patients 
with myelofibrosis. One patient, S.H., lost 
as much as four stones over a 3 year period 
and another J.G-., lost weight much more rapidly,
1 stone being lost in two months. The same 
variation was seen in chronic myeloid 
leukaemia where C.L. lost four stones in weight 
in four months and three other patients had 
loss of weight. It would seem obvious that
/in debilitating disease this could be due to 
lack of food but this is not the case here as 
only half of these patients admitted any 
deterioration of appetite. The basal metabolic 
rate is commonly raised in chronic myeloid 
leukaemia (Riddle and Sturgis, 1927) and it 
is generally accepted that increased metabolism 
is the cause of loss of weight as in 
thyrotoxicosis. That this is not due to 
increased activity of the thyroid gland has 
been shown by studies of gland uptakes with 
radioactive iodine (Albright and Middleton, 
1950).
Scott (1957) noted the occurrence of 
spontaneous haemorrhage in as much as 26.1 
per cent of 177 patients with chronic myeloid 
leukaemia and yet the explanation of this 
common feature remains obscure (Thomas et al, 
I960). Despite this bleeding tendency venous 
thrombosis sometimes occurs. This paradoxical 
situation was confirmed by the occurrence of 
spontaneous bruising in two patients and 
priapism, which is almost certainly the result
25
/of thrombosis, in another. The association 
of a haemorrhagic tendency and thrombotic 
tendency in the one disease was also seen 
in the patients with myelofibrosis where one 
patient had marked spontaneous bruising and 
another phlebothrombosis.
The abdominal discomfort often experienced 
by patients with chronic myeloid leukaemia 
or myelofibrosis is usually due to the gross 
enlargement of the spleen associated with these 
diseases. Less often, however, pain is of a 
sharper nature and is then aggravated by 
respiration. This type of pain, accompanied 
by splenic friction, was found in two patients 
with chronic myeloid leukaemia and one with 
myelofibrosis. While splenic infarcts are 
common in chronic myeloid leukaemia (Whitby 
and Britton, 1957) and are no doubt the cause 
of this pain, they are not common in 
myelosclerosis and perisplenitis may then be 
the cause (Leading Article, Brit. med. J., 1956).
Chronic myeloid leukaemia and myelofibrosis 
are the two conditions which, in this country,
Grade 0 Grade I Grade II Grade III
C .M .Lo 0 I 2 2
Mf# 0 I 4 4
Table 5 Splenomegaly in chronic myeloid leukaemia
and myelofibrosis# (C.M.L#= chronic myeloid 
leukaemia; Mf•= myelofibrosis)#
26
/are by far the most common causes of a massive 
splenomegaly. It does not follow that the 
spleen must be grossly enlarged before the diagnosis 
can be considered and as splenic enlargement 
takes some time to develop it seems possible 
that in the fairly early stages of these 
diseases the size of the spleen may bear some 
relation to the duration or severity of the 
disease. The size of the spleen has been 
estimated as follows:
Grade 0 The spleen is not palpable.
Grade I The spleen is enlarged to a point
between the costal margin and the 
umbilicus.
Grade II The spleen is enlarged to a point 
below the umbilicus but does not 
cross the midline.
Grade III The spleen is enlarged to a point
below the "umbilicus and crosses the 
midline.
The spleen was palpable in all cases but 
a considerable variation in size was found in 
both diseases (Table 3)* Gross splenomegaly
Pig. 3 Grade III splenomegaly.(Patient A.ft.)
Pig.4 Grade II splenomegaly. (Patient B.C.)
Fig.5 Grade I splenomegaly. (Patient S.H.)
(Patient M.C.)
Pig. 7 Gout in myelofibrosis. (Patient J.C.)
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/considered here and six of the nine with 
myelofibrosis had a palpable liver.
Lymphadenopathy was found in three patients 
with chronic myeloid leukaemia and in four 
with myelofibrosis but the nodes, with the 
exception of those in M.M. who had chronic 
myeloid leukaemia, were never large.
Other features are occasionally found.
Cough was present in one patient with each 
disease; true peripheral vascular disease in 
one patient with myelofibrosis and hypertension 
(B.P. 210/110 mm. Hg.) in another. Pigmentation 
of the skin was reported in a case of 
myelofibrosis by Beattie and Withey (1953) 
and this unusual feature was found in one 
patient.. Gout is a recognized complication 
of myeloproliferative disease due to the 
increased uric acid metabolism and this was 
seen in one patient with myelofibrosis (fig. 7).
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Summary
Chronic myeloid leukaemia and 
myelofibrosis are diseases of middle and 
later life.
In both diseases the presenting symptoms 
are usually those of asthenia, anaemia and 
abdominal swelling or discomfort. Loss of 
weight may be a striking feature of either 
disease and occasionally there may be the 
paradoxical situation of either a bleeding 
or a thrombotic tendency.
The spleen in both disorders is usually 
greatly enlarged and may reach enormous 
proportions. The liver is less constantly 
palpable and lymphadenopathy is sometimes 
found.
There is, therefore, a similarity in 
the age and sex incidence, the presenting 
symptoms and the physical signs in chronic 
myeloid leukaemia and in myelofibrosis.
THE HAEMATOLOGICAL FINDINGS IN 
CHRONIC MYELOID LEUKAEMIA 
AND
MYELOFIBROSIS
The diagnosis of many diseases of the 
blood rests mainly on the clinical picture, the 
examination of the blood and the histological 
appearances of the bone marrow. Occasionally 
other special investigations are required 
for precise diagnosis or for the elucidation 
of problems which have arisen in a particular 
disease or patient. When two diseases have 
similar clinical pictures the haematological 
and other investigations then assume 
considerable importance. As marked similarity 
has been shown to exist in the clinical 
features of chronic myeloid leukaemia and 
myelofibrosis, the results of haematological 
investigation are of great interest and importance.
The striking feature on examination of the 
blood of patients with chronic myeloid leukaemia 
is the great number of circulating leucocytes.
The white cells usually number from 100,000 per 
c.mm. to 400,000 per c.mm. though counts up to 
and over one million cells have been recorded 
(Scott, 1957). This high count was found in 
all five cases, the levels ranging from
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8 Marrow in chronic myeloid leukaemia. 
(Patient J.L.) (May-G-runwald-Griemsa
x 375)
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/Occasional nucleated red cells may be found 
in the peripheral blood (Scott, 1957) and 
platelets are usually abundant except in the 
terminal stages. The striking feature of a 
blood film of typical chronic myeloid leukaemia 
is the greatly increased number of leucocytes. 
In such cases the diagnosis can usually be 
made confidently from the blood and bone 
marrow examination is seldom necessary.
If marrow examination is made then gross 
myeloid hyperplasia is seen (fig. 8) and the 
diagnosis is established.
In myelofibrosis the white cell count is 
often within the normal range in contrast to 
the greatly elevated counts of chronic myeloid 
leukaemia. Although Hickling (1953) reported 
a count of 70,000 cells per c.mm.the highest 
figure reported in a series of 28 cases 
investigated by Leonard, Israels and Wilkinson 
(1957) was 42,000 per c.mm. Most authors are 
agreed that the white cell count is usually 
normal or slightly elevated but that counts 
of over 50,000 cells per c.mm. are occasionally
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/seen. A count of 100,000 cells per c.mm. 
appears to be a convenient dividing line between 
chronic myeloid leukaemia and myelofibrosis. 
Korst, Clatanoff and Schilling (1956) reported
two patients with white cell counts of 112,500 
and 232,000 per c.mm. but these high levels 
are quite exceptional. Of the nine cases 
reported here only one had a white cell count 
of over 50,000 cells per c.mm. and none had 
counts of 100,000 per c.mm. Primitive white 
cells were often present and the results of 
differential white cell counts are seen in 
table 5* Anaemia was always present and the 
haemoglobin levels ranged from 4.1 g per cent 
to 12.4 g per cent (mean 9.2 +2.5). Iron 
deficiency was usually found but on examination 
of the blood film the mature red cells often 
showed marked poikilocytosis and 'tear drop' 
cells (Cook et al, 1953) were commonly seen 
(fig. 9). A characteristic feature is the 
finding of nucleated red cells in the peripheral 
blood. Although they may be scanty or 
occasionally absent they are present usually
OOP*
Pig. 9 Marked anisopoikilocytosis with
’tear drop' cells in myelofibrosis.
(Patient R.C.) (Leishman x 400).
/in considerably higher proportions than are 
found in chronic myeloid leukaemia. Two 
patients had 17 nucleated red cells per 100 
white cells in the blood but Leonard et al 
(1957) report a patient with as many as 61 
per 200 white cells. The origin of these 
immature cells and the mechanism of their 
release into the blood is obscure but it has 
been suggested by Rosenthal (1950) that they 
may originate in sites of extramedullary 
erythropoiesis.
Platelet numbers are variable and range 
from levels of thrombocytopenia to those of 
thrombocythaemia. Often, however, the platelets 
are seen to be abnormal, as was noted in two of 
these patients, and occasionally megakaryocytes 
or fragments of megakaryocytes are found in 
the blood.
Thus, the blood picture in myelofibrosis 
is characteristically that of leuco- 
erythroblastosis which was defined a quarter 
of a century ago by Vaughan (1936) as 
"an anaemia characterised by the presence in
36
/the peripheral blood of unusually immature 
red cells and a few immature white cells 
of the myeloid series. The anaemia is not 
necessarily severe, nor is there usually a 
marked leucocytosis."
The diagnosis of myelofibrosis, however, 
cannot be made with certainty purely from the 
examination of the blood. The nature of the 
condition demands examination of the bone 
marrow. The conventional marrow puncture 
technique usually yields a fdry tap* although 
a few drops of marrow or blood may occasionally 
be obtained, whereas in chronic myeloid leukaemia 
ample marrow is normally obtained without 
difficulty. A 'dry tap' will arouse 
considerable suspicion but a marrow trephine 
biopsy is required to substantiate the 
diagnosis of myelofibrosis.
Histological examination of the marrow 
trephine specimen usually reveals a hypoplastic 
marrow although there may be areas of hyperplasia. 
This appears to indicate that at least in the 
early stages the disease is of patchy
Pig. 10 Iliac crest marrow showing an 
increase in reticulum in 
myelofibrosis. (Patient S.H.) 
( x 675).
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/distribution. Trie hypoplasia is most marked 
for erythropoietic tissue which may be 
virtually absent but there is commonly some 
increase in leucopoietic tissue and 
megakaryocytes until the later stages of the 
disease. An increase in reticulum, which 
may be quite striking (fig. 10), usually is 
seen and, of course, by definition fibrous 
tissue is present. Bony trabeculae may be 
broadened and interlaced and give rise to marked 
increase in osteoid tissue.
Leonard, Israels and Wilkinson (1957) 
attempted to classify the histological 
appearances seen in the marrow trephine specimens 
in myelosclerosis according to the stage of the 
disease and they describe bony changes only 
in the intermediate and late stages. Thus, 
they consider fmyelofibrosis* as an early stage 
of Myelosclerosis'. This suggests that the 
disease is not fully developed until bony 
changes are present. Many patients, however, 
never develop bony changes even after several 
years and may die with pure 'myelofibrosis'.
Big. 11 Marrow trephine showing the early
stage of myelofibrosis (Patient J.C.) 
(H. & E. x 150).
12 Marrow trephine showing the
intermediate stage of myelofibrosis
(Patient M.G.B.) (H. & E. x 210).
38
/It would seem, therefore, more satisfactory 
to regard the disease as ‘myelofibrosis1 and 
to accept ‘myelosclerosis' as an occasional 
complication due to the involvement of the 
bony trabeculae in an otherwise identical 
disease, For this reason the whole group 
hereafter is regarded as myelofibrosis and the 
term ‘myelosclerosis* is used only when it 
is desired to stress the occurrence of bony 
changes,
The histological classification of Leonard, 
Israels and Wilkinson does give however, a 
very satisfactory method of comparing the 
disease process from one patient to another.
They described three stages. In the early stage 
they noted hypoplasia with patchy fibrosis and 
an increase in the number of megakaryocytes 
present but normal haemopoietic tissue was 
seen in some parts of the specimen (fig, 11).
The intermediate stage was characterised by 
widespread fibrosis, increase in megakaryocytes 
and some increase in bony trabeculae (fig. 12). 
The late stage showed broad bony trabeculae,
Pig. 13 Marrow trephine showing the late
stage of myelofibrosis (Patient A.S.) 
(H. & E. x 130).
Pig, 14 Marrow trephine in chronic myeloid 
leukaemia. (Patient A.R.)
(H. & E. x 210).
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/acellular fibrosis, virtual absence of 
haemopoietic tissue and scanty or absent 
megakaryocytes (fig. 13). Using this 
classification, the histological appearances of 
the marrow trephine on the eight patients on 
whom this investigation was carried out showed 
four patients to be in the early stage, two 
in the intermediate stage and two in the 
late stage of the disease. This distribution 
is not surprising because, firstly, the 
biopsies were done in most instances when the 
patient presented for the first time and, 
secondly, as mentioned previously, some patients 
do not develop bony changes and so will never 
qualify for classification in the late stage.
It is likely, then, that these patients form 
a representative group.
Marrow trephine biopsy was carried out on 
three patients with chronic myeloid leukaemia.
In each case there was gross myeloid hyperplasia, 
but no obvious increase in megakaryocytes, no 
fibrosis and no increase in bony trabeculae.
An illustration of the histological appearance
/of the trephine biopsy in one of these patients 
is seen in fig, 14. In one case there was an 
occasional focus of increased reticulum but 
this was not comparable to that seen in 
myelofibrosis.
There is, then, a striking difference in the 
histological appearances of the marrow in chronic 
myeloid leukaemia and of that in myelofibrosis 
and this is a simple and satisfactory way in 
which the two diseases can be differentiated.
The gross enlargement of the spleen in 
both diseases suggests that it is the site of 
a major pathological disturbance. It is 
generally accepted that in myelosclerosis this 
is due to myeloid metaplasia (Wintrobe, 1956) 
though Engell (1947) stated that myelosclerosis 
could exist without myeloid metaplasia.
Moeschlin (1951) considered that the diagnosis 
could be determined by examination of splenic 
aspirate but Block and Jacobson (1950) went 
even further and stated that microscopic 
examination of the splenic tissues was the 
most important step in diagnosis. Splenic
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/puncture was carried out on two patients with 
chronic myeloid leukaemia and four with 
myelofibrosis and the results of differential 
counts of five of these are seen in table 6.
The striking difference is the proportion of 
lymphocytes found. In chronic myeloid leukaemia 
they are very much less than normal and 
Moeschlin (1951) interpreted this as indicative 
of disruption of the splenic architecture.
If this is the case then the splenic architecture 
is better preserved in myelofibrosis where the 
proportion of lymphocytes is higher and this 
is in agreement also with the experience of 
Leonard, Israels and Wilkinson (1957). In 
chronic myeloid leukaemia the great majority 
of the cells are of the granulocyte series 
but in myelofibrosis the numbers of granulocytes 
and lymphocytes, though variable, often are 
not greatly different. The results of these 
splenic punctures agree well with those of 
the other workers mentioned but the counts of 
nucleated red cells are rather lower. If 
splenic erythropoiesis is indicated by the
Fig. 15 Splenic aspirate showing nucleated 
red cells in myelofibrosis. 
(Patient S.H.) (Leishman x 525).
Splenic aspirate showing nucleated 
red Gills in chronic myeloid
leukaemia. (Patient O.L.)
(Leishman x 525).
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/presence of moderate numbers of nucleated 
red cells in the splenic aspirate then this is 
not a necessary accompaniment of myelofibrosis 
as only one of the four cases so investigated 
showed this (fig* 15). Significant numbers of 
nucleated red cells were found also on splenic 
puncture of one patient with chronic myeloid 
leukaemia (fig.16).
This suggests that the occurrence of 
splenic erythropoiesis is not a prerogative 
of myelofibrosis but can occur in some cases 
of chronic myeloid leukaemia. The number of 
patients investigated by splenic puncture 
is small because the procedure is 
contraindicated in the presence of recent 
splenic infarcts or a bleeding diathesis. 
Furthermore, it was considered that splenic 
histology might be significantly altered, and 
therefore unacceptable, if the spleen had been 
previously subjected to irradiation. Splenic 
erythropoiesis, can, however, be estimated 
by other methods and this subject is considered 
in more detail later.
/ Anaemia is usually caused by lack of 
production of red cells, blood loss or an 
increased rate of haemolysis. In chronic 
myeloid leukaemia and myelofibrosis haemorrhage 
is rarely a factor in the production of anaemia 
and although a few patients admitted to easy 
bruising none admitted to external bleeding 
and there was no reason to suspect blood loss. 
Lack of red cell production is a possible 
factor and this could be related to a 
dyshaemopoietic defect; but it is not difficult 
to visualise the mechanical problem of 
erythropoiesis in a marrow cavity obliterated 
by fibrous or bony tissue to the degree seen 
in some patients. This is simulated in chronic 
myeloid leukaemia by the gross myeloid 
hyperplasia which has been thought to cause 
"crowding out” of the red cell precursors.
The enlargement of the spleen has been considered 
to be related to extramedullary erythropoiesis 
compensatory to the marrow destruction; this 
extra source of red cells raises a further 
complication to the problem of the mechanism of
44
/the anaemia in these diseases; furthermore, 
the question of increased haemolysis has yet 
to he raised.
The whole problem of the causation of 
anaemia is better considered after red cell 
production and destruction have been investigated 
by more definitive studies involving the.use 
of radioactive substances. The routine 
haematological investigations however, provide 
the means to precise diagnosis and give 
information of value in assessing a possible 
relationship between chronic myeloid leukaemia 
and myelofibrosis..
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Summary
The results of examination of the 
blood, the bone marrow and splenic aspirate 
are compared in chronic myeloid leukaemia and 
myelofibrosis.
In both disease anaemia is usually present 
but the striking difference is seen in the 
white cell count which is greatly increased 
in chronic myeloid leukaemia. A count of 
100,000 cells per c.mm. appears to be a 
convenient dividing line. The anaemia of 
myelofibrosis is leuco-erythroblastic and 
nucleated red cells are seen in higher proportion 
than occurs in chronic myeloid leukaemia.
Platelet levels are variable in both diseases.
Sternal puncture characteristically yields 
a fdry tap* in myelofibrosis whereas ample 
marrow is usually obtained in chronic myeloid 
leukaemia. Marrow trephine biopsy is necessary 
for the diagnosis of myelofibrosis and the 
histological findings are discussed.
The results of splenic puncture suggest 
that splenic architecture is better preserved 
in myelofibrosis and indicate that splenic
/erythropoiesis may occur in either disease.
Thus the two diseases can be differentiated 
on haematological grounds. Although there are 
similarities in the blood pictures the 
correct diagnosis can often be made from this 
alone but marrow trephine biopsy is required 
to substantiate the diagnosis of myelofibrosis. 
Splenic erythropoiesis does not appear to be 
essential for the diagnosis of myelofibrosis 
and the findings suggest that it occurs in 
chronic myeloid leukaemia.
STUDIES WITH 
RADIOACTIVE IEOH AND CHROMIUMi ; —
IS
CHRONIC MYELOID LEUKAEMIA 
AND
MYELGEIBfiOSIS
The advent of radioactive substances has
allowed a new and more dynamic approach to the
problems of blood production and destruction.
Prior to this reliance was placed mainly on
the routine examination of the blood and the
histological appearances of the bone marrow
for estimation of blood production, and on
pigment excretion studies and the application
of the method of differential agglutination of
red cells for estimation of blood destruction.
Although these procedures provided valuable
information, and may still constitute an important
part of investigation, there remained a distinct
lack of knowledge of the quantitative aspects
of blood production and of the survival of the
patient's own cells in his own circulation.
,59 \The use of radioactive iron ( Pe) and
,51 %radioactive chromium v Cr) has allowed a 
study of these problems, because, while 
behaving in all respects like the naturally 
occurring non-radioactive elements, the 
emission of radioactivity permits tracking of 
their metabolic pathways in the living subject.
Counts ° ~ °  Normal
(°/o in i t ia l  »-— .+ Increased
counts)
100
50
10
25 302010 150 5
Days
Pig. 17 Illustration of normal and increased 
rates of haemolysis as determined by 
the radiochromium technique.
/ In 1950 Gray and Sterling demonstrated 
the ability of radioactive chromium (^Cr) 
in the form of sodium chromate to ’label* the 
red cells by attachment to the globin 
moiety. When a patient's red cells are labelled 
in this way and reinjected into the circulation 
elution of chromium into the plasma occurs 
at the rate of about one per cent per day 
(Jones and Mollison, 1956). This is 
insignificant over the short period required 
for mixing and so accurate blood volume 
measurements can be obtained by application 
of the dilution technique (Sterling and Gray, 
1950). Decrease of radioactivity in the blood 
is otherwise due to the natural decay of the 
radioactive chromium and to the removal from 
the circulation of cells containing it. In 
the normal subject the radioactivity is 
reduced to half (T-g-) in 25 - 30 days but in 
patients with increased haemolysis the half 
life may be much less (fig.17). Furthermore, 
if during this period the red cells are being 
sequestered and destroyed by the spleen, there
/will be a marked accumulation of radioactivity 
in the spleen as compared to the liver or heart 
(Jandl et al, 1956). The spleen/liver ratio 
in normal subjects at T-| is less than 1..5/1 
and definite sequestration and destruction 
of red cells by the spleen is considered to be 
present when the ratio is 2.5/1 or more.
Thus, the use of radioactive chromium 
allows measurement of the blood volume, 
indicates the rate of red cell destruction and 
provides information about the spleen as an 
organ of sequestration and destruction of red 
cells.
59When radioactive iron ( Fe) is injected 
intravenously in the form of ferric chloride 
it immediately labels the plasma iron pool 
and then passes within one hour to the sites of 
haemoglobin formation.. If the radioactivity 
is counted at intervals for a period of 100 
hours over the heart, (as a measure of blood 
radioactivity) the sacrum (as normal site of 
blood formation), the liver and spleen, (as 
possible sites of erythropoiesis) the results
c /  m in
7,000 -i
NORMAL H E A R T
6,000' - ■O L IV E R
-----  SACRUM
5,000-
4,000-
3,000 ?
2,000 “
1,000-
0 10 100
hours
Fig. 18 Normal surface pattern of radioiron 
uptake•
(reproduced by permission from 
•Clinical Radiology),
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/can be plotted on a graph to give a radioiron 
•profile1 for each patient (Ledlie and Baxter, 
1954). The 'profile* for a normal subject 
(fig.1 8 ) shows a fall in heart counts and a rise 
in sacral radioactivity as the iron passes 
from the plasma to the marrow. There is a 
later decrease in marrow counts and a rise of 
heart counts as the iron, incorporated within 
newly formed red cells, returns to the blood. 
There is no significant change in the 
radioactivities of the spleen or liver. Thus, 
a radioiron profile may indicate the site or 
sites of erythropoiesis provided it is remembered 
that the surface counts are affected also by 
the radioactivity of the blood flowing through 
the organs. Wetherley-Mein, Hutt, Langmead and 
Hill (1956) describe four such profiles: the 
normal, the aplastic, the hypoplastic and the 
extramedullary.
If samples of blood are examined at 
intervals the radioactivity of the blood will 
be found to increase for about ten days (fig.19) 
(Wetherley-Mein et al 1956) as the red cells
Iron Ut i l isat ion
100
80
60
40
20
0
0 5 1C 15 20 25
Days
Pig. 19 Normal utilisation of injected 
radioiron.
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/containing the radioactive iron are released 
into the blood stream. This gives a measure 
of the utilisation of the injected iron.for 
haemoglobin formation which is 6 8-8 3$ of the 
injected dose in normal subjects (Pinch et al, 
1949). The utilisation of injected iron 
depends mainly on the rate and amount of 
red cell production and on the state of the 
iron stores. ?/hen the iron stores are low the 
iron is incorporated rapidly into haemoglobin 
and so gives a high utilisation which, 
however, does not indicate that the amount of 
erythropoiesis is greater than normal.
Provided the state of the iron stores is 
considered the iron utilisation can give an 
indication of the amount of red cell production.
Thus, information on the amount and sites 
of red cell production and of the rate and 
sites of red cell destruction can be gained 
from these investigations with radioiron and 
radiochromium.
Besuits
Radioiron studies were carried out on the
53
/patients with chronic myeloid leukaemia and 
those with myelofibrosis. One patient with 
chronic myeloid leukaemia died of a cerebro­
vascular accident before the iron utilisation 
could be completed and before radiochromium 
studies were commenced. Red cell survival 
was estimated on all patients and sequestration 
studies were carried out on eight patients 
with myelofibrosis. As each patient presents 
a different problem in relation to anaemia,
and as these investigations provide so 
much information about the mechanisms of blood 
production and destruction, the results 
obtained for each patient are considered 
separately. Iron deficiency was present only 
where indicated..
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Fig. 20 Eadioiron profile in patient E.W.
(chronic myeloid leukaemia).
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Fig. 21 Bed cell survival by radiochromium 
technique in patient E.W.
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/Chronic Myeloid Leukaemia
E.W. - Chronic Myeloid Leukaemia 
The radioiron profile is seen in fig. 20 
and shows no significant increase in radioactivity 
over marrow, spleen or liver. This indicates 
markedly reduced or absent marrow erythropoiesis
and there is no evidence of extramedullary 
erythropoiesis. Lack of splenic erythropoiesis 
was confirmed by splenic puncture. Utilisation 
of the injected radioactive iron was 31 
(normal 68 - 83^) and this low figure indicates 
a diminished amount of red cell production.
The red cell survival as estimated by 
radiochromium was 16 days (fig.21) and this is 
evidence of a markedly increased rate of 
red cell destruction..
Thus, the anaemia in this patient is 
caused by a combination of marrow hypoplasia 
and an increased rate of haemolysis.
There is no splenic erythropoiesis.
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Fig.23 Red cell survival by radiochromium 
technique in patient C.L.
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C.L. - Chronic Myeloid Leukaemia
The pattern of iron uptakes is seen 
in fig. 22. In this patient there is no 
significant alteration in marrow level hut 
a marked increase of radioactivity is seen 
over the spleen. This evidence of splenic 
erythropoiesis was confirmed hy splenic 
puncture. The iron utilisation was 73% and 
red cell half life was 20 days, (fig.,23).
Thus the anaemia in this patient is 
related to marrow hypoplasia associated 
with increased haemolysis. The normal 
utilisation of iron occurs in the absence 
of iron deficiency and indicates that the 
total red cell production must he around 
normal. The spleen, therefore, must play 
an important part in erythropoiesis.
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Pig. 24 Radioiron profile in patient J.L.
(chronic myeloid leukaemia)
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Pig, 25 Red cell survival by radiochromium 
technique in patient J.L.
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J .L., - Chronic Myeloid Leukaemia
In this patient the radioiron profile 
indicates diminished marrow production of 
red cells hut the spleen appears to he very 
active in erythropoiesis. (fig.24). The 
iron utilisation was very high (96fo) hut 
this is artificially high because of 
deficiency of iron, (serum iron 20ug, total 
iron binding capacity 450ug, haemoglobin 
6.1 g$, M.G.H.C. 30.5/6)# The red cell half 
life was only ten days (fig.25).
Here the anaemia is due to marrow 
hypoplasia and a greatly increased rate of 
haemolysis. Extramedullary erythropoiesis occurs 
in the spleen, the iron utilisation is very 
high hut in view of the iron deficiency, the 
total red cell production is not increased 
and is almost certainly reduced.
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Pig. 26 Radioiron profile in patient A.R. 
(chronic myeloid leukaemia)
A.R. - Chronic Myeloid Leukaemia
This patient unfortunately died of a 
cerebral vascular accident during 
investigation and consequently the only 
result is that of the pattern of 
radioiron uptakes (fig.26). The marrow 
uptake is not significant but the high 
splenic uptake indicates that the spleen 
had a major erythropoietic function.
Thus, the anaemia probably is due to 
marrow hypoplasia.
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Pig. 27 Radioiron profile in patient M.M. 
(chronic myeloid leukaemia)
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Pig. 28 Red cell survival by the radiochromium
technique in patient M.M.
M.M., - Chronic Myeloid Leukaemia
The radioiron profile (fig.27) shows 
absence of any significant uptake in radioiron 
in any of the possible sites of erythropoiesis. 
The utilisation of the injected radioactive 
iron is very low (24%) and there is an 
increased rate of haemolysis (T-g- - 14 days) 
(fig.2 8 ). In this patient there is marrow 
hypoplasia and no evidence of extramedullary 
erythropoiesis and the total amount of 
red cell production is greatly reduced. 
Increased haemolysis also appears to be a 
major factor in the causation of anaemia.
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Fig. 29 Radioiron profile in patient S.H.
(myelofibrosis). (reproduced by 
permission from 'Clinical Radiology')
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Fig. 30 Red cell survival by the radiochromium
technique in patient S.H.
Myelofibrosis
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S.H. - Myelofibrosis
The radioiron profile is seen in fig.29 
and demonstrates marked increase in splenic
radioactivity but no significant alteration 
in marrow counts. The iron utilisation 
was normal (80fo) and the red cell survival 
time, T-|, was also normal (30 days) (fig.30).
The anaemia is due to marrow hypoplasia 
and there is no haemolytic factor. There 
is marked splenic erythropoiesis, confirmed 
by splenic puncture and this is probably the 
main source of red cells.
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Pig. 31 Radioiron profile in patient J.G. 
(myelofibrosis)
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H e . 32 Sequestration studies and red cell
survival by the radiochromium technique
in patient J.G.
60
J.G. - Myelofibrosis
The pattern of radioiron uptakes (fig.31) 
shows no significant alteration in the levels 
of radioactivity in any organ. Iron 
utilisation was low (33$)* Reel cell half 
life estimation was 17 days but at a later 
date was further reduced to 11 days at which 
time the spleen/liver ratio was 2.5/1. 
(fig.32).
Thus the anaemia is due to a combination 
of marrow hypoplasia and an increased rate of 
haemolysis. The spleen plays no significant 
part in blood production, confirmed by splenic 
puncture, but appears to be the site of red 
cell sequestration and destruction.
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.Fig. 33 Hadioiron profile in patient M.C.
(myelofibrosis)
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ffig. 34 Sequestration studies and red cell
survival by the radiochromium technique
in patient M.C.
M.C. - Myelofibrosis
The radioiron profile is seen in fig.33 
and shows no significant uptake in any organ. 
The iron utilisation is 100$ due to severe 
iron deficiency (serum iron 35ug, total iron 
binding capacity 235ug, haemoglobin 9.2 g$, 
M.C.H.C. 25.5°/o) Radio chromium studies 
showed T-g- to be 13 days but at a later date 
it was 25 days and the spleen/liver ratio 
at this time was 2.65/1 (fig.34).
Thus the presenting anaemia is due to 
marrow hypoplasia and increased haemolysis. 
The spleen has no erythropoietic function 
but is later shown to be an organ of 
sequestration and destruction of blood. .
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ffjg* 35 Badioiron profile in patient !.Q.
(myelofibrosis)
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Fig. 36 Sequestration studies and red cell
survival by the radiochromium technique 
in patient T.Q..
T.Q., - Myelofibrosis
In this patient the radioiron profile 
(fig.35) shows some increase in marrow and 
splenic uptakes of radioactive iron. The 
iron utilisation is only 42$. The radiochromium 
studies are seen in fig.36. Increased 
haemolysis is present (T-J- = 14 days) and 
spleen/liver ratio at T^ - is 3/1.
The anaemia is therefore due to a 
combination of hypoplasia and an increased 
rate of haemolysis. The marrow shows some 
sign of continuing activity but the total red 
cell production is obviously low as the iron 
utilisation is only 42$. The spleen shows 
evidence of erythropoiesis, though splenic 
puncture failed to reveal this, but it is 
mainly an organ of erythrocyte sequestration 
and destruction.
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Fig. 37 Radioiron profile in patient J.C.
(myelofibrosis)
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Fig*. 38 Sequestration studies and red cell
survival by the radiochromium technique 
in patient J.C.
J.C. - Myelofibrosis
The iron uptake patterns are demonstrated 
in fig.37. There is no increase in marrow 
radioactivity but an increase in splenic 
activity is seen. The iron utilisation is 
rather low at 55fo and the red cell half life 
is 22 days. At a later date was 25 days 
and the spleen/liver ratio was then 2.3/1 
(fig.38).
These results indicate that the 
presenting anaemia is due to marrow 
hypoplasia but slightly increased haemolysis 
may be a minor contributory factor. The 
spleen has moderate erythropoietic activity 
but no significant sequestration is 
demonstrated.
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ffig* 39 Badioiron profile in patient A.S.
(myelofibrosis)
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Big.. 40 Sequestration studies and red cell
survival by the radiochromium technique 
in patient A.S.
A.S. - Myelofibrosis
The radioiron profile is shown in fig.39. 
There is marked increase in splenic radioactivity 
but no significant alteration in marrow counts.
A normal utilisation of radioiron of 64i° 
is present and T-J- is virtually normal at 
24 days. The spleen/liver ratio at T-J is 
2/1 (fig-40).
The anaemia of this patient is due 
principally to marrow hypoplasia and there is 
no significant increase in the rate of 
haemolysis.
The spleen has a marked erythropoietic 
function and does not appear to sequester red 
cells.
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Rig. ,41 Radioiron profile in patient R.C.
(myelofibrosis)
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Rig. 42 Sequestration studies and red cell
survival by the radiochromium technique
in patient R.C.
R.C. - Myelofibrosis
The radioiron profile is seen in fig.41. 
There is no increase of marrow radioactivity 
but there is some uptake of radioactive iron 
in the spleen. The iron utilisation is rather 
low (53ft) despite iron deficiency (serum iron 
45ug, total iron binding capacity 480ug, 
haemoglobin 10.4 g?°9 M.C.H.C. 26fo) and the 
red cell half life is 15 days which is 
considerably reduced. At T-J- the spleen/liver 
ratio is 1.32/1 (fig.42).
Thus, the anaemia of this patient is due 
to a combination of hypoplasia and increased 
red cell destruction. The spleen has some 
erythropoietic function but is not an organ of 
sequestration of red cells.
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Big* 43 Radioiron profile in patient M.G.B.
(myelofibrosis)
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Pig, 44 Sequestration studies and red cell
survival by the radiochromium technique
in patient M.G.B.
M.G.B. - Myelofibrosis
The radioiron profile (fig.43) shows no 
significant increase in marrow radioactivity 
but there is a moderate rise of splenic 
radioactivity. The iron utilisation of only 
21% is very low. Red cell survival is 
diminished (Tj- = 16 days) and the spleen/liver 
ratio at T-J is 2.4/1 (fig.44).
The anaemia is due to hypoplasia and 
excessive haemolysis. In view of the very 
low iron utilisation the total red cell 
production must be greatly reduced. The 
spleen has an erythropoietic function and 
sequestration of red cells is not definitely 
present.
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45 Badioiron profile in patient W.P. 
(myelofibrosis)
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Pig.- 46 Sequestration studies and red cell
survival by the radiochromium technique 
in patient W.P.
W.P., - Myelofibrosis
The radioiron profile is seen in fig.45. 
There is a rise in radioactivity in the marrow 
and to a greater degree in the spleen. The 
iron utilisation is 63f<> and the red cell half 
life is 14 days. At T-g- the spleen/liver 
ratio is 2.7/1 (fig.46).
Thus, a major factor in the production
of anaemia in this patient is increased
haemolysis. There is evidence of some
continuing erythropoietic activity in the
marrow and the iron utilisation is almost
normal which indicates, in the absence of 
iron deficiency, that total red cell
production cannot be greatly reduced and may
be a minor factor only in the causation of
anaemia.
The spleen has the dual function of 
production and destruction of red cells.
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Discussion
Radioisotopic investigations have allowed 
a determination of erythrocyte survival and 
a study of the dynamics of erythropoiesis.
The results obtained are a great advance on 
what could be inferred from routine haematological 
procedures and provide more detailed 
knowledge of the mechanisms of anaemia both in 
individual patients and in particular diseases.
A summary of the results in the chronic 
myeloid leukaemia group is seen in table 7.
The lack of uptake of radioactive iron by the 
bone marrow is a feature of all five cases and 
this indicates that marrow erythropoietic 
activity is greatly reduced. It must be 
remembered that the utilisation of injected 
iron is dependent on the state of the iron 
stores as well as on the amount of red cell 
production. When iron deficiency is present 
or when erythropoiesis is greater than normal 
the utilisation of iron will be high.
Therefore, if the iron utilisation is high and 
iron deficiency is present to account for this,
69
/the utilisation is no guide as to the amount of
erythropoiesis. On the other hand if
utilisation is high in the absence of iron
deficiency then the amount of erythropoiesis
must be greater than normal. When iron
utilisation is low the state of iron stores is
irrelevant as red cell production must be
diminished. Thus the iron utilisation may be
used as an indication of the total amount of
red cell production provided the state of the
iron stores is kept in mind. It cannot, however,
be used in a quantitative manner, with any 
accuracy unless elaborate corrections are made.
It is of interest that the very low 
iron utilisation figures of 24 per cent and 
31 per cent are seen in two patients with iron 
deficiency and no demonstrable activity in marrow 
or spleen. There is, therefore, in these 
patients greatly reduced red cell production.
In the three other patients, marrow hypoplasia 
is again present but there is evidence of 
considerable splenic erythropoiesis. In one 
of these patients there is no iron deficiency
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/yet the utilisation of iron is in the 
normal range and this is evidence that the 
spleen plays a major part in red cell production. 
Thus, splenic erythropoiesis may compensate 
(at least partly) for diminished marrow 
production.
The red cell survival times in the four 
patients so investigated demonstrate an 
increased rate of haemolysis, sometimes to 
a severe degree, in all. Thus, the anaemia 
of chronic myeloid leukaemia is due usually 
to a combination of marrow hypoplasia and an 
increased rate of haemolysis* Splenic 
erythropoiesis occurs in some patients with 
chronic myeloid leukaemia and may partly 
compensate for the marrow deficiency.
A summary of the results obtained in the 
nine patients with myelofibrosis is seen 
in table 8.
Marrow hypoplasia is present in seven 
of the nine patients but in the other two there 
is evidence of some continuing activity. The 
iron utilisation is low in approximately half
71
/of the patients in all of whom the total 
red cell production must be less than normal, 
and in the others it is probably less than 
normal. The spleen, though sometimes a major 
source of red cells, does not always take 
part in erythropoiesis.
An increased rate of haemolysis occurs 
in most of the patients with myelofibrosis 
and in some the spleen is the site of 
erythrocyte sequestration and destruction.
Thus the anaemia of myelofibrosis is due 
usually to a combination of marrow hypoplasia 
and an increased rate of haemolysis. Splenic 
erythropoiesis is not necessarily present 
in myelofibrosis but occurs in most cases 
and may help to compensate for the diminished 
marrow production. Sequestration and destruction 
of red cells may also occur in the spleen.
It is clear that the radioisotopic studies 
have provided real information about the basic 
mechanisms ooncerned with the production of 
anaemia. On comparison of the two groups of 
results there is seen to be no specific pattern
/of radioiron uptakes for either disease.
Reduced marrow function occurs in all cases, 
though in two patients with myelofibrosis 
there is evidence of some continuing 
erythropoiesis, and the anaemia of both diseases 
appears to be due usually in part to hypoplasia 
and in part to increased haemolysis, either of 
which may be the dominant factor. The spleen 
may be the seat of erythropoiesis in either 
disease and this may compensate to some extent 
the reduced marrow production.
While the evidence of splenic 
erythropoiesis as derived from histological 
examination of splenic aspirate agrees well 
with that of splenic uptake of radioactive 
iron, the more accurate estimate of the amount 
of red cell production is undoubtedly that of 
radioiron. Histological study of splenic 
aspirate demonstrates the approximate proportion 
of red cell precursors in the spleen but there 
is no indication of the proliferative activity 
of these cells or of their release from the 
site of origin. The radioactive iron, however,
/travels to the sites of red cell formation 
and is incorporated in haemoglobin in the 
newly formed red cells. The accumulation of 
radioactive iron in an organ indicates that 
it is the site of erythropoiesis and thereafter 
the rise of blood radioactivity due to cells 
containing the radioisotope proves that 
there is no failure of release of the cells 
from their site of origin. This is,therefore, 
a more accurate estimate of the functional 
and effective erythropoiesis.
On the basis of the radioiron results 
splenic erythropoiesis is present to a moderate 
or marked degree in three of the patients with 
chronic myeloid leukaemia and five of those with 
myelofibrosis. Rosenthal (1950) suggested 
that the immature cells in the blood are derived 
from the sites of extramedullary erythropoiesis 
because these sites lack the regulatory release 
mechanism of the bone marrow. If this is true 
then there should be some correlation between 
the degree of splenic erythropoiesis and the 
numbers of immature cells in the blood. This
Patient
59
Fe
Splenic
Uptake
Nucleated 
red cell3 
(per c.mm.)
Reticulocytes 
(per c.mm.)
M .M « 0 5.250 <76,000
J.L. +++ 1,700 147,000
C.L. +++ 1,500 140,000
E.Wo 0 5,400 75,000
A.R. +++ 3,000 130,000
M.C.
1 .
0 900 196,000
J.C. ++ 2,555 144,000
J.G. 0 420 330,000
R.C. + 464 82,000
T.Q. + 135 286,000
M.G.B. ++ 340 52,000
S.H. +++ 0 <80,000
W.P. ++ 357 704,000
A.S . +++ 250 <84,000
59Table 9 A comparison of 'Fe splenic uptake and
nucleated red cell and reticulocyte counts 
in chronic myeloid leukaemia and myelofibrosis.
/correlation is absent both in chronic myeloid 
leukaemia and in myelofibrosis when the radioiron 
result is compared with the numbers of circulating 
nucleated red cells with or without reticulocytes 
(Table 9). Thus it seems unlikely that the 
immature cells are derived solely from the 
extramedullary sites of erythropoiesis. It 
is more probable that their occurrence in the 
blood is related entirely to the efforts of 
all sites of haemopoiesis, including those 
in the bone marrow, to compensate for the 
reduced marrow cavity and the consequent 
anaemia, by releasing cells before they are 
fully mature.
In myelofibrosis the spleen is, in some 
cases, a site of erythropoiesis but in seven 
patients there is also increased haemolysis.
The role of the spleen as an organ of erythrocyte 
destruction has yet to be considered* The 
sequestration studies show accumulation of 
radiochromium in the spleen to a level indicative 
of splenic sequestration, and destruction of 
labelled red cells in about half of those cases
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/with an increased rate of haemolysis. Thus, 
the spleen in myelofibrosis may act either as 
an organ of red cell production or as an organ 
of red cell destruction. In some of the patients 
with splenic sequestration there was also splenic 
erythropoiesis indicating that in some patients 
the spleen may act in both capacities at the 
same time,
Donhauser (1908) first suggested that blood 
formation occurred in the spleen as a compensatory 
mechanism and Marson and Meynell in 1952 
stated that it was then generally accepted 
that splenomegaly was compensatory to marrow 
involvement. These radioisotopic studies show 
that extramedullary erythropoiesis may compensate 
partly for diminished blood formation in the 
marrow; but as splenic erythropoiesis is absent 
in some patients who have marked splenomegaly 
and severe marrow cavity obliteration, it 
cannot be simply compensatory to marrow 
involvement,
Summary
The radioactive iron and chromium 
studies carried out in the patients with 
chronic myeloid leukaemia and those with 
myelofibrosis provide information on the 
mechanisms of anaemia in these diseases.
The radioiron studies demonstrate that 
the same pattern of iron uptakes occur in both 
diseases. Splenic erythropoiesis may be present 
in either condition and the studies do not 
substantiate the suggestion that the spleen 
in myelofibrosis is merely an organ of 
compensatory erythropoiesis.
The basic mechanisms of anaemia are the 
same in each disease, namely, a combination 
of hypoplasia and increased haemolysis.
Although the spleen in myelofibrosis may
act as a source of red cells it is sometimes 
seen to act as an organ of destruction and
these two functions may co-exist.
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Fig. 47 Hepatomegaly and grade II splenomegaly
in patient W.M.
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Dameshek (1951), in supporting the theory 
of the existence of an aetiological relationship 
of the myeloproliferative disorders, emphasises 
the occurrence of many ‘transition* forms.
By this, he implies that while each disease 
may have a specific pattern or syndrome whereby 
it can be identified, there may be such variation 
in the manifestations of the disease that many 
cases cannot be satisfactorily classified. 
Leonard, Israels and Wilkinson (1957) oppose 
this view and state that if * transition* forms 
occur at all commonly then constant patterns 
for each accepted disease would not be expected. 
This opinion is based mainly on the finding 
of constant biochemical patterns in each disease 
but this, of course, is only one aspect of the 
problem. If transition forms do occur, some 
of their features should be identical with those 
of one recognised disease and some with those 
of another. An answer to the question of 
relationship of the myeloproliferative disorders 
may well depend on the existence of these 
"linking” forms, whose importance, therefore,
Big. 48 Hepatomegaly and grade III splenomegaly
in patient M.B.
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/cannot be overemphasized.
The clinical, haematological and radio­
isotopic comparisons of chronic myeloid 
leukaemia and myelofibrosis have been made 
and two patients apparently 'intermediate1 
between these two diseases will now be 
discussed under similar headings*
Clinical Picture
One patient, W.M., was a male of 57 years 
of age and the other, M.B., a female of 33 years 
of age, at the time of diagnosis.
Patient W.M* when first seen complained of 
breathlessness on exertion, ankle swelling, 
abdominal discomfort and tiredness of about 
four to five months duration* He had observed 
also some weight loss and increasing pallor.
A few small lymph nodes were palpable and he 
had hepatomegaly and grade 2 splenomegaly (fig. 
47). Some brown pigmentation of the backs of 
his hands and around his ankles was also noted.
Patient M.B., presented with breathlessness 
on exertion, ankle swelling and abdominal 
discomfort of two to three months duration* She
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/had noted also excessive and severe menstrual 
loss for the previous year and on examination 
was found to have a few palpable lymph nodes, 
hepatomegaly and grade 3 splenomegaly (fig.4 8 ).
Thus the clinical features of these patients 
are consistent with a diagnosis of either 
chronic myeloid leukaemia or myelofibrosis.
Haematological Investigations
Both patients were anaemic, one with 
associated iron deficiency, and both had 
elevated white cell counts. It is of interest 
that the counts of 1 4 0 ,0 0 0  cells per c.mm. 
and 1 9 6 ,0 0 0  cells per c.mm. are well above 
the usual range for myelofibrosis although such 
high counts have been reported (Korst et al, 
1956). They are not however, of the very high 
levels characteristically associated with 
chronic myeloid leukaemia. The blood films 
of W.M. showed no abnormality of the mature red 
cells but those of M.B. showed some anisocytosis 
and poikilocytosis, and typical 'tear drop' 
cells were not uncommon. Platelet counts in
0 0 1 r—l Hj-
SP9H P9^ eI°nIT iH
its
^  seq.^ooxe^uieq.ei/11 -d-
i—1
rH
«H
^  seq jC o o xe jC jt
ir \•
-cf
CM
OS
in
^  sq.S'exqoia^ M Ot—1
i—1
^  s e x ^ o o u o i CM CM
^  se c^ o o q d iiu C x VO CM
^  sxpqcIos'Bg; Oi—1
CM
rH
LTV
O
^  s x x i;t(2o u I s o 0 c—
^  s x x q d o u q -n e u ir\CM KSVO
Or—> O  '
“u n iro  j e d 8*» rv
*o*a*A\ 3
rH
VO
ON
rH
q.uexq.'Bjj
*
£•
•
«•
m Ta
bl
e 
11 
Di
ff
er
en
ti
al
 
wh
it
e 
ce
ll
 
co
un
ts
 
in 
2 
in
te
rm
ed
ia
te
* 
ca
se
s
/both patients were higher than normal. The 
principal haematological findings are 
summarised in table 10 and the differential 
white cell counts in table 1 1 . In one patient 
(W.M.) neutrophil polymorphonuclear leucocytes 
accounted for only 25 per cent of the total 
white cells but eosinophil and basophil 
leucocytes were both increased and immature 
white cells totalled 4 9 .5  per cent including 
10.5 per cent ‘blast1 cells. Nucleated red 
cells were present in the proportion of 11  
per 100 white cells. The other patient 
(M.B.) had 21 per cent primitive white cells 
but only 1 per cent 'blast' cells; nucleated 
red cells were seen in the proportion of 
4 per 1 0 0 white cells.
Thus, in one patient there is a blood 
picture rather like chronic myeloid leukaemia, 
apart from the high proportion of immature red 
cells and the only moderately raised white 
cell count, and in the other a picture 
compatible with myelofibrosis except for the 
very high v/hite cell count.
Pig, 49 Iliac crest marrow showing an increase 
of reticulin in 'intermediate' disease 
(patient W.M.). ( x U00 ).
/ Marrow puncture on each patient, despite 
repeated attempts at various sites, yielded, 
like myelofibrosis, a 'dry tap*. Marrow 
trephine biopsy was therefore carried out and 
in each case showed a marked degree of myeloid 
hyperplasia and a definite increase in reticulum 
(fig.49) but no fibrosis. One patient (W.M.) 
also had some increase in megakaryocytes in 
the marrow.
Thus, these two patients had anaemia and 
elevated platelet counts compatible with 
either diagnosis. The white cell counts were 
much higher than is usual in myelofibrosis 
but in one patient the differential white cell 
count was more in keeping with the diagnosis of 
myelofibrosis yet this was the patient with 
the higher white cell count (1 9 6 ,0 0 0  per c.mm.). 
Repeated marrow punctures, as in myelofibrosis, 
yielded 'dry taps' but marrow trephine showed 
myeloid hyperplasia but a marked increase in 
reticulum.
It seems that these two patients have some 
features of chronic myeloid leukaemia and others
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/of myelofibrosis; as judged by the criteria 
used for defining chronic myeloid leukaemia 
and myelofibrosis, they must be classed as 
'intermediate* as each set of criteria is 
satisfied only partially.
The radioactive isotope investigations 
previously described were carried out on these
two patients and are summarised in table 1 2 .
c / min W. McA. I
7,000
6,000 - -• SACRUM
5,000 "
4.000 ~
3,000 “
2,000 "
1,000 _
10010O
hours
ffig..50 Radioiron profile in patient W.M. 
(‘intermediate* disease)
Counts 
(% initial
W.M. •  Blood radioactivity
counts) O Spleen/liver ratio100
5 0
a.w p.0 -0/j
0 5 10 15 20 2 5 3 0
Days
Rig. 51 Sequestration studies and red cell
survival "by the radio chromium technique
in patient W.M.
W.M. - intermediate* disease
The radioiron profile is seen in fig.50.
In this patient the marrow radioactivity does 
not rise significantly but there is a considerable 
increase in the counts over the spleen indicating 
a moderate degree of splenic erythropoiesis.
The iron utilisation is low, only 16 per cent, 
and there must be, therefore, a greatly reduced 
total red cell production. The red cell 
survival time is reduced to 20 days, indicating 
an increase in the rate of haemolysis, and the 
spleen/liver ratio at this time is 2 .3 / 1  
(fig.5l) which does not indicate significant 
sequestration of erythrocytes.
Thus the anaemia of this patient is due 
to greatly reduced red cell production combined 
with an increased rate of haemolysis. The 
spleen has an erythropoietic function and appears 
not to sequester red cells.
c / min M.B. I
7,000-] HEAR T
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Fig. 52 Radioiron profile in patient M.B, 
('intermediate1 disease)
Counts
(°/o in i t ia l  
counts)
M.B.
100
50
10
2520
Days
Fig* 33 Red cell survival by the radiochromium
technique in patient M.B.
M.B. — 'Intermediate' disease
The radioiron profile for this patient is 
seen in fig. 52, and again shows no significant 
increase in marrow radioactivity but a moderate 
increase in splenic activity. The utilisation 
of the injected radioactive iron is 97 per cent 
and this high figure is due to iron deficiency 
(haemoglobin 9.1 g%, M.C.H.C. 26%, serum iron 
7 0ug % and total iron binding capacity 
270ug %). The red cell survival time is greatly 
reduced to 12 days (fig.5 3 ) and indicates a 
markedly increased rate of haemolysis. 
Sequestration studies were not carried out.
Thus, there is again marrow hypoplasia and 
increased haemolysis and the spleen is the site 
of red cell formation.
/ It is, therefore, easily seen from these
investigations that these two patients occupy 
a very interesting position in the study of 
chronic myeloid leukaemia and myelofibrosis.
The clinical pictures show nothing to distinguish 
either from these diseases and the blood 
findings are of no real help. The white cell 
counts are more in the range of chronic myeloid 
leukaemia but are not diagnostic and in one 
patient the differential white cell count 
resembles that of myelofibrosis much more than 
that of chronic myeloid leukaemia. Repeated 
marrow puncture at several sites yielded, in 
both patients, a 'dry tap', the characteristic 
result in myelofibrosis. The histology of 
marrow trephine biopsies, however, demonstrated 
myeloid hyperplasia, almost of the degree 
typical of chronic myeloid leukaemia but there 
was a marked increase in reticulum in each 
patient to the degree seen in myelofibrosis.
Thus, on the criteria used for definition 
of chronic myeloid leukaemia and myelofibrosis, 
there is no doubt that these two patients lie
/between the two, resembling myelofibrosis 
in some ways and chronic myeloid leukaemia 
in others, and can be classed as truly 
'intermediate *.
The radioisotope studies are o f . 
considerable interest for here again is seen 
the pattern of anaemia produced by combined 
hypoplasia and haemolysis and in both cases 
the spleen ehows evidence of active erythropoiesis. 
Thus, the radioisotopic investigations, too, 
show no specific pattern and are compatible 
with either diagnosis. Marrow erythropoietic 
hypoplasia can therefore occur without the 
gross myeloid hyperplasia seen in chronic 
myeloid leukaemia and yet without the fibrosis 
and marrow obliteration of myelofibrosis. 
Splenomegaly is not as great as in these 
other diseases and the presence of the enlarged 
spleen is seen to be beneficial to each 
patient in that it is the seat of erythropoiesis.
While there may be varying opinions on 
the relationship of the myeloproliferative 
group of disorders, the demonstration of these
/ ’intermediate* eases is strong evidence in 
favour of a relationship between chronic 
myeloid leukaemia and myelofibrosis.
Summary
Two patients whose clinical features 
are those of chronic myeloid leukaemia or 
myelofibrosis are described.
The blood and marrow findings are not 
consistent with either disease but lie 
between the two and the cases are therefore 
classed as 'Intermediate1.
The radioisotopic studies show that the 
anaemia of these patients is due to combined 
marrow hypoplasia and an increased rate of 
haemolysis.
The occurrence of 'Intermediate' cases 
is considered evidence in favour of a 
relationship between chronic myeloid 
leukaemia and myelofibrosis.
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S U M M A R Y  0 1 
S E C T I O N  II
A study is carried out of five patients 
with chronic myeloid leukaemia and of nine 
patients with myelofibrosis.
The clinical pictures of these diseases 
are very similar and the symptoms and signs are 
usually related to asthenia, anaemia or 
splenomegaly. Weight loss is often prominent 
and splenomegaly is striking. The haematological 
investigations demonstrate differences in the 
blood pictures of these diseases which usually 
suggest the diagnosis. Marrow trephine biopsy 
is necessary to substantiate the diagnosis of 
myelofibrosis and the histological features 
of the marrow suggest that myelosclerosis is 
in fact a complication of some cases of 
myelofibrosis. Splenic puncture is helpful 
in making the diagnosis but splenic erythropoiesis 
may occur in either condition. The radioisotopic 
investigations show that the anaemia in each 
disease is usually due to marrow hypoplasia 
and increased haemolysis. Splenic erythropoiesis 
may compensate partially for marrow hypoplasia
/but is not secondary to marrow involvement.
While chronic myeloid leukaemia and 
myelofibrosis are distinct diseases with certain 
characteristic features of diagnostic importance, 
they do possess features in common and the 
basic mechanisms of the anaemia appear to be 
the same in each disease.
The demonstration of two patients who 
appear to lie between the two diseases and 
are classified after investigation as 
1 Intermediate* or 1linking forms* is taken 
as strong evidence in favour of relationship 
between chronic myeloid leukaemia and 
myelofibrosis. It is concluded that if the 
other myeloproliferative diseases have similar 
features and basic abnormalities and if 
transition forms are found, then relationship 
of the whole group of disorders is most likely.
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S E G I I 0 H III . 
O T H E R
M Y E L O P R O L I F E R A T I V E '
D I S E A S E S
POLYCYTHAEMIA VERA
Since the original articles by Vaquez 
(1892) and Osier (1903) many further publications 
on various aspects of Polycythaemia Vera have 
appeared in the literature. Perhaps the most 
comprehensive study of a large number of patients 
with this disease is that of Lawrence, Berlin 
and Huff (1953) who review the previous 
literature and discuss the clinical, 
physiological and therapeutic aspects of 207 
patients. Despite this extensive review, which 
reveals many interesting aspects of the disease, 
there are still many problems in relation to 
Polycythaemia Vera, not least the relationship 
to other myeloproliferative disorders.
Five patients with Polycythaemia Vera have 
been studied and the results are discussed 
under the headings of ' clinical picture1,
1haematological findings’ and 'radioisotopic 
investigations *.
Clinical Picture
Polycythaemia Vera is a disease of middle 
life and is slightly more common in males 
than in females (Wintrobe, 1956). Three males
/and two females are described in this study 
and the ages range from 37 to 70 years at the 
time of onset of symptoms. The onset is usually 
insidious and the most common complaints are 
of headaches, limb pains, asthenia, attacks of 
mental depression, dyspnoea on exertion, 
tinnitus and lightheadedness. Of the five 
patients, two complained of lack of energy, 
two had lightheadedness, one dyspnoea, one 
limb pains and one abdominal discomfort..
It is of interest that two patients had symptoms 
of intermittent claudication, despite satisfactory 
haemoglobin levels and this is almost certainly 
due to peripheral vascular disease, which is a 
known complication of Polycythaemia Vera 
(Brown and Giffin, 1930). One patient was so 
troubled with attacks of mental depression that 
when first seen she was an inmate of a Mental 
Hospital. This underlines the importance of 
the recognition of even severe mental depression 
as a possible symptom of Polycythaemia Vera.
The occurrence of gout in two patients is no 
doubt the result of increased uric acid
/metabolism and high blood uric acid levels.
The spleen is said to be palpable in about 
66 per cent of cases and the liver in 25 per cent 
of cases (Tinney et al, 1943). A palpable 
spleen was found in four of the five patients 
and a palpable liver in two. Considerable 
variation was noted in splenic size and 
whereas in one jd;ient the spleen was impalpable, 
in another the spleen extended below the level 
of the umbilicus but in no case did it reach 
the dimensions found in some cases of chronic 
myeloid leukaemia or myelofibrosis.
One of the characteristic features of 
patients with polycythaemia vera is the dusky 
red appearance of the face. This was present 
in four patients but in the other the skin ^ 
and mucous membranes were pale as a result 
of a recent severe gastro-intestinal haemorrhage 
and one other patient gave a history of previous 
melaena. The occurrence of haemorrhage in 
polycythaemia vera is well recognised but so 
also is the liability to thrombosis and it is 
stated that vascular disasters, either
/haemorrhage or thrombosis, occur in about one 
third of all cases. (Whitby and Britton, 1957). 
Thus, the coexistent tendencies to bleed and 
to thrombose, as seen in chronic myeloid 
leukaemia and myelofibrosis, again occur. 
Gastro-intestinal bleeding is often associated 
with peptic ulcer, as in the above patients, 
and this association occurs more commonly 
than can be attributed to chance. Tinney et al 
(1943^ report peptic ulcer in 7 per cent of 
patients with polycythaemia vera and Rosenthal 
and Bassen (1938) in 10 per cent.
The occurrence of hypertension is noted 
in 50 per cent of patients by Lawrence et al 
(1953) who consider a systolic pressure of 
150 mm. Hg. or more and/or a diastolic pressure 
of 90 mm. Hg. or more to be evidence of 
hypertension. Using these criteria, hypertension 
is present in four of the five patients 
described here but in fact only one of these 
had a diastolic pressure of over 100 mm.Hg. 
G-aisboek (1922) describes a group of patients 
with polycythaemia who have hypertension but in
/whom the spleen is impalpable, and so patient 
F.K. who has a blood pressure of 190/100 mm.
Hg. and in whom the spleen is not palpable 
may well be considered to have Gaisbock’s 
disease. Such patients, however, are sometimes 
observed to develop splenomegaly at a later 
date (Harrop and Wintrobe, 1936) and clearly 
do not constitute a separate disease syndrome. 
Haematological Findings
The essential haematological feature of 
polycythaemia vera is the occurrence of red 
cells in greater than normal numbers in the 
blood. This feature was found in the current 
series in all patients and counts from 
8.00 to 10.32 million red cells per c.mm. 
were noted at one time or another for each 
patient. These high numbers of red cells were 
not constantly present especially in the two 
patients with major bleeding episodes and it 
is of interest that two patients, including
one of the above, actually presented with 
anaemia. All five patients, however, had
evidence of iron deficiency as determined by
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/M.C.H.C. estimations of below 30 per cent.
Thus despite the usually high haemoglobin 
levels and erythrocyte counts the red cells 
are often hypochromic and uhis is probably 
related to large or repeated bleedings either 
spontaneous or therapeutic in origin 
(Wintrobe, 1956). The principal haematological 
features found at the first attendance are 
summarised in table 13.
Emphasis has been laid on the involvement 
of white cells and platelets in about three 
quarters of all patients with polycythaemia 
vera and the white cell counts are often in 
the region of 10,000 to 25*000 per c.mm. 
but occasionally counts of over 50,000 cells 
per c.mm. have been recorded (fiosenthal and 
Basson, 1938). Elevated platelet counts of 
over 300,000 per c.ma. are seen in 65 per cent 
of patients (Lawrence et al, 1953) but it must 
be remembered that these figures are modified 
by recent therapy which lowers both the white 
cell and platelet counts; in untreated patients 
the counts are in all probability somewhat
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Of the five patients investigated, 
three had white cell counts of over 10,000 
cells per c.mm. and the highest was 40,000 
per c.mm. These three also had platelet counts 
over 300,000 per c.mm. but the platelet 
levels were normal in the other two patients. 
The predominant white cell is the 
polymorphonuclear leucocyte though some 
immature cells may be seen; no primitive 
white cells were present in these patients 
but polymorphonuclear leucocytes constituted 
70 to 92 per cent of the total white cells 
(table 14.).
The histological features of the bone 
marrow are those of hyperplasia of the 
erythropoietic and leucopoietic tissues and of 
the megakaryocytes. It is this increase of 
megakaryocytes and white cell precursors that 
Britton and Neumark (1949) consider the 
principal feature of differentiation from 
secondary erythrocytosis. These findings were 
present in all five patients and the typical
Fig. 54 Marrow histology in polycythaemia 
vera (patient A.McA.) 
(May-G-runwald-G-iemsa x 400).
/marrow appearance is illustrated in fig.54 
which is taken from patient A.McA. The 
hyperplasia is easily seen and in particular 
the abundance of megakaryocytes is observed. 
Radioisotope Investigations
The iron uptake patterns and iron 
utilisation were estimated in all five 
patients and the red cell survival time in 
four. The results of these investigations 
are considered separately for each patient. 
There was no evidence of blood loss at the 
time of these studies.
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Fig. 55 Radioiron profile in patient A.McA. 
(polycythaemia vera)
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Fig. 56 Red cell survival by the radio chromium,
technique in patient A.McA.
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A.McA. - Polycythaemia Vera
The iron uptake profile is seen in fig.55.
There is evidence of activity in the bone
marrow but not in the spleen. The iron
utilisation is 94 per cent which is high and
51the red cell survival ( Cr) is 22 days (fig.56).
These results are interpreted as showing
continuing marrow red cell production and no
splenic erythropoiesis. The high iron
utilisation was obtained at a time when the
patient was not anaemic, but was iron deficient
(haemoglobin 16.9 g$, M.C.H.C. 29$, serum iron
35ug $, total iron binding capacity 345ug $)
and is probably partly due to iron deficiency.
51Cr Ti of 22 days indicates a minor, if any, 
increase in the rate of haemolysis.
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Fig. 57 Radioiron profile in patient M.S.m
(polycythaemia vera)
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Fig, 58 Red cell survival by the radiochromium
technique in patient M.S.
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M.S. - Polycythaemia Vera
The radioiron profile is seen in fig.57. 
There is an increase of marrow radioactivity 
but no significant alteration in the splenic 
level. The iron utilisation is 88 per cent
of the injected dose and T-J- is 24 days (fig.58).
Thus, marrow production continues and 
there is no splenic erythropoiesis. There 
is no significant increase in the rate of 
red cell destruction.
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Fig. 59 Radioiron profile in patient F.N. 
(polycythaemia vera)
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Fig. 60 Red cell survival by the radiochromium
technique in patient F.N.
ff.N. - Polycythaemia Vera
The radioiron uptake patterns are 
indicated in fig.59. There is again some 
evidence of marrow activity but none of 
splenic erythropoiesis. The iron utilisation 
is normal (74$) but there is a distinctly 
increased rate of haemolysis (T-|- = 17 days) 
(fig.60). An interesting feature is the 
presence of excessive haemolysis in this 
one patient.
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ffig. 61 Radioiron profile, in patient J.G.
(polycythaemia vera)
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Fig. 62 Radioiron profile in patient J.C. 
(polycythaemia vera)
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Fig. 63 Red cell survival by the radiochromium
technique in patient J.C.
J.C. - Polycythaemia Vera
The radioiron profile is seen in fig.62 
and shows a moderate increase in marrow 
radioactivity hut no significant alteration 
in the splenic level. The iron utilisation 
is within the normal range (83$) and T-J is 
24 days (fig.6 3 ).
Thus, there is definite marrow activity, 
no splenic erythropoiesis and no significant 
increase in the rate of haemolysis.
Discussion
The five patients investigated appear to 
form a group representative of polycythaemia 
vera as determined by the clinical pictures 
and haematological findings. The splenomegaly 
associated with the condition is seen to vary 
in degree from that of an impalpable spleen 
to that of a fairly large spleen but never 
seems to reach the size often attained in 
chronic myeloid leukaemia and myelofibrosis.
In common with these diseases, however, occur 
other features such as asthenia, dyspnoea, 
abdominal discomfort, bone pains and gout.
It is also noteworthy that in polycythaemia 
vera there is often a bleeding tendency, such 
as seen in the two patients with severe gastro­
intestinal haemorrhage, despite the normal or 
high platelet levels, and yet there is also an 
increased liability to thrombotic complications. 
The elevated leucocyte and platelet counts are 
seen also in chronic myeloid leukaemia and 
myelofibrosis and megakaryocytie increase is 
a characteristic feature of the bone marrow in
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/myelofibrosis. Thus, from the clinical and 
haematological aspects, polycythaemia vera 
has much in common with chronic myeloid 
leukaemia and myelofibrosis.
Patients with polycythaemia vera usually 
are not anaemic unless there has been recent 
blood loss but the mechanism of blood 
production and destruction is of considerable 
interest. The results of the radioactive 
isotope studies are summarised in table 15. 
Although the iron uptake profiles can be 
interpreted only quantitatively and cannot 
be used as a precise quantitative estimation, 
it is seen that in only one of the five patients 
is there much increase in marrow radioactivity, 
in the others there is little increase and 
in one no significant alteration. This seems 
surprising in view of the appearance of marked 
hyperplasia seen on histological examination 
of the marrow. It would be expected that 
there should be a high uptake of iron for 
use of the proliferating red cells and this 
can only be explained by a failure of maturation
/or a failure of the release mechanism. A 
similar iron uptake pattern is reported by 
Finch et al (1956) in cases of untreated 
pernicious anaemia where again there is gross 
erythroid hyperplasia but low marrow iron 
uptakes. This, combined with the low iron 
utilisation, illustrates what Finch et al 
have termed "ineffective” erythropoiesis.
The marrow hyperplasia of polycythaemia vera 
usually extends the full length of the bones 
and as the marrow can expand to 6 to 8 times 
the normal amount (Crosby and Ackeroyd, 1952) 
it is of importance to note that the red cell 
mass is seldom more than twice normal even 
in the absence of significantly increased 
haemolysis (Vide infra). Thus, although the 
total red cell production is increased and 
the iron utilisation normal or high, this is 
not proportionate to the increased marrow 
cellularity and so favours the presence of 
’ineffective1 erythropoiesis. As a result 
the ’effective' erythropoiesis is ’diluted' 
over a much wider area than normal and this
/may account for the apparently low or normal 
marrow iron uptake patterns in most patients.
Lawrence et al (1953) describe splenic 
erythropoiesis, as determined by radioiron 
studies, in a few patients with polycythaemia 
vera. In such patients, however, they observe 
that the marrow is usually hypoplastic, aplastic 
or fibrotic and fails to take up radioactive 
iron. Furthermore, these patients usually 
have very large spleens and markedly elevated 
white cell counts. It seems probably that 
they are, in fact, early cases of myelofibrosis 
and this passage from one disorder to the other 
is very suggestive of an aetiological relationship.
Berlin et al (1951) describe two red cell 
populations in polycythaemia, one with a 
shortened life span and one with a normal life 
span, but other workers (London et al, 1949,
Szur et al, 1959) have found normal cell 
survival. Thus the overall picture may be 
that of a normal or slightly increased rate 
of haemolysis but in the five patients studied 
here a significant degree of haemolysis was
/noted in only one and this suggests that 
increased haemolysis is only of minor 
importance in polycythaemia vera.
The radioisotopic results demonstrate 
the relatively low marrow iron uptake yet 
normal or high utilisation. In one patient 
there is an absence of significant uptake 
in the marrow and spleen and a low iron 
utilisation. This patient also has the largest 
spleen and the highest white cell count and 
the history dates back 24 years to the time 
of diagnosis of polycythaemia. Although the 
bone marrow is still histologically hyperplastic 
and mature white cells only are present in 
the blood the radioiron patterns suggest 
that the disease is at a different phase 
in development than in the other patients.
The iron studies show changes in the fundamental 
pattern of erythropoiesis and resemble those 
of some patients with chronic myeloid leukaemia 
or myelofibrosis* Thus, the disease is probably 
in a ’transitional’ phase and, although splenic 
erythropoiesis has not yet developed, is one
/of the type described by Lawrence et al 
(1953) destined to develop myelofibrosis.
This is quite in keeping with the results 
of the investigations as the radioiron 
studies are a sensitive index of cellular 
activity and illustrate changes which are not 
yet reflected in the cruder histological 
features of the marrow.
This association of polycythaemia 
vera and myelofibrosis or myelosclerosis is 
well known and there have been several reports 
of patients with myelosclerosis who presented 
initially with polycythaemia vera (Stone and 
Woodman, 193$; Vaughan and Harrison, 1939; 
Marson and Meynell, 1949; Hutt, 1950).
It has, of course, been suggested that the 
development of fibrosis could be related to 
therapy but Wasserman (1954) found no good 
evidence to substantiate this. Korst et al 
(1956) stressed the association of these 
two disorders and found that myelofibrosis 
could be present during the polycythaemic phase 
as well as in the advanced or 'spent* phase.
/Furthermore, some well authenticated cases 
have been reported in which leukaemia has 
developed in untreated patients (hameshek,
1950).
All this evidence of transition from one 
disease to the other, the similarities of 
clinical picture and haematological findings, 
and the alteration of patterns of erythropoiesis 
points to a close relationship between 
polycythaemia vera and other myeloproliferative 
disorders.
Summary
Five cases of polycythaemia vera are 
described and the investigations recorded.
The patients appear to form a group 
representative of the condition.
The clinical and haematological features 
show considerable resemblance to the other 
myeloproliferative states already described.
The radioactive iron uptake patterns 
suggest diminished marrow production, despite 
the high blood counts, and this is explained 
on the basis of ’ineffective1 erythropoiesis.
Haemolysis appears to play little or 
no part in the final determination of the 
blood counts.
A case of 24 years duration is described 
and the radioiron studies indicate an impending 
’transitional* state. This patient seems to 
be one of the type likely to develop 
myelofibrosis or chronic myeloid leukaemia.
The evidence is discussed and is considered 
to support the relationship of polycythaemia 
vera to other myeloproliferative disorders.
L I G-UGrLIELMO1S DISEASE
Investigation Result
Haemoglobin
(g$)
7.4
P.C.V. ($Q 23
M.C.H.C. ( f o ) 32
W.B.C*
(per c.mm.)
2,300
Platelets 
(per c.mm#)
25,000
Reticulocytes
(*)
4
Table 16 The principal findings on
examination of the blood in a 
case of Di Guglielmo’s disease
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Di G-uglielmo (1923) described the rare 
and invariably fatal condition which now bears 
his name or alternatively is known as 
'erythraemic myelosis'. The disease is 
characterised by an abnormal proliferation 
of the red cell precursors in the bone marrow 
and yet, despite this hyperplasia, an anaemia 
which may be severe is always present..
During the period of study of myelo­
proliferative disorders one patient with this 
rare condition was seen and investigated 
with the following results.
Clinical Picture
The patient, a 77 year old man, was 
admitted to hospital because of breathlessness 
on exertion, tiredness and loss of weight over 
the previous four months. On examination, 
the mucous membranes and palmar creases were 
found to be pale and a few petechiae were 
seen on his legs. The liver and spleen were 
not palpable and no other physical abnormalities 
of note were detected.
*Dig. 64 Megaloblastic erythropoiesis in patient 
G-.McF. (Di G-uglielmo' s disease). (May- 
Grunwald-Giemsa x 1500). (reproduced by 
permission from the "Scottish Medical
Journal')
Fig. 65 Multinucleated well haemoglobinised 
red cells in patient G.McF. (Di 
Guglielmo's disease). (May-Grunwald- 
Giemsa x 1500). (reproduced by 
permission from the 'Scottish Medical
Journal1)
/Haematological Investigations
The principal features of the blood 
examination are recorded in Table 16. There 
was a normocytic normochromic anaemia. Blood 
films revealed anisocytosis and poikilocytosis 
and occasional nucleated red cells were seen. 
The white cell count was 2,300 cells per c.mm. 
and a differential count showed the cell types 
to be present in normal proportions. Few 
platelets were seen on examination of the blood 
films and the platelet count was only 
25>000 per c.mm.
Sternal marrow puncture was carried out 
and marrow tissue was easily obtained; smears 
and sections showed erythroid hyperplasia., 
Erythropoiesis was predominantly megaloblastic 
(fig.64) and many bizarre forms were seen.
A striking feature was the characteristic 
presence of well haemoglobinised multinucleated 
red cells (fig.65). Megakaryocytes and cells 
of the myeloid series appeared reduced in 
numbers but otherwise normal. Stainable iron 
was present in the marrow
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.Fig* 66 Radioiron profile in patient G.McF
(Di Guglielmo's disease)
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Fig. 67 Red cell survival by the radiochromium
technique in patient G.McF.
Radioisotopic investigations
The radioiron profile is seen in'fig.66
and the absence of a significant rise in
marrow counts is indicative of diminished
marrow uptake. There is no evidence of splenic
erythropoiesis. The low utilisation of the
injected radioactive iron (38%) in the
absence of iron deficiency (haemoglobin
7.4 g%, M.G.H.G. 32%, serum iron 115ug, total
iron binding capacity 155ug, stainable iron
present in the marrow) confirms grossly
deficient red cell production. Red cell half- 
51life, by the Cr technique, of 8 days was 
greatly diminished and indicative of a marked 
increase in the rate of haemolysis (fig.67). 
Thus, the anaemia is characterised by 
anisopoikilocytosis, the presence of occasional 
nucleated red cells in the blood and a low 
platelet count. Megaloblastic erythropoiesis 
is seen on marrow examination, many bizarre 
forms occur and many well haemoglobinised, 
multinucleated red cells are present. The 
anaemia appears to be due to marrow hypoplasia
/and an increased rate of haemolysis.
One of the striking features is the 
occurrence of anaemia in the presence of 
a histologically hyperplastic marrow. This 
is similar to the findings in untreated 
pernicious anaemia, where also there is 
the apparent anomaly of diminished, red 
cell production despite erythroid hyperplasia 
in the hone marrow. This suggests that although 
proliferation of the red cell precursors 
is taking place, the cells are not released 
from the marrow; thus erythropoiesis may he 
'apparent* or 'effective*. The difference 
between these two is what Finch et al (1956) 
term 'ineffective' erythropoiesis and this 
has been confirmed, as in this case of 
Di Guglielmo's disease, by radioiron studies.
Two further points of resemblance to pernicious 
anaemia are present: firstly, increased 
haemolysis is present in both conditions and 
secondly, erythropoiesis in each disease is 
predominantly megaloblastic. Here, however, 
the similarity ends for the defect causing
/megaloblastic erythropoiesis in pernicious 
anaemia is deficiency of vitamin B^. Serum 
vitamin levels have been recorded in 
only four cases of Di Guglielmo's disease 
and in three of these were high (Baldini 
et al, 1959) and in the other normal 
(Adams and Seaton, I960). Thus, the causation 
of megaloblastic change is by a different 
mechanism and this will be discussed in 
a later chapter.
Baldini et al (1959) in a study of 11 
cases of Di Guglielmo's disease found no 
evidence of an immunological mechanism to 
account for the increased haemolysis and 
concluded that the defect, leading to the 
rapid rate of erythrocyte destruction, was 
at a cellular level. Such a defect could 
originate in the existence of excessively 
fragile red cells and, indeed, it was 
suggested by Di Guglielmo (1942) that such 
cells were the result of the abnormal 
erythroblastic proliferation. As the marrow 
is normally able to expand to a degree
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/sufficient to cope with haemolysis six 
times as rapid as normal (Crosby and Ackeroyd, 
1952) the increased rate of haemolysis 
in this case must be only one factor in the 
production of anaemia and inadequate marrow 
production must be another. This impression 
is confirmed by the reticulocyte count which, 
though usually slightly raised, is not 
elevated in proportion to the degree of anaemia 
or haemolysis. The reticulocytes and nucleated 
red cells present in the blood may, in fact, 
be the consequence of abnormal erythropoiesis 
and resultant failure of the normal mechanism 
to regulate the release of solely mature cells 
into the circulation. All this evidence points 
to defective red cell production as the major 
factor in the production of anaemia and to the 
increased rate of haemolysis as a secondary 
or contributory factor.
This form of fpuref erythroblastic 
involvement is rare and it is more common 
to find mixed forms such as erythroleukaemia, 
(Di G-uglielmo, 1917) where the leucopoietic
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/tissue is involved in the proliferation 
as well as the erythropoietic tissue. It 
is of considerable interest and importance 
that some patients with fpuref erythraemic 
myelosis have developed erythroleukaemia with 
the passage of time (Schwartz and Critchlow, 
1952; Hindmarch and Wickham, 1955) and some 
have terminated as acute myeloblastic 
leukaemia (Discombe and Mchol, 1954). The 
description of such cases which pass from 
one phase to another has led Baldini et al 
(1959) to refer to the whole group as the 
Di Guglielmo syndrome and is strong evidence 
in favour of a relationship between 
erythraemic myelosis and other members of 
the myeloproliferative group.
Summary
A case of Di G-uglielmo*s disease 
(erythraemic myelosis) is described. The 
anaemia is due to a combination of defective 
red cell productions and an increased rate 
of haemolysis. There is no evidence of 
splenic erythropoiesis.
It is considered that the apparent 
marrow hyperplasia is due mostly to 
1 ineffective 1 erythropoiesis.
The development of erythroleukaemia and 
sometimes with myeloblastic leukaemia is 
considered evidence of relationship of these 
diseases.
IDIOPATHIC MEGAKABYOCYTIC 
THBOMBOCYTHAEMtA
Thrombocythaemia is the term applied 
to the presence of a persistently raised 
platelet count. This occurs secondarily in 
some cases of chronic myeloid leukaemia and 
some of polycythaemia vera but the occurrence 
of primary or idiopathic megakaryocytic
thrombocythaemia (haemorrhagic thrombocythaemia) 
is much more rare. Wintrobe (1956) records 
one case and other patients with this disease 
are reported by Fanger et al (1954) Woodrow 
and Cope (1955), and Fountain (1953). A 
review of the condition is made by Hardisty 
and Wolff (1955).
One case of this disease has been 
investigated and is reported here.
Clinical Picture
Idiopathic thrombocythaemia is not 
a hereditary disease and is said to occur 
mainly in elderly people (Whitby and Britton, 
1957). The principal features are splenomegaly, 
a liability to bleed from mucous membranes 
and a tendency to venous thrombosis. This 
patient, at the time of her first attendance
Fig. 68 Hepatomegaly and splenomegaly in 
patient J.D. with megakaryocytic 
thrombocythaemia.
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/at hospital in 1956 had noted spontaneous 
bruising for four months and had seen both 
fresh and altered blood in her stools on 
several occasions. She was seen to have many 
bruises and spleen was found to be palpable 
two finger breadths below the costal margin; 
by 1959 the spleen was rather larger and 
hepatomegaly also was present (fig.68). At 
this time also she had further severe 
haematemeses which necessitated the 
transfusion of blood.
Haematological Findings
The disease may be associated with 
polycythaemia (Uotila, 1938) when there has 
been no recent bleeding, or with anaemia 
after recent blood loss (Whitby and 
Britton, 1957). Leucocytosis is common, 
bizarre platelets are often seen in the 
blood and the platelet counts usually exceed 
one million per c.mm. At the time of first
attendance the figures recorded on 
patient J.h. were as follows: haemoglobin 
12.5 g per cent, white cell count, 35»200
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Table Differential white cell count in a case of 
idiopathic megakaryocytic thrombocythaemia.
/per c.mm., and platelet count, 1.35 million 
per c.mm. The differential white cell count 
is shown in table 17. Over the next three 
years, however, fluctuation in these levels 
was noted and the haemoglobin was seen to 
range from 10.4 g per cent to 17.6 g per cent, 
the white cell count from 25,000 to 50,000 
cells per c.mm. and the platelet count rose 
to the high reading of 2.14 million per c.mm. 
Histological examination of the bone marrow 
revealed normoblastic erythropoiesis with 
apparent reduction in the numbers of red cell 
precursors. There was, however, some myeloid 
hyperplasia and a marked increase in the number 
of megakaryocytes present (fig.69) which is 
typical of idiopathic thrombocythaemia.
It has been suggested that the bleeding 
tendency is due to a qualitative defect in 
the platelets as determined by the 
thromboplastin generation test (Hardisty and 
Wolff, 1955). A slight defect of this nature 
was demonstrated in this case when the platelets 
were reduced to 250,000 — 500,000 per c.mm.
Fig. 69 Marrow histology in patient J.D.
(megakaryocytic thrombocythaemia)
(Leishman x 150).
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/(Cook, I960). High, concentrations of these 
platelets, however, produced an inhibitory 
effect on thromboplastin formation as reported 
previously by Spaet et al (1956). It seems 
possible that in conditions of venous stasis, 
which would normally favour thrombosis, very 
high platelet levels may have an anti- 
thromboplastic effect (Cook, I960). On this 
basis treatment should aim at reducing 
platelet levels and radiophosphorus would, 
therefore, appear to be the treatment of choice. 
Radioisotope Investigations
The radioiron profile is seen in fig.70. 
There is a definite increase in marrow activity 
but no alteration in splenic activity. Thus 
the uptake j)attern is normal but the iron 
utilisation is only 22.6 per cent of the 
injected dose. The radiochromium studies 
indicate a normal red cell survival of 27 days 
and the spleen/liver ratio at this time is 
1.3/1 (fig. 71).
Thus the pattern is probably due to iron 
deficiency (haemoglobin 16 g%, M.C.H.C. 28%,
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Fiff. 71 Sequestration studies and red cell
survival by the radiochromium
technique in patient J.D.
/serum iron 20ug per 100 ml, total iron binding 
capacity 320ug per 100 ml) resulting in marked 
uptake of iron by the marrow; the low 
utilisation of the iron in the presence of 
a high haemoglobin and erythrocytosis 
(7.99 million per c.mm.) suggests that there 
is a defect of incorporation of iron into the 
red cells. There is no increased rate of 
destruction of the red cells and the spleen 
shows no evidence of either erythropoiesis 
or sequestration of the red cells.
This interesting patient appears to fulfil 
the criteria required for the diagnosis of 
idiopathic megakaryocytic thrombocythaemia 
(Beid, 1940). She has splenomegaly, hepatomegaly 
and a bleeding tendency. There was in the 
initial stages an anaemia and later a 
polycythaemia but this fluctuation is 
characteristic. The myeloid hyperplasia and 
leucocytosis are usually found but the striking 
feature is the greatly elevated platelet count 
and the presence of a marked increase in 
megakaryocytes in the marrow. Furthermore,
/the coagulation defect described previously 
in idiopathic thrombocythaemia has been 
demonstrated in this case.
The radioisotopic findings, carried out 
during a polycythaemic phase are of interest.
In contrast to the relatively low marrow uptake 
of radioactive iron seen in polycythaemia 
vera there is a very definite marrow uptake 
in this case. This is a significant finding 
as it occurs in the presence of reduced 
numbers of red cell precursors in the marrow 
and not, as in polycythaemia vera, in the 
presence of increased numbers. This, and the 
low iron utilisation despite an elevated 
red cell count, suggest that the defect is 
probably in incorporation of iron whereas 
in polycythaemia vera it appears to be a 
failure of the release mechanism which results 
in 'ineffective1 erythropoiesis. This shows 
that idiopathic megakaryocytic thrombocythaemia 
is, even in the polycythaemic phase, a 
separate entity and not merely a form of 
polycythaemia vera.
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/ There are, however, many resemblances 
to polycythaemia vera and some to chronic 
myeloid leukaemia and the tendencies to bleed 
and yet to thrombose are features common to 
most myeloproliferative diseases. On this 
basis it seems likely that idiopathic
megakaryocytic thrombocythaemia is a disease 
in its own right but that it is related to
the other myeloproliferative disorders.
Summary
A case of idiopathic megakaryocytic 
thrombocythaemia is described and seems 
typical of this condition.
The clinical and haematological 
features are discussed and found to 
resemble those of other myeloproliferative 
disorders.
The radioisotopic investigations 
demonstrate a pattern distinct from that 
of polycythaemia vera which is resembled 
closely in other ways.
Idiopathic megakaryocytic 
thrombocythaemia is considered to be a 
separate entity but one closely related to 
other myeloproliferative disorders.
'TRANSITION1 
MYELOPROLIFERATIVE STATES.
The myeloproliferative group of disorders 
comprises chronic myeloid leukaemia, 
myelofibrosis, and myelosclerosis, polycythaemia 
vera, megakaryocytic thrombocythaemia and 
erythraemic myelosis. These conditions have 
been studied and reported as have cases 
intermediate between chronic myeloid leukaemia 
and myelofibrosis. There remains the 
controversial question of other transitional 
disorders. The existence of such is supported 
by Rosenthal (1950) and Dameshek (1951) 
but opposed by Wintrobe (1951) and Leonard et 
al (1957).
Four patients who could not be given 
a precise diagnosis are now presented and 
discussed.
Patient - J.N.
Clinical Picture
This patient, a 54 year old male, 
presented first with joint pains of several 
months duration. He also complained of 
abdominal discomfort and was found to have 
a grossly enlarged spleen (grade 3) over
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/which friction was audible. The liver was 
palpable two finger breadths below the 
costal margin and a few small axillary nodes 
were detected. The patient did not appear 
to be anaemic and no other findings of 
significance were noted.
Haematological Findings
The haemoglobin was 13*4 g per cent but 
the M.C.H.C. was only 27.25 per cent which 
indicated iron deficiency even at this 
scarcely anaemic level. The white cell count 
was 20,500 per c.mm. of which 80 per cent were 
neutrophil polymorphonuclear leucocytes, 
though occasional myelocytes were seen.
The differential white cell count is seen 
in table 18. The platelet count was normal 
(210,000 per c.mm). Blood films revealed some 
hyrochromia of the red cells but the presence 
of a few myelocytes and a few nucleated red 
cells was noted. Ample marrow was easily 
obtained on sternal puncture and histological 
examination demonstrated hyperplasia of myeloid
72 Marrow histology in patient J.In
(May-Grunwald-G-iemsa x 660).
/and erythroid tissues and a marked incfea,se 
in the number of megakaryocytes present 
(fig.72).
Radioisotopic investigations
The radioiron profile is seen in fig.73. 
There is no significant uptake of radioactive 
iron by the marrow but there is a definite 
increase in the level of splenic radioactivity. 
The iron utilisation, despite iron deficiency, 
is only 43 per cent and the red cell half 
life is normal at 25 days. At this time the 
spleen/liver ratio is 2.1/1 (fig.74).
Thus the picture is that of marrow 
hypoplasia with splenic erythropoiesis.
The effective marrow output is low, as 
indicated by the iron utilisation, there is 
no irjcrease in haemolysis and the spleen 
does not appear to sequester red cells.
Comment
The histology of the marrow is 
characteristic of polycythaemia vera. The 
leucocytosis and peripheral blood findings are 
compatible also with this diagnosis. The
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R.jg. 74 Sequestration studies and red cell
survival by the radiochromium technique
in patient J.R.
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/gross splenomegaly, however, is greater than 
usually is- seen in polycythaemia vera and is 
an indication that the case may not be 
classical. The low marrow iron uptake and 
low utilisation of iron in the presence of 
apparent erythroid hyperplasia suggests 
’ineffective' erythropoiesis as occurs 
in polycythaemia vera; the low utilisation 
of iron, however, is not typical of polycythaemia 
vera. The presence of nucleated red cells 
and myelocytes in the blood and the occurrence 
of splenic erythropoiesis as indicated by the 
radioactive iron studies place this case in 
the category described by Lawrence et al 
(1953) as destined to develop myelofibrosis.
Thus, in this case the disease appears 
to be in a state of transition from 
polycythaemia vera to myelofibrosis.
Patient - J.McG.
Clinical Picture
This patient presented with exertional 
dyspnoea of one year's duration and following 
dental extraction about that time he had bled
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/considerably for five or six hours. Since 
then he had noticed a ready tendency to bleed 
or bruise. Pallor had been observed for 
four months and tiredness and lethargy for 
three months. On examination the mucous 
membranes were seen to be pale and the 
liver was found to be two finger breadths 
enlarged below the costal margin. The spleen 
was not palpably enlarged and no other findings 
of significance were detected.
Haematological Pindings
The patient was very anaemic and the 
haemoglobin was only 3*6 g per cent. There 
was no evidence of iron deficiency but the 
red cells showed anisocytosis, poikilocytosis 
and some degree of inacroeytosis. The white 
cell count was 11,000 per c.mm. and the platelet 
count 975*000 per c.mm. The differential 
white cell count was normal and the proportions 
of cells are seen in table 19. Marrow 
examination revealed a marked increase in 
megakaryocytes (fig.75) hut the surprising 
feature was a myeloid hyperplasia to a degree
Fig. 75 Marrow histology in patient J.McG.
showing megakaryocytic proliferation. 
(May-G-runwald-G-iemsa x 210)
Fig. 76 Marrow histology in patient J.McG. 
showing myeloid hyperplasia. 
(May-Grunwald-Giemsa x 375)
/compatible with the diagnosis of chronic 
myeloid leukaemia (fig.76). There was no 
maturation arrest and white cells were seen 
at all stages of development but erythropoietic 
tissue was scanty.
Radioisotopic Investigations
The radioiron profile is seen in fig.77 
and demonstrates a typical aplastic pattern 
with no evidence of splenic erythropoiesis.
The iron utilisation is only 8 per cent and 
the red cell survival time is more or less 
normal with Ti of 24 days (fig.7b).
Thus the anaemia is due to pure deficiency 
of red cell production and there is no significant 
increase of haemolysis.
Comment This patient presents a most 
interesting picture. The duration of the 
disease from the time of the first symptoms 
to the fatal outcome was only 18 months.
The spleen was never palpable yet the 
histological appearance of the marrow was 
akin to that of chronic myeloid leukaemia.
The white cell count however, was only
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Fig. 78 Red cell survival by the radiochromium
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/ll, 000 per c.mm. and the proportions of 
the various cells were normal. There is 
nothing to suggest hypersplenism to account 
for the normal white ceil count; there is no 
increase in haemolysis of the red cells and 
the platelet count is in fact very high.
It would be distinctly unusual to get a 
selective leucocytic destruction resulting 
in a normal differential white cell count 
in a case of true chronic myeloid leukaemia 
and it seems more likely that this is an 
aleukaemic or incipient chronic myeloid 
leukaemia.
The platelet count in chronic myeloid 
leukaemia may well be high but seldom reaches 
a level of one million per c.mm. and probably 
never reaches this level in the absence of 
a marked leucocytosis..
Thus the myeloproliferative process 
appears mainly to affect the megakaryocytes 
with a resultant high platelet count. The 
myeloid tissue also is affected but this 
proliferation has not yet resulted in any
ffig« 79 Illustration of abdominal mass
found on palpation in patient J*McD.
/abnormality of the white cells in the 
peripheral blood.
This disease, could, therefore, be 
classified as a transition state between 
megakaryocytic thrombocythaemia and chronic 
myeloid leukaemia.
Patient J»McD.
Clinical Picture
In 1956 this patient first presented 
with weakness and lassitude and was found to 
have marked hepatosplenomegaly. In 1959 she 
attended again with weakness, lassitude, breath­
lessness on exertion and swelling of the 
ankles. At this time, the spleen and liver 
were still palpable but the spleen appeared 
to be smaller than in 1956 and there was 
present below the spleen a large firm mass 
extending to the pelvis (fig.79). This mass 
appeared to be quite distinct from the spleen 
but no such mass had been noted in 1956.
G-reat difficulty was found in deciding the 
nature of this mass which was considered to 
be either pelvic tumour or ectopic spleen.
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Table 20 J*McD - Differential white cell count*
/Haematological bindings
In 1956 the haemoglobin was reported to 
be 14*1 g per cent and the white cell count 
16,000 per c.mm. but when the patient was 
seen for investigation in 1959 the haemoglobin 
had dropped to 7.3 g per cent and the M.O.H.C. 
to 28.1 per cent. There was then anisocytosis 
and poikilocytosis and some hypochromia of the 
red cells. The white cell count was 3,500 per 
c.mm. and the differential count is demonstrated 
in table 20; four nucleated red cells were 
seen per 100 white cells. The platelet count 
was low at 70,000 per c.mm. Marrow puncture 
yielded an almost 'dry tap' but histological 
examination of the aspirate showed about 
50 per cent of the cells to be myeloblasts. 
Radioisotopic Investigations
The radioiron profile is seen in fig.80. 
This shows some increase in the level of 
radioactivity of the marrow and the abdominal 
mass over the period of 100 hours but no 
significant alteration of the level of splenic 
radioactivity. Thus the abdominal mass
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ffig, 81 Sequestration studies and red cell
survival by the radiochromium technique
in patient J.McD.
/appears to contain erythropoietic tissue 
and is in all probability ectopic spleen.
Red cell survival time, Ti, is 20 days and 
the mass/liver ratio at this time is 
2.7/1 (fig.81), This confirms the impression 
that the mass is in fact spleen, and shows that 
in addition to producing red cells it sequesters 
and destroys red cells.
Thus the marrow is productive of red 
cells but the total red cell formation is 
diminished. There is increased haemolysis 
and the spleen, including the ectopic part, 
plays a part both in erythrocyte production 
and destruction. The anaemia appears to 
be due to combined hypoplasia and excessive 
haemolysis.
Comment
This interesting patient has possibly 
been a case of polycythaemia vera in 1956 
and has now developed anaemia with leucopenia, 
thrombocytopenia and nucleated red cells in 
the peripheral blood. The abdominal mass 
is shown to be spleen (confirmed later at 
laparotomy (fig.8 2 )) and is very large and
Pig. 82 Illustration of the findings at 
laparotomy in patient J.McD..
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/this indicates that the patient is probably 
one of the type destined to develop marrow 
hypoplasia which is now confirmed by radioiron 
studies. This is not the whole picture', however, 
as the marrow contains many myeloblasts; 
it seems likely that the patient is in 
fact developing a leukaemic process. While 
there is excessive haemolysis and sequestration, 
marrow hypoplasia seems to be the major factor 
in the production of anaemia but whether the 
low white cell and platelet counts are related 
to diminished marrow activity or to excessive 
destruction is not known. In view of the red 
cell sequestration it appears probable that 
’hypersplenism1 is the cause.
Thus the patient appears to be a case of 
polyeythaemia vera who has developed hypersplenism 
and marrow hypoplasia and is in the process of 
developing leukaemia.
Patient A.McG.
Clinical Picture
In 1946 this patient presented with 
pain and swelling of the legs and she had
/also noted excessive bleeding after dental 
extractions about this time. She was found 
to have a thrombophlebitis of the left lower 
leg. In 1950 she again attended and was then 
seen to be of ruddy complexion and the spleen 
was three fingerbreadths palpable below the 
left costal margin. Her condition was 
diagnosed as polycythaemia vera and she was 
thereafter treated by removal of one pint of 
blood at intervals over the next six years.
By 1956 she had pain and swelling of her 
joints and small yellow-white deposits were 
seen at some joints. She complained also of 
weakness and tiredness. Physical examination 
revealed gout and a thrombophlebitis and both 
liver and spleen were three to four finger­
breadths palpable below the costal margin. 
When seen for investigation in 1959 she had 
hypertension (blood pressure 190/100 mm.Hg) 
gout, and splenomegaly.
Haematological Bindings
When the patient first presented in 
1946 the haemoglobin was 17.1 g per cent
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Table 21 A.McG. - Differential white cell count
/and the white cell count 12,200 per c.mm.
By 1950 the haemoglobin had risen to 19.4 g 
per cent but in 1 9 5 6 the patient was anaemic 
and the level was then only 1 1 .1  g per cent 
and the white cell count 7 , 0 0 0  per c.mm. 
Platelets were noted to be abundant on 
examination of a blood film.
At the time of investigation in 1959 
the haemoglobin was 1 0 . 0  g per cent and the 
M.C.H.C. 27.25 per cent. The white cell count 
was 9 , 2 0 0  per c.mm. and the differential 
count is seen in table 21. The platelet 
count was elevated to as much as 600,000 per 
c.mm. Bone marrow histology showed the 
appearances of some red cell hyperplasia, 
marked white cell hyperplasia and gross 
megakaryocytic proliferation.
Radioisotope investigations
The radioiron profile is seen in fig.8 3 . 
There is only slight increase in the 
radioactivity of the marrow and none of the 
spleen. The iron utilisation is very low, 
only 17 per cent of the injected dose. Red
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Fig. 83 Radioiron profile in patient A.McG. 
(* transition* disease)
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Fig* 84 Sequestration studies and red cell
survival by the radiochromium technique
in patient A.McG.
/cell survival T£ is 30 days and there is no 
significant sequestration of red cells by 
the spleen as the spleen/liver ratio at is 
1.9/1 (fig.8 4 ).
Thus the anaemia is due to diminished 
erythrocyte production and the spleen plays 
no significant role in either production or 
sequestration of red cells.
Comment
This patient appears to have been a case 
of polycythaemia vera and she has now entered 
an anaemic phase due to the development of 
functional hypoplasia of the marrow. Although 
the precursors of all three cellular elements 
of the blood are involved in the proliferative 
process in the marrow, the megakaryocytes 
principally are affected. As there are no 
immature cells in the blood and no splenic 
erythropoiesis the case is not as yet one of 
the type described by Lawrence (1953) but 
seems to be progressing towards this state. 
Furthermore, the marked megakaryocytic increase 
and the elevated platelet count suggest that 
thromboeythaemia may well be developing.
/ Thus, it seems likely that the disorder 
in this patient lies between megakaryoeytic 
thrombocythaemia and 'spent* polyeythaemia 
vera.
Discussion
Many of the so called 'myeloproliferative' 
diseases can be given a precise diagnosis.
These diseases, therefore, differ in many 
ways and a different set of criteria is 
demanded for each disease. There is however, 
a considerable overlap of features and this 
has been the basis for the hypothesis of 
relationship of the myeloproliferative diseases.
If this hypothesis is to be substantiated there 
must be more than a mere demonstration of 
similarity of disorders: if relationship is 
intimate then there should occur not uncommonly 
forms which possess features of myeloproliferative 
disease but do not satisfy the criteria for any 
one diagnosis. These 'transitional* forms 
should resemble closely two of the recognised 
diseases and yet apparently lie between the 
two. Four such cases have been described and
/comment has been made on each. One appears 
to lie between polyeythaemia vera and leukaemia, 
one between polyeythaemia vera and myelofibrosis, 
one between megakaryocytic thromboeythaemia 
and chronic myeloid leukaemia and one between 
spent polyeythaemia vera and megakaryocytic 
thromboeythaemia. Furthermore, description 
has alreaay been made of two cases which lie 
between chronic myeloid leukaemia and 
myelofibrosis.
Thus, of twenty seven cases investigated, 
six are transitional forms of myeloproliferative 
disease and represent a fairly high incidence 
of 'impure* forms. The not uncommon occurrence 
of such 'linking' forms is considered strong 
evidence in favour of relationship of the 
myeloproliferative disorders.
Summary
Four cases are described which do not 
conform to the criteria for any precise 
diagnosis. These cases resemble more than one 
disease and apparently lie between these 
diseases. Such cases appear to be 
'transition1 forms as described by 
Dameshek (1951). The occurrence of such 
'linking* forms is considered important 
evidence in favour of the relationship of the 
various myeloproliferative disorders.
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S E C T I O N  III
Cases of polyeythaemia vera, erythraemic 
myelosis and megakaryocytic thromboeythaemia 
are described and the results of the 
investigations discussed.
There are many clinical and haematological 
features in common but a precise diagnosis can 
be determined by careful study of these 
features.
The radioisotopic patterns show that 
there is no pattern of erythrocyte production 
and destruction which is specific for any of 
these diseases though markedly increased 
haemolysis is not common in polyeythaemia vera. 
ineffective1 erythropoiesis is a feature of 
note in polyeythaemia vera and in erythraemic 
myelosis.
Pour cases are discussed which appear to 
be transition forms, resembling one disease 
in some ways and another disease in other ways. 
No precise diagnosis can be made in these 
cases.
The results of the investigations and 
the not uncommon occurrence of 'transition*
/forms is considered strong evidence in 
favour of relationship of the whole group 
of myeloproliferative disorders.
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MYELOPROLIFERATIVE DISEASE
The anaemia of myeloproliferative 
disease has been shown to be due mainly to 
diminished red cell production or to an increased 
rate of haemolysis or to a combination of 
these mechanisms. In some states, however, 
comment has been made on the occurrence of 
a histologically hyperplastic marrow in 
association with a diminished effective 
cellular production and this has been 
compared with the findings in pernicious 
anaemia. There are several possible 
explanations for this but the most likely 
mechanism appears to be a failure of release 
of the cells from the marrow cavity., The 
resemblance to pernicious anaemia could be 
carried a step further in the presence of 
megaloblastic erythropoiesis and this finding 
is reported in Di Guglielmo's disease 
(Baldini et al, 1959, Adams and Seaton, I960) 
and in other forms of myeloproliferative 
disease (Wellington and Whitcomb, I960). The 
occurrence of megaloblastic erythropoiesis 
suggests a defect most probably in the
1 5 9
/absorption or metabolism of vitamin 3 ^  or 
of folic acid. If this defect is in the 
absorption of vitamin or folic acid then 
a satisfactory response should be obtained 
by the parenteral administration of the 
deficient substance. Some workers on 
myelofibrosis (Hutt, 1950, Hickling, 1953) 
record no response to injections of liver 
extract which suggests that the defect is 
more likely to be in the metabolism of one 
or other or both of these substances. On the 
other hand Croft (1956) records a patient 
with a megaloblastic anaemia who responded 
on two occasions to injections of liver 
extract. Thus, knowledge of megaloblastic 
erythropoiesis in myeloproliferative disease 
is limited and information on other cases with 
megaloblastic erythropoiesis may provide some 
further insight into this interesting state.
Three cases with suspected abnormality 
of vitamin or f°lic acid metabolism are
described.
160
/Case Report 1 - Myelofibrosis
Patient M.C. first attended hospital 
in 1949 because of lethargy and abdominal 
swelling. The spleen was markedly enlarged, 
sternal puncture yielded a 'dry tap' and there 
was gastric achlorhydria. Blood films revealed 
a macrocytic picture. She was treated at 
that time by thyroid extract without benefit. 
Three months later she was readmitted and 
examination of the blood then revealed a 
haemoglobin of 65 per cent, a red cell count 
of 1.8 million per c.mm., a colour index of 
1.8, a white cell count of 5,200 per c.mm. 
and a reticulocyte count of 1 per cent.
Blood films again showed macrocytosis and 
poikilocytosis. She was then treated with 
'Anahaemin1 and the reticulocytes rose to 
12 per cent on the seventh day after the 
first injection. Within two months the 
haemoglobin was recorded as 100 per cent 
but the blood film remained macrocytic.
Thus, she responded to 'Anahaemin' at an 
early stage in the development of
1 6 1
/myeloproliferative disease.
The reason for this response remains 
obscure but it seems likely that the patient 
was at that time suffering from a deficiency 
of vitamin or folic acid. In the more 
advanced stages of myelofibrosis, however, 
when anaemia returned there was no response 
to vitamin and no further evidence of 
vitamin B^  or folic acid deficiency. Thus, 
there may be a stage early in the development 
of myelofibrosis, where deficiency of 
vitamin B ^  or folic acid occurs.
Case report 2 - myelofibrosis
Patient M.G-.B. first attended hospital 
in 1956 with abdominal discomfort and lethargy. 
The spleen was markedly enlarged. Examination 
of the blood revealed a haemoglobin of 
5,1 g per cent, a red cell count of 
1.3 million per c.mm., a colour index of 1.3* 
a haematocrit of 15 per cent, a mean 
corpuscular volume of 115 cu and a reticulocyte 
count of 1 per cent. Marrow puncture yielded 
a dry tap but examination of the peripheral
to to® Mxaxto
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/blood films revealed the presence of some 
megaloblasts (fig.55). Free acid was found 
in the gastric secretion. The serum 
vitamin B12 level (Hutner et al, 1956) 
was 25 uug/ml. Following administration of 
vitamin B -^2 ^be reticulocyte count rose to a 
maximum of only 6 per cent by the tenth day. 
The absorption of radioactive vitamin B
C U
( Co) was estimated by the urinary excretion 
method (Schilling, 1953) as described by 
Adams and Seaton (1961). This gave normal 
results both with and without intrinsic 
factor, 23.8 per cent and 23*2 per cent 
respectively of the dose given being excreted 
in the urine within 24 hours.
The low serum vitamin B ^  level is 
therefore not attributable to malabsorption 
and is an unusual finding in myeloproliferative 
disease as Mollin and Ross (1955) have 
described very high levels in cases of chronic 
myeloid leukaemia and moderately high levels 
in a few cases of myelofibrosis. The low 
serum B12 level, however, and the presence
Examination Result(uug/ml.)
Total serum vitamin B^p 150
Free serum vitamin B^p 25
Bound serum vitamin B^p 125
Serum vitamin B^p 
binding capacity.
845
Table 22 Results of serum vitamin B^p
investigation by microbiological assay 
in patient Gr.McP«
/of megaloblasts in the peripheral blood 
before but not after administration of 
vitamin suggest an abnormal metabolism 
or excessive utilisation of vitamin B ^ .
The cause of this is probably related to 
the basic myeloproliferative process but 
the mechanism of its production is not clear., 
Case Report 3 - Pi Guglielmo's disease
Patient G. McF. first attended hospital 
because of symptoms of anaemia. The 
haemoglobin level was 7.4 g per cent, 
haematocrit 23 per cent and the reticulocyte 
count 4 per cent. Sternal marrow examination 
revealed predominantly megaloblastic 
erythropoiesis and free acid was present 
in the gastric juice. Serum vitamin B ^  
levels were normal (table 22) and radioactive 
vitamin B12 (58Co) absorption (Schilling test) 
also appeared normal with a 24 hour urinary 
excretion of 1 8 .4  per cent of the dose 
administered. Polic acid clearance also was
normal (table 23).
Thus there was no demonstrable deficiency
Time 
after injection 
(min)•
Result 
(m ug/ml).
3 208
13 70
30 50
Table 23 Folic acid clearance in patient
G.McF. (after intravenous injection 
of 0.9 mgm. folic acid)0
/of vitamin B12 or of folic acid and the 
administration of these substances had no 
effect.
There is little information on 
megaloblastic erythropoiesis in Di Guglielmo's 
disease but Baldini et al (1959) record 
megaloblastic erythropoiesis in 11 cases. 
Dameshek and his co-workers (Dameshek, 1958; 
Dameshek and Baldini, 1958; Baldini et al,
1959) stress the importance of megaloblastosis 
in relation to the aetiology of the disease.
It is generally accepted that megaloblastic 
erythropoiesis represents a deficiency or 
deficient utilisation of vitamin of 
folic acid or their derivatives at some stage 
in the development of the red cells. Serum 
vitamin B^2 levels appear to have been 
estimated in only 3 other cases (Baldini et al, 
1959) and were high whereas in this case 
the result was normal.
In addition there was no evidence of 
abnormality in the binding of vitamin B^2 
to the serum protein. The folic acid clearance
165
/was normal thus excluding folic acid deficiency 
(Ghanarin et al, 1958),
There were therefore none of the usual 
abnormalities of vitamin B or folic acid 
metabolism but defective utilisation is not 
excluded. In this way the megaloblastosis of 
Di Guglielmo's disease appears to resemble 
that caused by anticonvulsant drugs 
(G-irdwood and Lenman, 1956; Chanarin et al, 
1958a) although these anaemias respond to 
folic acid or occasionally to vitamin B^.
Thus the megaloblastosis of Di Guglielmo1s 
disease may be due to a defect in the 
metabolism of vitamin B-^ or folic acid 
at a cellular level.
Summary
Three cases with evidence of abnormality 
of vitamin or folic acid metabolism are 
described. Two of them were patients with 
myelofibrosis and the other had Di Guglielmo*s 
disease.
In myelofibrosis the abnormality appears 
to be due to vitamin deficiency or 
metabolism.
In Di Guglielmo*s disease it seems likely 
that the defect is at a cellular level 
and may concern either vitamin B.^ or folio 
acid metabolism.
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INFECTION
AID
HYPO GAMMA(tLOBULINAEMIA
It has for many years been apparent 
that patients with leukaemia are particularly 
susceptible to infection. The reason for this 
is still not clear; the increased incidence 
of infection has been attributed to poor 
state of health of these patients especially 
in the later stages of the disease. The high 
white cell counts of chronic myeloid and 
chronic lymphatic leukaemia afford no 
protection to these patients and this 
presumably is due to the fact that the great 
majority of the cells are abnormal.
It has been noted in recent years that 
hypogammaglobulinaemia, whether primary or 
secondary, leads to increased susceptibility 
to infection. Jim and Reinhard (1956) reported 
one patient with chronic lymphatic leukaemia 
and agammaglobulinaemia. Since then several 
reports of secondary hypogammaglobulinaemia
in the leukaemias and in myeloproliferative 
disease have been published. (Jim, 1957;
Hudson and Wilson, 1957; Teitelbaum et al, 
1959). In view of the possibility of this
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/occurrence in myeloproliferative disease and 
its probable relation to infection, a study 
of the serum proteins was carried out on 
12 normal controls and on 10 patients with 
myeloproliferative disease.
Results
Control subjects
The results in the 12 healthy normal 
adults aged 21 years to 50 years, who acted 
as controls are seen in table 24* The serum 
gammaglobulin in normal subjects is over 
500 mgm. per 100 ml. (Cohn et al, 1944;
Hawk et al, 1947) and the figures obtained 
in this series are in agreement. Only one 
control subject had a gammaglobulin level 
of less than 500 mgm. per cent with an 
estimated 482 mgm. per cent and this slight 
difference is within the error of the method. 
Myeloproliferative disease
The results in the 10 patients with 
myeloproliferative disease are seen in table 25• 
Two patients with polycythaemia vera, one 
patient with ‘transition1 myeloproliferative 
disease and one patient with chronic myeloid
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/leukaemia had normal levels of gammaglobulin.
One patient with 'intermediate1 disease was 
examined and found to have hypogammaglobulinaemia 
with a level of 290 mgm. per cent. Of 5 patients 
suffering from myelofibrosis, 2 had 
hypogammaglobulinaemia with levels of 467 mgm. 
per cent and 286 mgm. per cent.
Thus, hypogammaglobulinaemia was found 
in 3 out of 10 patients with myeloproliferative 
disease.
There were only two instances of bacterial 
infection during the period of observation of 
these 10 patients and both infections occurred 
in patients with hypogammaglobulinaemia.
Case reports of patients with bacterial infections 
1* Patient M.B., with 'intermediate* disease, 
as shown on examination of peripheral blood 
and bone marrow trephine, had had a large 
spleen for at least 3 years and developed 
a haemolytic anaemia which required frequent 
blood transfusion. As splenic irradiation 
and steroid therapy failed to control the 
haemolytic process splenectomy was carried out. 
Following this operation the patient improved
/initially but later developed pyrexia,
cough and a purulent sputum. The operation 
wound became infected and culture of the 
pus gave a heavy growth of coagulase 
positive staphylococci. She then developed 
an abscess in the left subcostal region and 
pus aspirated from this site gave a similar 
growth. At this time her serum albumin was 
3*3 g per cent, serum globulin 1.6 g per cent 
and the gammaglobulin level was 290 mgm. per 
cent. Despite antibiotic therapy her 
condition deteriorated steadily and she 
died 2 months after splenectomy.
2. Patient M.C., with myelofibrosis, had 
been known to have gross splenomegaly for 
10 years. She had been in hospital on 
several occasions for treatment of her 
myelofibrosis. In 1959 she was readmitted 
because of nausea, vomiting, lassitude, 
pyrexia (104°F) and rigors. A growth of 
E. Goli was obtained from urine and blood 
cultures on several occasions. At this time 
her serum albumin was 2.9 g per cent,
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/serum globulin 1.0 g per cent and the 
gammaglobulin level was 286 mgm. per cent.
She was treated with chloramphenicol and her 
symptoms subsided and the temperature returned 
to normal. She remained well for a further 
3 months before eventually dying in severe 
shock after splenectomy.
Discussion
The increased incidence of bacterial 
infections in the leukaemias is well known 
and although this could be related to abnormalities 
of the leucocytes it seems likely that low 
gammaglobulin also plays an important part 
in some cases. The occurrence of 
hypogammaglobulinaemia in association with the 
only two infective episodes in the 10 patients 
examined is much in favour of a direct 
relationship. It is possible that infection 
and toxaemia could suppress gammaglobulin 
formation but this seems improbable for two 
reasons; firstly, infection is the usual 
stimulus to increased production of gammaglobulin 
and secondly, in primary hypogammaglobulinaemia 
the low levels persist after eradication of
173
/infection and this has been observed also 
in hypogammaglobulinaemia secondary to leukaemia 
and reticuloses (Teitelbaum et al, 1959).
It seems more probable that the 
hypogammaglobulinaemia is a result of the 
disease and when it occurs, leads to an 
increase in the individual susceptibility to 
infection.
A striking feature is the severity of the
infections encountered. One patient died as a
result of bacterial infection but the other
patient survived despite a severe urinary tract
infection and septicaemia. It is said that 
hypogammaglobulinaemia occurs late in the
disease (Ultmann et al, 1959) and this is in
agreement with the 3 examples found in this
series. All three patients are now dead.
One had myelofibrosis for almost 11 years and
the other for at least 3 years and the patient
with *intermediate' disease had attended
hospital for over 3 years. All three died
at a stage when treatment had little or no
effect on the primary process and it does
appear that they were all advanced cases.
/ In view of the not uncommon occurrence 
of hypogammaglobulinaemia in myeloproliferative 
disease and of the severity of infection which 
may ensue, routine investigation of the 
serum proteins in all cases with bacterial 
infection or unexplained pyrexia is desirable.
Summary
Serum protein electrophoresis was 
carried out on 10 cases of myeloproliferative 
disease and hypogammaglobulinaemia was found 
in 3 patients; two of these had myelofibrosis 
and the third was classed as 1intermediater 
disease.
The only two instances of bacterial 
infection encountered in the 10 patients
occurred in patients with hypogammaglobulinaemia.
The severity of the infections which may 
be associated with hypogammaglobulinaemia is 
stressed and it is thought that this is more 
likely to occur in advanced cases of 
myeloproliferative disease.
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C h a p t e r  13
URIC A d D  STUDIES 
AND GOUT
1 7 7
The occurrence of gout in 
myeloproliferative disease dates back at least 
to 1889 when Duckworth included a probable 
case of chronic myeloid leukaemia in his 
treatise on gout. This association was 
thought to be coincidental and more recently 
Forkner (1938) considered the simultaneous 
occurrence of gout and leukaemia to be so 
rare that any real relationship was doubtful.
Hickling (1937), however, reported cases of 
non leukaemic myelosis with gouty arthritis 
and hyperuricaemia; later he wrote of 9 cases 
with gout, splenomegaly and immature cells in 
the circulating blood and observed that 5 of 
these had been polycythaemic at some stage 
(Hickling, 19533)* Further examples of this 
association of gout with polyeythaemia vera 
were described by Beattie and Withey (1953)*
The occurrence of gout in myeloproliferative 
disease extends also to myelofibrosis and 
myelosclerosis and korst et al (1956) found 
5 of 14 patients to have blood uric acid levels 
of over 7 mgm.per cent; 2 of these patients had
Patient Diagnosis Gout Serum uric acid 
(mgms.$)
Li.G.B. Mf. - 8.7
J.C. Mf. + 10.5
A.McA. P.V. + 8.1
P.P. P.V. - 9.2
J »C . P.V. + 8.5
J.F. T - 9.4
A.McG. T + 9.0
Table 26 The incidence of gout in the 7 patients
with elevated serum uric acid levels.
(Mf. as myelofibrosis; P.V. = polycythaemia 
vera; T = *transition1 disease).
1 7 8
/gout. Hickling (1953) reported 2 cases of 
myelosclerosis with gout and it is of interest 
that one of these patients had attacks of 
gout after each of 7 courses of splenic 
irradiation. Leonard et al (1957) record 
another such patient who developed gout after 
X-ray treatment for polycythaemia vera.
The occurrence of gout in myeloproliferative 
disease is related to the increased uric acid 
metabolism in these patients. The precipitation 
of attacks of gouty arthritis by X-ray treatment 
probably is due to the rapid breakdown of cells 
and their nucleic acids, the excessive release 
of uric acid and the consequently high blood 
uric acid levels.
Serum uric acid levels and urinary uric 
acid excretion were estimated in 24 patients 
with myeloproliferative disease.
Results
1. G-out and serum uric, acid levels
A serum uric acid level of over 7 mgm. 
per cent was found in 7 of the 24 patients 
examined and 4 of these 7 had gout (table 2 6 ).
Patient
Urinary uric acid excretion
mgm. /2 4 hours mgm./kg' / 24 hours
A,McA• 657 11.1
P.IT. 413 6.0
i v l  •  o  • 603 10.0
J.C. 394 4.8
Mean 517 8.0
Table 27 Urinary uric acid excretion in 4 patients 
with polycythaemia vera
Patient
Urinary uric acid excretion
mgm. /2 4  hours mgm./Kg. /2 4  hours
A .S. 755 14.0
M.G.B. 1500 23.1
R.C • 596 9.6
S.H. 802 14.8
J.G. 983 11.8
;
| J. C 0 346 5.2
!
1 M.C • 1 950 17*6
| T.Q. 1053 22 .4
| Mean 87 6 14o8
Table 28 Urinary uric acid studies in 8 patients 
with myelofibrosis.
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/Thus, a high serum uric acid level did not 
necessarily indicate gouty arthritis but gouty 
arthritis always was associated with a high 
serum uric acid level. Of the 4 patients 
with gout two had polycythaemia vera, one had 
myelofibrosis and the other was classified 
as 'transition* myeloproliferative disease.
Gout and high serum uric acid levels are 
obviously not related to the level of the 
peripheral blood white cell count;* in chronic 
myeloid leukaemia where the white cell counts 
numbered hundreds of thousands there was no 
case of gout and no raised serum uric acid level; 
and in polycythaemia vera where the highest 
white cell count was 40,000 per c.mm. three 
patients had elevated serum uric acid levels 
and two of these had gout.
2. Urinary uric acid excretion
Polycythaemia vera
The results are seen in table 27. The 
mean 24 hour urinary uric acid excretion is 
517 mgm. and the mean 24 hour excretion per
kilogram of body weight is 80 mgm. These
Patient
...  .... |
Urinary uric acid excretion
mgm. /2 4  hours mgm./Kg/2 4  hours
A.R. 1115 13.5
C.L. 861 14.8
E.W. 953 19*9
J.L. 1260 17 oO
M.M. 1773 37.7
~ 'Mean 1192 2 0 o6
Table 29 Urinary uric acid studies in 5 patients 
with chronic myeloid leukaemia
Patient
Urinary uric acid excretion
mgm/2 4 hours mgm/kg/2 4 hours
M.B. 960 15.5
W.M. 220 3ok
J.McG. 452 8.2
J.N. 1067 18.1
J .McD • 596 9.9
A.McG. 533 7.7
Mean 488 10.5
Table 30 Urinary uric acid studies in 6 patients
with ’intermediate’ or ’transition’ disease
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/values are a little above the mean normal 
levels of 399 mgm. per 24 hours and 8 mgm. 
per kilogram of body weight per 24 hours.
(Sandberg et al, 1956) but there is overlap 
of the individual levels.
Myelofibrosis
The results are seen in table 2 8 .
There is a wide range of individual results 
from within normal limits to well above 
normal but the mean 24 hour excretion is 876 mgm. 
and the mean 24 hour excretion per kilogram of 
body weight is 14.8 mgm. Thus, both these 
values are well above the normal and much 
higher than the levels found in polycythaemia vera. 
Chronic myeloid leukaemia
The results are seen in table 29.
Again there is a wide range of individual 
results but the mean results are well above 
normal. The mean 24 hour excretion is 1192 mgm. 
and the mean 24 hour excretion per kilogram of 
body weight is 20.6 mgm.
Thus, the mean excretion in chronic myeloid 
leukaemia is greater than in either polycythaemia
/vera or myelofibrosis.
'Intermediate1 and ’transition* cases 
The results are seen in table 3 0 .
As might be expected with the wide variety of 
disorders included in this group the results 
range from normal to very high. The mean 
value for 24 hour excretion is 488 mgm. and 
for 24 hour excretion per kilogram of body 
weight is 10.5 mgm.
Megakaryocytic Thrombocythaemia
The one patient with megakaryocytic 
thrombocythaemia had a 24 hour excretion of 
625 mgm. i.e. an excretion of 13.3 mgm. per 
kilogram of body weight per 24 hours. Thus 
both values are higher than normal.
Discussion
The relationship between gout and 
myeloproliferative disease is well known 
but while gout is obviously secondary to 
elevated blood uric acid levels, although 
not a necessary accompaniment of them, the 
problems of uric acid metabolism in these 
diseases are not yet solved. It is doubtful
/if many conclusions are justified from 
the results obtained in this small series 
as many factors influence the findings and 
affect their interpretation. Firstly, 
urinary excretion of uric acid will partly 
depend on renal function which is known to 
become impaired in some cases of long standing 
gout with elevated blood uric acid levels; 
secondly, the contribution to uric acid 
metabolism by non-haemopoietic tissue is not 
known; thirdly, the peripheral blood white 
cell count is not necessarily a true reflection 
of total white cell mass; and, fourthly, the 
white cell survival time in these cases is not 
known. For these reasons, impressions only 
are gained from studies of this type and 
additional information is required before 
these can be substantiated.
The total urinary excretion of uric acid 
is shown to be very high in chronic myeloid
leukaemia, moderately raised in myelofibrosis
and only slightly increased in polycythaemia
vera. The same order is maintained when the
/figures are corrected for the influence of 
body weight. This suggests that the white 
cell count may be related to the urinary 
uric acid excretion but, as already mentioned, 
the occurrence of gout is not related to white 
cell count. Further, the mean serum uric acid 
level is greatest in polycythaemia vera, next 
in myelofibrosis and least in chronic myeloid 
leukaemia i.e. the reverse order; this, however, 
is the order of the frequency of gout as a 
complication of these diseases.
It is suggested that the differences shown 
to occur in uric acid excretion and blood uria 
acid levels in the disorders studied may be 
related to fundamental differences in the 
disease process. However, not only is there 
some overlap, but the wide scatter of results 
in the 'intermediate1 and 'transition* group 
of cases gives an impression of some common 
factors which suggest relationship between 
the disorders.
Summary
Urinary uric acid excretion and serum 
uric acid levels were estimated in 24 patients 
with myeloproliferative disease. The 
relationship of gout to uric acid metabolism 
is discussed.
Different patterns are seen to occur in 
different disorders. There is some overlap 
which, when considered with the wide scatter 
of patterns in 'transition' cases, suggests 
that although each disease may be a separate 
entity there are probably factors common to all.
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C h a p t e r  14
RADIOLOGICAL FEATURES OF 
MYELOPROLIFERATIVE DISEASE
Fig. 86 Chest X-ray in polycythaemia vera.
(Patient J.C.)
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There are few radiological features of 
importance in the myeloproliferative group 
of diseases with the exception of myelofibrosis. 
In the other members of this group any 
radiological features present are usually 
secondary to the disease rather than part 
of the disease.
Thus, in polycythaemia vera the increased 
blood volume may lead to increased pulmonary 
vascular markings and may also, as a result 
of the increased cardiac work, produce an 
enlargement of the cardiac shadow. The cardiac 
size may sometimes be increased because of 
systemic hypertension. Of the five patients 
with polycythaemia vera, cardiomegaly was 
noted in two, and increased pulmonary vascular 
markings in three patients. These appearances 
can be seen in fig. 86. Gout is occasionally 
seen in polycythaemia vera, secondary to 
increased uric acid metabolism, and was found 
clinically and radiologically in two patients.. 
Slight osteoporosis was noted in two patients 
but is not assumed to be related to the
Fig. 87 Chest X-ray in patient M.M. with 
chronic myeloid leukaemia.
/diagnosis of polycythaemia vera.
No radiological abnormalities were found 
in the patients with Di G-uglielmo's disease 
and megakaryocytie thrombocythaemia. Skeletal 
abnormalities are rare in chronic myeloid 
leukaemia. Craver and Copeland (1935) in a 
study of 82 cases of myeloid leukaemia found 
only one patient with radiological changes. 
This patient, a female aged 59 years, had a 
white count up to but never exceeding 34,000 
per c.mm., myelocytes were a constant finding 
in the peripheral blood and the X-rays showed 
mottling at the upper ends of the femur.
Thus, even this one patient was probably a 
case of myelofibrosis. None of the 5 cases 
in this study had radiological changes in the 
skeleton although X-ray of the chest in one 
patient revealed a left sided pleural effusion, 
mottling of the right lung and an enlarged 
right hilum (fig.87). These appearances 
indicated extension of the leukaemic process 
to the hilar glands and to the pulmonary 
parenchyma. At this time, of course, the
Fig. 88 X-ray appearances of gout in patient 
A.McG-. with ’transition* disease.
/disease was in its terminal stages.
In the radiological study of the 
'transition' myeloproliferative diseases 
no skeletal abnormalities were found apart 
from the appearances of gout in one patient 
(fig.88).
The most interesting myeloproliferative 
disorder from the radiological point of view 
is, of course, myelofibrosis. Radiological 
changes are common in this disease and are 
usually found in one third to one half of the 
cases examined. Rosenthal and Erf (1943) 
found radiological changes in 6 of 17 patients, 
Korst et al (1956) in 11 of 22 patients 
and Mulcahy (1957) in 9 of 19 patients 
investigated. The bones most frequently 
affected are those constituting the central 
part of the skeleton and changes are commonly 
seen in the ribs, vertebrae, pelvis, femora 
and humeri. Abnormalities distal to the elbow 
and knee joints are much less common but 
have been recorded (Mulcahy, 1957) and the 
skull is said to be exempt from changes
N O R M A L
Fig. 89 Comparison of normal humerus and
a humerus with the early changes of 
myelofibrosis (patient T.Q.)
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/(Schinz et al, 1951; Leonard et al 1957).
The usual changes are of widening and 
coarsening of the trabeculae. There are 
often areas of irregular deposition of bone 
and patches of osteoporosis which result 
in a granular or mottled appearance in the 
medulla of the long bones. Despite the 
increased density of the bone, the cortex 
usually is not thickened although the inner 
aspect may be rarefied and appear to merge 
with the medulla.
The early radiological changes may prove 
difficult to detect and Brailsford (1953) 
recommends comparison with X-rays from 
normal subjects. Even using this technique, 
Leonard et al (1957) find difficulty and state 
that skeletal radiographs are the least useful 
of all the diagnostic procedures undertaken 
in their series of patients. There is no 
doubt, however, that this technique can be of 
value in detecting early changes in some 
patients (fig.89). As the radiological changes 
depend on alteration of the bony structure,
Fig. 90 Changes of myelofibrosis at the upper 
end of a femur (patient M.G-.B.).
Fig. 91 Changes of myelofibrosis at the lower 
end of a femur (patient M.G-.B.).
/some correlation would be expected with 
the histological features of the bone marrow. 
Nelson (1954) found no X-ray changes in one 
patient in whom the marrow trephine showed 
increased trabeculae but Richmond and Duncan 
(1956) noted a close relationship between 
radiological appearances and the histological 
features in 8 patients with radiological 
changes. Leonard et al (1957) classified 
patients on histological appearances as early, 
intermediate or late but found an early case 
with radiological changes and some late cases 
with no radiological changes.
Skeletal surveys were carried out on 
nine patients with myelofibrosis and 
radiological features of the disease were 
found in six patients. Three of these patients 
had been histologically classified as early 
cases, two as intermediate cases and one as 
a late case. No radiological features were 
found in the remaining early case, in an 
intermediate case or in the patient who was 
not classified as no marrow trephine had been 
performed. Thus, correlation between the
Fig. 92 Changes of myelofibrosis in a humerus 
(patient A.S.)
Fig. 93 Osteolytic areas in the skull of a 
patient with myelofibrosis.
(patient M.G-.B.).
/histological appearances and the radiological
appearances is not established in the patients 
reported here.
Coarsening of the trabeculae at the upper 
end of the femur of one patient is illustrated 
in fig.90, and patchy osteoporosis of the 
lower end of the femur in fig.91. The humerus 
was affected in other patients (fig.92) and 
on occasions even the scapula and lumbar 
vertebrae were found to have radiological 
changes typical of the condition. It is of 
interest that in one patient two areas of bone 
destruction were seen in the skull (fig.93).
These have the appearance of osteoplastic 
metastases but in other sites would be 
compatible with a diagnosis of myelofibrosis.
No other cause for these lesions was found
and it is possible that they were related
to myelofibrosis. This patient died six
months later in another hospital but unfortunately
no autopsy was obtained and the possibility
of other causes cannot be excluded completely.
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Summary
The radiological appearances of twenty- 
seven cases of myeloproliferative diseases 
are presented.
The occurrence of gouty arthritis was 
noted in 2 cases of polycythaemia vera, 1 of 
♦transition* myeloproliferative disease and 
one of myelofibrosis. Significant skeletal 
changes were otherwise seen in myelofibrosis 
only.
In polycythaemia vera cardiomegaly and 
increased pulmonary vascular markings were 
found and X-ray of chest in one patient with 
late chronic myeloid leukaemia revealed 
pulmonary involvement.
The cases of Di Guglielmo’s disease, 
megakaryocytic thromboeythaemia and ’transition* 
myeloproliferative disease had no significant 
skeletal changes.
The radiological features of myelofibrosis 
were found in 6 of 9 patients. There appears 
to be no definite correlation between the 
radiological changes and the histological
135
/appearances of the hone marrow.
BLOOD VOLUME STUDIES
195
It is well known that blood volume 
changes occur in polycythaemia and indeed 
the one essential criterion for this diagnosis 
is an increased red cell volume- Changes 
are found also in anaemia and it is to be 
expected, then, that changes in blood volume 
will occur in myeloproliferative states.
Wintrobe (1956) gives the normal blood 
volume as derived from the results of several 
workers as approximately 6 6 -  88 ml. per kg. 
of body weight. Szur et al (1959) define their 
ranges for red cell volume as 28 - 35 ml. 
per kg., for plasma volume as 40 - 50 ml. 
per kg., and for total blood volume as 
68 - 85 ml. per kg. of body weight. There is 
little difference between these figures and 
the figures of previous workers and so those 
of Szur et al (1959) being the most recently 
reported are accepted as the normal range 
for the purpose of this study.
KESULTS
Polycythaemia vera
Szur et al (1959) in a study of 35 cases
Patient Blood Volume 
(ml/kg.body 
weight).
Plasma Volume 
(ml/kg. body 
w e i g h t ),
1 e d Cell Volume 
(ml/kg. body 
w e i g h t ).
A.McA. 107 51 56
F.H. 72 35 37
M.S. 90 45 45
J .0 . 119 56
V
O
T /"t
J  * v' 0 90 35 55
Table 31 Blood volume studies in polycythaemia 
vera.
Patient Blood Volume 
(ml/kg.body 
weight)
Plasma Volume 
(ml/kg. body 
weight)
Red Cell Volume 
(ml/kg. body 
weight)
J .Bo 129 61 68
Table 32 Blood volume studies in a case of 
megakaryocytic thrombocythaemia•
/of untreated polycythaemia vera report the 
red cell volume as increased in 34 patients, 
the blood volume as increased in 22 patients 
and the plasma volume as low in 16 patients 
and high in 3 patients. Similar results are 
found in the 5 patients studied here (table 31). 
The blood volume is increased in 4 patients,
and the red cell volume in all 5 patients.
Plasma volume is increased in 2, normal in 1
and decreased in 2 patients. Thus, the
blood volume increase is due mainly to increase 
in red cell volume and may or may not be 
accompanied by an increase in plasma volume.. 
Megakaryocytic thrombocythaemia
This patient was polycythaemic at the time 
of investigation and not only is the total 
blood volume increased but both components, the 
red cell volume and the plasma volume, are also 
increased (table 32).
Chronic myeloid leukaemia
Pour cases of chronic myeloid leukaemia 
were studied and the results are seen in table 33. 
The total blood volume is increased in 2 patients
Patient Blood Volume 
(ml/kg*, body 
weight).
Plasma Volume 
(ml/kg. body 
weight).
Red Cell Volume 
(ml/kg. body 
weight).
M.M. 62 47 15
C.L. 71 56 15
E.W. 99 75 24
J.L. 101 02 19
Table 35 Blood volume studies in chronic myeloid 
leukaemiao
Patient Blood Volume 
(ml/kg. body 
weight).
Plasma Volume 
(ral/kg. body 
weight).
Red Cell Volume 
(ml/kg. body 
weight)•
W.M. 91 73 18
M.B. 110 88 22
Table 34 Blood volume studies in intermediate* 
disease.
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/and the plasma volume in 3 patients. In all 
4 patients the red cell volume is diminished. 
'Intermediate* disease
Both patients show an increase in 
total blood volume and plasma volume but a 
diminished red cell volume (table 34). 
Myelofibrosis
The results obtained from 9 cases of 
myelofibrosis are seen in table 35.. The 
total blood volume is increased in 5 patients, 
normal in 3 patients and diminished in 1 
patient. The plasma volume is the component 
which forms the main contribution to the 
blood volume increase as it is increased in 
all 5 patients having an increased blood 
volume. The plasma volume is also high in 
one other patient with a normal blood volume.
In all but one case the red cell volume is 
below the normal range and in this one case 
it is slightly increased and indicates a degree 
of polycythaemia. This polycythaemia is not 
apparent from the peripheral blood findings 
but it is worthy of note that this patient
Patient Blood Volume 
(ml/kg, body 
weight)
Plasma Volume 
(ml/kg. body 
weight)
Red Cell Volume 
(ml/kg. body 
weight)
S.H. 85 60 25
M.C • 76 50 26
J.C. 103 66 37
J.G. 118 91 27
R.C. 69 49 20
M.G.B. 100 81 19
A.So 76 55 21
W.P. 67 48 19
T • Q* 124 109 15
Table 35 Blood volume studies in myelofibrosis.
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/had the highest white cell count (73,000 per 
c.mm.) recorded in the group with myelofibrosis. 
Thus, although this patient was never seen 
in an obviously polycythaemic phase she could 
have had polycythaemia vera without severe 
symptoms until the development of myelofibrosis. 
When first seen she had gross splenomegaly 
and thus may have had a myeloproliferative 
disorder for some time. Further, she presented 
with gout which is a more common complication 
of polycythaemia vera than any other 
myeloproliferative disease.
* Transition1 myeloproliferative disease
The results of these four patients are 
seen in table 3 6 . One patient only shows an 
increase of total blood volume, and this is 
due to increase of plasma volume. Plasma 
volume is increased in one other patient with 
a normal blood volume. The red cell volume 
is low in all cases and in one patient all 
three values are low.
Pi Guglielmo's disease
This patient shows a normal blood volume,
Patient Blood Volume 
(ml/kg. body 
weight)
Plasma Volume 
(ml/kg. body 
weight)
Red Cell Volume 
(ml/kg. body 
weight).
J.F. 60 36 24
J.HcD. 99 82 17
A.McGo 46 36 10
J .McG. 73 58 15
Table 36 Blood volume studies in ’transition* 
myeloproliferative disease.
Patient Blood Volume 
(ml/kg. body 
weight)
Plasma Volume 
(ml/kg.body 
weight)
Red Cell Volume 
(ml/kg. body 
weight).
G.McF. 72 61 11
Table 37 Blood volume studies in a case of 
Di Guglielmo*s disease#
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/an increased plasma volume and a low red 
cell volume (table 37).
Discussion
Blood volume studies appear to be of 
diagnostic value in polycythaemia vera.
The total red cell volume must, by definition 
be increased, the total blood volume is usually 
raised and the plasma volume may be high, 
normal or even low. The results of this study 
agree with those of other workers and the 
cases appear to be representative.
In two other patients an increase of red 
cell volume is found. One of these is the 
patient with megakaryocytic thromboeythaemia,
a condition often associated with polycythaemia, 
and the increase affects all three volumes 
as sometimes seen in polycythaemia vera.
The other patient is one of myelofibrosis 
with gross splenomegaly and the high white 
cell count of 73,000 per c.mm.; this patient 
also had gout and in view of these findings 
the possibility of her being a late case of 
polycythaemia vera complicated by myelofibrosis
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/must be considered.
In all other cases the red cell volume 
is found to be low, in keeping with the 
anaemia found on examination of the peripheral 
blood. It is interesting that the red cell 
volume is less seriously diminished in 
myelofibrosis at the time of diagnosis than 
in the other myeloproliferative diseases and 
this finding may be related to the rather better 
prognosis in myelofibrosis.
Despite the low red cell volume usually 
found in myeloproliferative disease (with the 
exception of polycythaemia vera) the total 
blood volume often is increased due to the 
presumably compensatory increase in plasma 
volume. This is not in agreement with 
McMichael et al (1943) who report a decrease 
in blood volume despite a relative increase 
in plasma volume in many anaemias. The 
difference may be attributable to the gross 
splenomegaly accompanying many cases of 
myeloproliferative disease and the large 
amount of blood which may be * stored' in the
State
Blood Volume 
(ml/kg. body 
weight)
Plasma Volume 
(ml/kg. body 
weight)
Red Cell Volume 
(ml/kg. body 
weight)
after
haematemesis
78 48 30
polycythaemic 129 61 68
Table 38 Blood volume studies in patient J.D. with 
thrombocythaemia after a haematemesis and 
when polycythaemic.
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/spleen..
The blood volume and its components were 
estimated in the case of megakaryocytic 
thrombocythaemia 3 months after a large 
haematemesis and later when she had regained 
her previous polycythaemic state (table 3 8 ).
In the polycythaemic state there was increase 
in total blood volume, red cell volume and 
plasma volume. After haematemesis, however, 
there was a fall in all three volumes to normal 
levels. One might have expected the blood 
volume to be maintained at a high level by 
a further increase in total plasma volume; 
that this did not occur (except possibly in 
the immediate post-haemorrhagic state) suggests 
that the increase in total blood volume and 
plasma volume seen in the polycythaemic 
state may be the result of efforts to dilute 
the cells to a more normal concentration.
When the red cell volume returns to normal 
after bleeding the need for excess plasma 
no longer exists and so the plasma, and 
consequently the total blood volume returns
Date Blood Volume 
(ml/kg. body 
weight)
Plasma Volume 
(ml/kg. body 
weight)
Red Cell Volume 
(ml/kg. body 
weight)
March,1957 103 66 37
July, 1958 100 69 31
June,1959 93 75 18
Table 39 Blood volume studies at approximately 
yearly intervals in a case of 
myelofibrosis (J.C.).
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/to normal.
The myelofibrosis patient with slight 
polycythaemia had blood volume studies 
carried out on 3 occasions at intervals of 
approximately one year. The results are seen 
in table 39. Over the 2 year period the 
red cell volume fell steadily. The plasma 
volume increased but not sufficiently to 
prevent a fall in total blood volume. Thus 
the patient is observed to leave the 
polycythaemic phase and enter the more usual 
myelofibrotic state.
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Summary
Blood volume, red cell volume and plasma 
volume studies are reported in 26 cases of 
myeloproliferative disease. The red cell 
volume is increased in polycythaemia vera, 
and the total blood volume usually is 
increased also.
In other myeloproliferative states the 
red cell volume is diminished, but the plasma 
volume and total blood volume often are 
increased and this may be related to the gross 
splenomegaly so frequently present.
The red cell volume is less seriously 
diminished in myelofibrosis and this is 
compatible with the slightly better prognosis 
in this condition.
The blood volume measurements after a 
haematemesis and in the polycythaemic state 
in megakaryocytic thrombocythaemia are discussed.
One case of myelofibrosis had repeated 
studies carried out and was observed to pass 
from a polycythaemic state to the more usual 
anaemic state in myelofibrosis.
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C h a p t e r  16
THE DIAGNOSIS OF HAEMOLYSIS
The main diagnostic features in a patient 
with increased haemolysis depend on three 
factors; firstly, the shortened life span of 
the red cells; secondly, the alteration of 
pigment excretion as a result of excessive 
haemoglobin breakdown; and thirdly, the efforts 
of the marrow to increase production in an 
attempt to compensate for the more rapid 
destruction of the red cells. It is obvious 
that the first factor Is a direct measure 
of haemolysis whereas the second and third 
factors are only indirect measurements.
The measurement of red cell life span by 
radiochromium is the most direct measurement, 
but for the radiochromium T-g to be used as 
an index to the true survival time of the red 
cells, certain corrections require to be made 
(Jones and Mollison, 1956). Nevertheless, the 
T-g- is a guide to the degree of haemolysis 
and is apparently more accurate than any 
indirect method.
The faecal excretion of urobilinogen 
has been used as a measure of haemolysis
/by Miller et al (1942). They provide a 
1haemolytic index* which takes into account 
the total mass of circulating haemoglobin and 
the difference between the actual normal 
excretion figures and the theoretically 
expected excretion. The normal range for the 
haemolytic index is 11 - 21 and an index of 
over 21 is indicative of increased haemolysis.
The reticulocyte count is a measurement, 
not of haemolysis, but of the efforts of the 
erythropoietic tissue to compensate for 
increased haemolysis. If marrow production 
is adequate and equilibrium is reached then 
the level of the reticulocyte count may be 
an indication of the degree of haemolysis.
When the bone marrow responds to increased 
haemolysis there are released into the 
circulation not only reticulocytes but also 
other immature cells in the form of nucleated 
red cells. Thus, there may be a relationship 
between haemolysis and the presence of 
nucleated red cells in the peripheral blood.
Haemolysis was estimated by these methods
Patient Diagnosis Haemolytic
Index
51Cr Ti 
(days)
M «M • C.M.L. 23 14
C.L. C .M. L . 16 20
E.W. C.M.Lo 21 16
M.B, Int o 10 12
W .1:1 • Int. 53 15
M.C . Mf. 8 13
J.C. Mf. 12 22
J.G. Mf. 34 17
R.C. Mf. 47 15
t .q . Mf. 41 14
M.G.B. Mf . 114 16
S. II. Mf. 25 30
A.McA. P.V. 12 22
M.S. P.V. 21 24
J.McG. M.P. 66 24
G.McF. D.G. 90 8
5 1  iTable 40 Comparison of haemolytic index and Cr Tg-
in 16 patients with myeloproliferative disease*
(C.M.L. = chronic myeloid leukaemia;
Int. = 1 intermediate * disease; Mf. = myelofibrosi 
P.V, = polycythaemia vera; D.G. = Di Guglielmofs
disease)•
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/and the results obtained are compared.
The haemolytic index and radiochromium 
Ti were determined on 16 patients (table 40).
Of these patients, 15 have increased haemolysis 
as judged by the T£ but only 9 of these have 
a haemolytic index over 21 indicating increased 
haemolysis. One patient had no haemolysis 
by radiochromium but the haemolytic index is 
elevated. The radiochromium method is a 
direct measurement of the destruction of 
red cells and is therefore more reliable than 
any indirect method. If the radiochromium 
result is assumed to be correct then the 
haemolytic index is wrong in approx. 44 per 
cent of cases and thus is not a reliable 
measurement. Furthermore, there appears 
to be no correlation between the level of
the elevated index and the reduction from 
normal of the radiochromium half life.
The reticulocyte count, in absolute 
figures, is compared with the radiochromium 
half life. As reticulocytes may be present 
in the normal individual up to a figure of
Patient Diagnosis Reticulocytes 
(per c.mrn.)
51 1 Cr Tj-
(days)
M.M. C .Li * Xj 0 <76,000 14
J.L. C.M.L. 147,000 10
C.L. C.M.L. 140,000 20
E.W* C *M .L. 75,000 16
M.B. Int • 90,000 12
W.M. Int • 108,000 15
M . C * Mf . 196,000 13
J.C. Mf. 144.,000 22
J.G* Mf* 330,000 17
R.C. Mf. 82,000 15
T.Q. Mf . 286,000 14
H.G.B. Mf. 52,000 16
S.Ho Mf 0 < 80,000 30
W.P. Mf. 704,000 14
A.S. Mf . < 84,000 24
J *McG 0 M.Po < 19,800 24
A.McG. M.P. 85,400 30
! J.McDo M.Po 61,200 20
G.McF. D.G. 108,000 8
51 iTable JtL Comparison of reticulocyte count and Cr Tg- 
in 19 patients with myeloproliferative disease*
(C.M.L. = chronic myeloid leukaekia;
Into = intermediate1 disease; Mf* ■ myelofibrosis 
M*P. = transition1 myeloproliferative disease; 
D.G* =s Di Guglielmo’s disease)*
/2 per cent of the total red cell count, 
a level of 100,000 per c.mm. is taken as the 
upper limit of normal reticulocyte count.
This, of course, can apply only to patients 
with normal or low red cell counts as 2 per 
cent of an elevated red cell count will he 
over 100,000 per c.mm. Thus, all patients 
with polycythaemia at the time of investigation 
are excluded from this comparison; this leaves 
out five cases with polycythaemia vera, one 
case of megakaryocytic thrombocythaemia and 
one case of ‘transition’ myeloproliferative 
disease. No attempt was made to enumerate 
the reticulocytes when they constituted less 
than 2 per cent of the red cell count 
(i.e. less than 100,000 in a count of 
5 million red cells.
The results in 19 patients are compared 
in table 41. In eleven patients there is 
agreement; nine results indicate increased 
haemolysis by reticulocyte count and 
radiochromium technique, and two indicate 
a normal rate of haemolysis by each method.
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/In the other eight patients haemolysis is 
indicated by radiochromium study but the 
reticulocyte count is less than 100,000 
per c.mm* in each case.
The reticulocyte count depends upon 
productive activity and if compensatory 
hyperplasia does not or cannot occur then 
the reticulocyte count will not be raised..
A low radio iron utilisation indicates low 
red cell production and thus provides a 
method for analysis of the figures which do 
not agree with the radiochromium estimation.,
In 6 of the 8 cases of disagreement the radioiron 
utilisation is low and indicates erythropoietic 
hypoplasia thus accounting for the failure to
find an elevated reticulocyte count. In the 
other two cases there was doubtful haemolysis 
(T-J- = 24 days) or a just normal reticulocyte 
count (90,000 per c.mm.). Thus, of the nineteen 
cases 11 (58$) show complete agreement, and 
2 (10$) have borderline results. In the 
other 6 cases (32$>) there is disagreement 
which appears to be due to erythropoietic
Patient Diagnosis Nucleated 
Red Cells 
(per c.mm.)
51Cr T| 
(days)
M.M. C.M.L. 5,250 14
J.L. C.M.L. 1,700 10
C.L. C.M.L. 1,500 20
il .W • C.M.L. 5,400 16
M.B. Int. 7,840 12
¥ .M • Into 15,400 15
M.Co Mf. 900 13
J.Co Mf. 2,555 22
J.G. Mf o 420 17
R.C. Mf o 464 15
T.Q. Mf. 135 14
M.G.B. Mf. 340 16
S.Ho Mf . 0 30
7/.P. Mf o 357 14
■ A.S. Mf. 250 24
Table 42 Comparison of nucleated red cell count and 
-^Cr Tj- in 15 cases of myeloproliferative disease.
(C.M.L. = chronic myeloid leukaemia;
Int. ■ 1intermediate* disease; Mf. « Myelofibrosis)
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/hypoplasia and consequent failure of the 
reticulocyte count to rise.
Nucleated red cells were found in the 
peripheral blood in 14 of the 15 cases of 
chronic myeloid leukaemia, myelofibrosis and 
‘intermediate1 disease who had radiochromium 
studies carried out. In all these 14 cases 
there is increased haemolysis (table 42).
In the one case of myelofibrosis with no 
nucleated red cells there is no increase in 
the rate of haemolysis. (T^ - = 30 days). It 
is of interest that nucleated red cells are 
present in larger numbers in chronic myeloid 
leukaemia than in myelofibrosis with only 
one exception.
Discussion:
The most direct measurement of red cell 
survival is the radiochromium method,. The 
haemolytic index, which is dependent on the 
faecal excretion of urobilinogen does not 
appear to be a satisfactory method of estimating 
haemolysis as compared to the radiochromium 
method. It is, of course, an indirect
/assessment and must depend upon other factors 
such as each individuals normal excretion and 
liver function. For example, one person may 
normally excrete 50 mgm. of urobilinogen 
daily in the faeces. If haemoglobin breakdown 
is increased then this figure may rise to 
100 mgm. daily but will still be well within 
normal limits. Thus, it is not surprising 
that the haemolytic index is an inaccurate 
guide.
The reticulocytevcount depends upon the 
response of the erythropoietic tissue to 
increased haemolysis and in myeloproliferative 
disease this is often limited. If the absolute 
reticulocyte count is taken as a measure of 
haemolysis in myeloproliferative disease 
then there is about 60 per cent accuracy, 
but if it is remembered that the erythropoietic 
tissue cannot respond satisfactorily in many 
cases, and if this is taken into account, then 
there are few counts which are in complete 
disagreement with the radiochromium study. 
Further, if the reticulocyte count is applied
/only in such cases where the marrow can 
respond then it becomes a tolerably accurate 
method of estimating haemolysis.
It might be expected that the number of 
nucleated red cells in the peripheral blood 
provide a guide to increased haemolysis 
when the marrow attempts to compensate by 
releasing very immature cells. A good 
correlation is found but it must be remembered 
that increased haemolysis occurs in most cases 
of chronic myeloid leukaemia and myelofibrosis 
as in fact do nucleated red cells in the blood; 
this is not necessarily a direct relationship 
but may be merely the coincidental occurrence 
of two very common findings. Furthermore, 
the patients studied form a very selective 
group. It is of interest that whereas nucleated 
red cells in the peripheral blood are generally 
accepted as more common in myelofibrosis, 
the absolute figures indicate that higher 
numbers occur in chronic myeloid leukaemia.
This is no doubt because the accepted figures 
are read as a percentage of the white count;
/as the count is so much higher in chronic 
myeloid leukaemia a smaller proportion may 
represent a much higher absolute figure.
Summary
A comparison is made of the radiochromium 
estimation of red cell survival with the
haemolytic index, the reticulocyte count and 
the occurrence of nucleated red cells in the 
peripheral hlood.
The haemolytic index does not appear to 
be a reliable guide to haemolysis in 
myeloproliferative disease.
The reticulocyte count appears to be much 
more reliable provided erythropoietic activity 
can be assessed and taken into account.
Nucleated red cells in the blood seem 
to occur with increased haemolysis but this 
association is accepted with reservations.
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S U M M A R Y  OP 
S E C  T I G  I IT
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A study has been made of various 
aspects of myeloproliferative disease.
Megaloblastic erythropoiesis occurred 
in three patients. It is suggested that in 
hi (ruglielmo * s disease there may be a defect 
of vitamin B-^ or folic acid metabolism at a 
cellular level. In one case of myelofibrosis 
it is possible that there was a deficiency 
of vitamin B ^  or folic acid in the early 
stages but in the other case of myelofibrosis 
there was definite serum vitamin B-^ deficiency.
Infection was found to be related to 
hypogammaglobulinaemia in two patients but 
another patient with hypogammaglobulinaemia 
had no history of infection. All cases of 
hypogammaglobulinaemia occurred late in 
the disease.
Gout was found in four cases of 
myeloproliferative disease. Uric acid studies 
suggest that while each disorder may have its 
own pattern of uric acid metabolism there 
probably are factors common to all.
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The radiological features of 
myeloproliferative disease are discussed 
and one case with defects in the skull was 
noted in the myelofibrosis group*
Blood volume studies were carried out 
on patients with myeloproliferative disease and 
the results are discussed. One patient having 
myelofibrosis is of particular interest as 
initially she was polycythaemic but later 
developed more usual volumes of myelofibrosis.
Studies on the diagnosis of haemolysis 
suggest that provided the bone marrow is 
capable of response the reticulocyte count 
is a good index of the degree of increased 
haemolysis.
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S E C T I O N  7
T H E  T R E A T M E N T  O F
Y E L 0 P R O L I E E R A T  I Y E
D I S E A S E
THE GENERAL ASPECTS 
OF TREATMENT
All forms of myeloproliferative disease 
are eventually fatal. Treatment is, therefore, 
aimed at relieving symptoms and maintaining 
the general well-being of the patient. This 
is most successful in the case of polycythaemia 
vera where the patient may remain well for 
many years, and least successful in erythraemic 
myelosis which usually proves fatal within 
a short time despite any attempt at treatment.
Whereas treatment of polycythaemia vera 
with radioactive phosphorus (J P) appears to 
prolong life (Lawrence, 1955) it is less certain 
that the duration of life is extended in any 
other myeloproliferative disorder. There is 
no doubt, however, that life can be made 
much more comfortable for these patients.
This applies particularly to chronic myeloid 
leukaemia where frequent courses of treatment 
are often required but the patient may remain 
tolerably well for a few years..
Although there is a definite place for 
treatment of myeloproliferative disease, it is 
essential to realise that in some cases the
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/patient may remain well for long periods, 
sometimes for years, without any form of 
treatment. Patients J.G. and S.H. with 
myelofibrosis each remained well for over 
three years without treatment for myelofibrosis. 
Specific Therapy
This is applicable only to polycythaemia 
vera where the administration of radioactive
op
phosphorus (J P) appears to effect a 
haematological cure; more than one treatment, 
however, may be required to produce this. 
Supportive Therapy
Treatment is not uncommonly required for 
cardiovascular complications in myeloproliferative 
disease and the use of digitalis and diuretics 
may bring about marked improvement when 
cardiac failure is present. Leukaemic patients 
appear to be more susceptible to infection than 
normal and antibiotic therapy may be indicated 
on occasions.
Iron Therapy
The administration of iron was found to 
be indicated in the treatment of ten patients.
M.C.
Iron Therapy 
9 '• Commenced
Hb
6 “
3 -
0060
Days
30
94 Besponse to iron therapy in 
myelofibrosis. (Patient M.C.)
/The response was variable but sometimes 
iron proved remarkably effective (fig.94) 
and obviated the use of other treatment for 
some time. Although oral iron was found to be 
effective in most cases parenteral administration 
occasionally was required.
Blood Transfusion
Blood transfusion was necessary for many 
patients who did not respond to iron, or who 
had blood loss, or defective erythropoiesis, 
or excessive haemolysis; it is obvious that 
in the latter two the effect of transfusion 
would be of temporary benefit only but this 
is often of value in preparation for other 
treatment.
Blood transfusion was given in the 
treatment of 15 patients with myeloproliferative 
disease. In 5 patients this was in preparation 
for radiotherapy and in 4 patients in 
preparation for splenectomy. In 3 patients 
blood transfusion was given for excessive 
haemolysis with only temporary benefit and
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Pig. 93 Response to steroid therapy in 
myelofibrosis. (Patient W.P.)
/in 2 patients it was used during investigation 
of the cause of anaemia. One patient with 
polycythaemia vera required transfusion after 
an episode of melaena. The effect of blood 
transfusion was never prolonged but temporary 
benefit was obtained in many cases. 
Antimetabolite drugs
Busulphan was used in the treatment of 
one patient with chronic myeloid leukaemia 
and one with 'transition* myeloproliferative 
disease. In neither of these cases was 
anything other than temporary benefit derived. 
Polic acid antagonists are of occasional 
benefit in myeloblastic crises. Aminopterin 
was used in one case of terminal chronic 
myeloid leukaemia with no apparent effect. 
Corticosteroids
As myeloproliferative disease is often 
accompanied by increased haemolysis, 
corticosteroid therapy may be beneficial by 
reducing the haemolysis, especially if 
antibodies are present. With this possibility 
in mind, 'Prednisolone' was used in the
J.C.
W.B.C. / 
cmm
20,000-,
15,000-
10,000 -
5,000 -
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/treatment of 3 patients. In Di Guglielmo's 
disease and a case of ‘intermediate1 disease 
there was no apparent effect. In one patient 
with myelofibrosis, however, there was a good 
response and the haemoglobin level rose 
steadily with a dosage of 60 mgm. Prednisolone 
daily (fig.95). Thereafter the dose was 
reduced to 20 mgm. daily and the patient has 
remained clinically and haematologically 
satisfactory since then.
Radioactive Phosphorus
- i n
Radioactive phosphorus (J P) was used 
in all 5 patients with polycythaemia vera 
with good effect though 3 patients required 
more than one dose. The satisfactory response 
of one patient is illustrated in fig.96.
In the case of megakaryocytic thrombocythaemia, 
radiophosphorus appeared to be the treatment 
of choice and with this form of therapy the 
platelet count fell from over 2 million to 
under 300,000 per c.mm. and the patient to 
date has had no further haemorrhagie episodes.
One patient with 'transition*
/myeloproliferative disease with an excess 
number of cells of the myeloid series in the 
marrow though not in the blood, also was 
treated with radiophosphorus and again the 
response was favourable but temporary..
Comment
There are, therefore, many forms of therapy 
which may be of some value in the treatment of 
myeloproliferative disease. Radiophosphorus 
appears to be the treatment of choice in 
polycythaemia vera and occasionally in other 
forms of myeloproliferative disease. The 
other treatments mentioned previously have 
a temporary effect only but are sometimes of 
considerable benefit when some major form of 
therapy, such as splenic irradiation or
splenectomy, is contemplated. The usefulness 
of splenic irradiation and splenectomy 
in some forms of myeloproliferative disease 
is controversial and as these two treatments 
form the basis of effective therapy they are 
considered in later chapters.
Summary
The general aspects of the treatment of 
myeloproliferative disease are considered* 
Treatment is aimed at improving the 
patient's condition hut in polycythaemia vera 
the use of radioactive phosphorus may produce 
prolonged benefit.
In other myeloproliferative disease 
treatment usually is of temporary value only. 
Occasional satisfactory results however, may 
be obtained with radiophosphorus, corticosteroids 
or antimetabolite drugs.
22?
: 6  ■ - . . . . ; . . : 
i.H-i i  'if U. " ■ ' ■ - ■ . - ' / ■ '
0  3a a p t e r 18 ;
SPLENECTOMY
V' :V '■ - - ... • -^ .v
'w 0 lOH' lv .r.3-.'X ^ ' - l : ' ■■ :
229
Splenectomy in the treatment of 
myeloproliferative disease is an operation 
which is not performed frequently. Probably 
the first occasion of its use dates back about 
a hundred years when Bryant (1866) removed 
the spleen in a patient with chronic myeloid 
leukaemia. The patient died and the operation then 
went into disuse. More recently, however, it 
has again been described in the treatment of 
patients with chronic myeloid leukaemia. It is 
sometimes performed when there is severe 
anaemia, probably mainly haemolytie in origin, 
in the presence of a white cell count which is 
too low to permit radiotherapy. In such 
circumstances the patient may benefit 
considerably for a temporary period (Scott,
1957).
Splenectomy is rarely considered in other 
myeloproliferative states with the exception 
of myelofibrosis. In myelofibrosis there is 
great controversy regarding its usefulness 
and it is considered contraindicated by 
several authorities (Scott, 1949; Wintrobe,
/1951; Learmonth, 1951; Whitby, 1952;
Chatterjea et al, 1952). Hickling (1953), 
in a review of the subject, refers to 14 
patients on whom splenectomy was performed 
with mixed results. Beneficial results, 
however, are reported by other writers 
(Engell, 1947; Edwards, 1951; Andersen and 
Sorensen, 1952; Pranks and Richardson, 1952; 
Merskey and Budtz-Olsen, 1953; G-oldberg and 
Seaton, I960).
It is clear, then, that splenectomy may 
have harmful effects and it may even prove 
fatal within a few hours (Shinton, 1957) 
but on the other hand it may produce marked 
improvement for as much as 3 years (Relson, 
1954). Thus, there must be certain factors 
which determine the value of splenectomy.
It has been suggested that splenectomy could 
be undertaken because of the disability caused 
by gross enlargement of the spleen (Shinton, 
1957). This, however, must be a hazardous 
procedure as it takes into account none of 
the possible functions of the spleen.
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/Excessive haemolysis is considered an 
indication for splenectomy by some writers 
(Korst et al, 1956; Leonard et al, 1957) 
but this policy ignores the possible 
erythropoietic activity of the spleen.
Edwards (1951) states that the relative 
proportions of the spleen's favourable and 
unfavourable activities cannot be assessed 
except by its removal. This is no longer 
the case as the radioisotopic studies 
described in earlier chapters provide accurate 
information of the productive and destructive 
functions of the spleen. Splenectomy was 
carried out on four patients on the basis of 
these investigations and the results are 
reported.
Myelofibrosis
Patient T.Q. had a large bulky spleen and 
ample evidence of hypersplenism. She had a 
leucopenia, a thrombocytopenia and a haemolytic 
anaemia which necessitated frequent blood 
transfusion. The radioiron studies demonstrated 
some remaining marrow erythropoietic activity
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Pig. 97 Effect of splenectomy on patient T.Q.
with myelofihrosis.
(reproduced by permission from 
•Clinical Radiology*)
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/and only a small degree of splenic erythropoiesis. 
The radio chromium studies showed T-J- to be 
reduced to 14 days and the spleen:liver ratio 
to be 3:1. Thus the spleen had only a minor 
productive function but a major destructive
function. On this basis splenectomy was 
carried out. The effect on the blood findings 
is seen in fig.97. The haemoglobin rose and 
the need for transfusion ceased. The platelet 
count rose to normal or high levels and the 
white count, after an initial post operative 
peak, remained near normal figures. The 
patient’s general condition was greatly 
improved and one year later she was still 
at her work and has remained well without further 
treatment.
Patient M.C. had gross splenomegaly and 
over a period of 2 - 3 years her condition 
deteriorated steadily. Radioiron studies 
showed no significant splenic activity and 
the radiochromium studies showed T-| to be 
reduced to 14 days and the spleen:liver ratio 
to be 2.65:1. This again demonstrated that
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/the spleen was predominantly an organ of 
destruction and that splenectomy was indicated. 
The spleen was removed hut unfortunately the 
patient died in an unexpected post operative 
collapse after a technically satisfactory 
operation.
1Intermediate 1 Case
Patient M.B. with a condition intermediate 
between chronic myeloid leukaemia and 
myelofibrosis had been treated previously on 
several occasions by splenic irradiation.
She developed a marked haemolytic anaemia 
and required frequent blood transfusion.
This was not affected by a further course of 
splenic irradiation and removal of the spleen 
seemed the only hope for alleviation of her 
condition. The radiochromium had earlier 
been 12 days, at which time she was not in 
need of transfusion, and the rate of haemolysis 
obviously had increased since then. Eadioiron 
studies had demonstrated splenic erythropoiesis 
and no marrow activity but in view of the 
severity of the haemolysis it was felt
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/justifiable to proceed with splenectomy 
in the hope that other sites of erythropoiesis 
might compensate for the loss of the splenic 
source of red cells.
Following splenectomy the need for 
transfusion was greatly reduced and the level 
of haemoglobin was more easily maintained 
(fig.98). The platelets however, rose to 
over one million per c.mm. The patient*s
general condition improved considerably for 
a time but she developed severe bacterial 
infections and died about 2 months later. 
During this period her liver increased in size 
and soon extended to the right iliac fossa. 
This occurrence has previously been noted 
(Nelson, 1954; Richmond and Duncan, 1956) 
and presumably is due to an attempt by the 
liver to compensate for the removal of a 
major source of red cells.
* Transition* Myeloproliferative disease
Patient J.McD had a ’transition* disease 
which was considered to lie between
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Fig*.99 Effect of splenectomy on patient 
J.McD. with transition* disease.
/polycythaemia vera and chronic myeloid 
leukaemia. She had a large abdominal mass 
in which erythropoietic tissue was demonstrated 
by radioiron studies; this mass was, therefore, 
thought to be an atypical spleen. The marrow, 
however, still retained some erythropoietic 
function. Radiochromium studies showed 
slightly increased haemolysis with TJ of 20 
days and the spleen:liver ratio was 2.7:1.
The patient required frequent blood transfusions. 
These radioisotopic results suggested that if 
the abdominal mass was spleen then it seemed 
mainly to sequester and destroy red cells but 
had a little erythropoietic function. On these 
grounds and on the demonstration of persistent 
marrow erythropoiesis, laparotomy was performed. 
At operation the mass proved to be spleen on 
a long pedicle and was therefore removed. 
Following splenectomy the requirements for 
transfusion diminished and the haemoglobin 
level was better maintained (fig.9§). fhe 
white cell count, however, rose to leukaemia 
levels with 67 per cent neutrophils and
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/21 per cent myeloblasts.
Histological examination of the spleen 
showed that the normal architecture had been 
replaced by sheets of myeloid cells many of 
which were primitive.
Thus, the impression that this case was 
in a ‘transition' phase between polycythaemia 
vera and leukaemia appears confirmed and 
splenectomy seems to have precipitated the 
change to leukaemia. This patient was still 
well six months after operation but had required 
busulphan for her leukaemia.
Discussion
The place of splenectomy in myeloproliferative 
disease is limited but in selected cases may 
prove beneficial. Eour of the twenty seven 
patients with myeloproliferative disease were 
considered suitable for splenectomy which 
was then carried out. In one patient post 
operative collapse ensued and the patient 
died. In the other three patients the operation 
met with varying degrees of success. One has 
remained extremely well for over one year;
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/the second improved for a period but 
then succumbed to severe infections which were 
almost certainly related to hypogammaglobulinaemia; 
the third patient improved considerably but 
developed leukaemia.
Thus, the operation has proved to be a 
success when used to control a severe haemolytic 
anaemia with associated splenic sequestration 
of red cells. Unfortunately, these patients 
had complicating features which modified their
outlook. The radioisotopic studies have, 
therefore, proved useful in determining 
the haematological suitability of such patients 
for splenectomy, and in one case have proved 
to be of diagnostic value. It is suggested 
that all patients with myeloproliferative 
disease who are being considered for splenectomy 
should have radioiron and radiochromium studies 
carried out as these investigations provide 
an accurate and reliable indication of the 
role of the spleen in the production and 
destruction of the blood. It is essential 
that the patient*s general condition also is
23®
/ t a k e n  into account and that splenectomy
is not performed solely on the results of
these tests. For example, patient J.G.
had T £  of 17 days and the spleen:liver ratio
was 2.5:1. Splenectomy was not carried out
as the patient*s general condition remained
satisfactory and his erythrocyte production
was able to compensate for the sequestration
and increased rate of haemolysis of the red cells.
When radioisotopic studies are carried 
out to assess a patient*s suitability for 
splenectomy, less is left to chance and the 
operation is placed on a more logical and sound 
basis.
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Summary
Four cases of myeloproliferative disease 
were subjected to splenectomy mainly on the 
basis of radioiron and radiochromium studies.
The presence of a haemolytic anaemia and 
splenic sequestration of red cells is 
considered an indication for splenectomy provided 
the patient's condition requires treatment.
In three cases the operation met with 
success although this was modified by other 
complications in two of these patients.
The radioisotopic studies have proved 
helpful in assessing a patient's suitability 
for splenectomy. The development of frank 
leukaemia after operation in one 'transition* 
case is considered further evidence in favour 
of relationship of the myeloproliferative 
disorders.
IBBADIATION 
OF THE SPLEEN
2 k 1
For over fifty years radiotherapy has 
been the treatment of choice in chronic 
myeloid leukaemia. Recently other forms of 
treatment have come into use but as yet there 
is no convincing proof of any superiority over 
radiotherapy. In the case of myelofibrosis, 
however, radiotherapy is by no means accepted 
generally as a suitable form of therapy.
Some authorities consider splenic irradiation 
to be totally ineffective or even harmful 
(Jackson et al, 1940; Block and Jacobson,
1950; Cook et al, 1953) and fatal results have 
been recorded (Jackson et al, 1940; Cook et 
al, 1953; Cartwright, 1955). Others (Korst 
et al, 1956) note a fall in the leucocyte 
count but find no apparent change in the 
course of the disease. A limited use of local 
irradiation to relieve splenic pain is advocated 
by some writers (Marson and Meynell, 1952; 
Richmond and Duncan, 1956) but Hickling (1953) 
draws attention to the good general results 
which can be obtained in some patients with 
myelofibrosis.
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/ There is, therefore, considerable 
controversy as regards the place of splenic 
irradiation in the treatment of myelofibrosis 
and a comparison is made of the effect of 
this form of therapy in chronic myeloid 
leukaemia and in myelofibrosis.
Chronic Myeloid Leukaemia
Of the five patients with chronic 
myeloid leukaemia, four were treated by 
splenic irradiation in doses of 506 r to 
911 r given over 10 to 23 treatments. The 
conditions accepted as indications for therapy 
were 1) a falling haemoglobin; 2) a high 
and rising white cell count; and 3) clinical 
deterioration including splenic discomfort.
In all cases a good response was obtained; the 
patient’s general condition improved, the white 
cell count fell to normal figures and the 
haemoglobin level usually rose. A typical 
response as obtained in patient C,L. is 
illustrated in fig,100, It is of interest 
that in this patient the haemoglobin level 
rose during the period of irradiation.
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/Another patient, J.L., also had a rise of 
haemoglobin during splenic irradiation 
(fig.101). Such a definite response in the 
level of haemoglobin did not always occur 
and in patient A.R. there was a delayed rise 
which occurred towards the end of treatment 
or immediately after (fig.102). .In patient 
E.W., however, the haemoglobin level did not 
rise significantly during therapy and even 
after a blood transfusion the higher level was 
not maintained (fig.103). The most satisfactory 
response appears to be a rise during treatment 
as one patient with this survived 2 years 
and the other is still alive and well 24 years 
later. Patient W.R., who had a delayed response 
died 2 years later and patient E.W. with no 
significant response died within a year.
These results, though small in number, 
suggest that the response of the haemoglobin 
to splenic irradiation may give an indication 
of the stage of the disease.
It is worthy of note that three of the
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Pig. 104 Effect of 1st course of splenic 
irradiation on patient J.C. with 
myelofibrosis, (reproduced by 
permission from Clinical Radiology1)*
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/four patients treated by splenic irradiation 
had been shown by radioiron studies to have 
splenic erythropoiesis. This appears not to 
have influenced the results of treatment and 
the patient who died within a year had no 
evidence of splenic erythropoiesis on either 
radioiron studies or splenic puncture. 
Myelofibrosis
Two patients with myelofibrosis were 
treated by splenic irradiation and one of 
these was treated on three separate occasions. 
The doses of splenic irradiation in this 
patient were, successively, 290 r delivered 
in 6 treatments, 248 r in 10 treatments and 
364 r in 8 treatments. In the other patient 
324 r was delivered over 12 treatments.
All four treatments produced a satisfactory 
response in that the patient*s general condition 
improved, and the white cell counts and 
haemoglobin levels usually were restored to 
more normal figures.
Splenic irradiation was considered to be 
indicated in patient J.C. on each occasion
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Fig. 106 Effect of 3rd course of splenic 
irradiation on patient J.C. with 
myelofibrosis.
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patient M.G.B. with myelofibrosis
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/mainly because of the disability produced 
by the grossly enlarged spleen. At the 
time of the first treatment the white cell 
count was 32,400 cells per c.mm* and the 
haemoglobin 8.7 g per cent. The white cell 
count was restored to normal and the 
haemoglobin to 13 g per cent (fig.104).
On the second occasion there was little 
haematological upset but the white cell 
count fell to normal and the satisfactory 
haemoglobin level was maintained (fig.105).
The third treatment brought about a fall 
of the white cell count from 73>200 cells 
per c.mm. to normal and although the haemoglobin 
level fell during treatment it soon recovered 
to over 12 g per cent (fig.106). On each 
occasion there was a satisfactory clinical 
response. Splenectomy had been considered 
inadvisable because of the presence of splenic 
erythropoiesis and the lack of significant 
splenic sequestration.
Patient M.G-.B. had increased haemolysis,
Ti 17 days, and the spleen/liver ratio was 2.4/1
22^6)
/which is considered borderline evidence 
of sufficient red cell sequestration to 
justify splenectomy. This patient was also 
shown to have splenic erythropoiesis and the 
examination of the blood revealed a leucopenia 
(2,000 cells per c.mm.). She had recently 
had a myocardial infarction and was in cardiac 
failure and so splenectomy could not be 
considered. She was treated by splenic 
irradiation in a dose of 324 r in 12 treatments 
over 28 days. The haemoglobin level improved 
and the need for transfusion ceased and the 
white cell count rose to over 3,000 per c.mm. 
shortly after treatment was completed, (fig.107). 
This patient required no further treatment 
for her myelofibrosis for the next 6 months 
at which time unfortunately, she had a further 
myocardial infarction and died.
Thus, in each of these patients, splenic 
irradiation proved a satisfactory and effective 
form of therapy despite the presence of 
erythropoietic tissue in the spleen.
If the response of the haemoglobin to
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/splenic irradiation is now considered it is 
seen that patient J.C. had a satisfactory rise 
of haemoglobin during the first treatment.
At the second treatment the haemoglobin 
remained steady at an already satisfactory 
level and at the third treatment it fell 
during irradiation but later rose again to a 
satisfactory figure. This appears to be 
consistent with the observations made on 
chronic myeloid leukaemia and confirms the 
suggestion that the response of the haemoglobin 
may be an indication of the stage of the disease. 
"Intermediate1 cases
The "intermediate" cases were each treated 
by splenic irradiation. Patient M.B. was 
treated this way on five occasions, of which 
the first four produced a satisfactory clinical 
response and a fall in the white cell count#
The first treatment brought about a rise of 
haemoglobin the exact time of which is obscured 
by blood transfusion at the conclusion of 
treatment (fig.,108). The second and third 
treatments (figs. 109 & 110), caused a rise
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/of haemoglobin during treatment and the fourth 
treatment (fig.Ill) brought about a less 
marked rise to a less well maintained level on 
completion of the course of radiotherapy. By 
the time of the fifth treatment the patient 
had gross haemolysis and required frequent 
transfusion of blood. Splenic irradiation 
then had no apparent effect on the haemoglobin 
level and the requirements for transfusion 
were not altered (fig.112).
Patient W.M. had one course of splenic 
irradiation. The white cell count fell from 
over 200,000 per c.mm. to normal figures.
The need for transfusion ceased and the 
haemoglobin rose slowly after therapy had been 
completed (fig.113). There was marked 
clinical improvement. This patient survived 
for about 15 months after therapy and the late 
response of the haemoglobin is in keeping 
with a moderately advanced stage of the disease.
Extramedullary erythropoiesis was present 
in the spleen, in each of these patients and 
marrow uptake of radioiron was depressed.
/There were no ill effects from irradiation 
of the spleens which contained erythropoietic 
tissue.
Discussion
Prom the results of splenic irradiation 
in the above cases of chronic myeloid leukaemia, 
myelofibrosis and 'intermediate' disease, it 
seems that this form of therapy can be equally 
effective in each condition. Whereas splenic 
irradiation is probably the treatment of choice 
in chronic myeloid leukaemia, it requires 
careful consideration before being used in 
the treatment of myelofibrosis, and even then 
must be well controlled and possibly given
in lower dosage over a long period. With these 
precautions satisfactory results can be obtained 
(Goldberg and Seaton, I960).
Hickling (1953) found that in myelofibrosis 
the patients with high white cell counts were 
the ones who responded to splenic irradiation. 
Patient M.G.B. however, who had a leucopenia, 
had a good response to splenic irradiation; 
this demonstrates that a high white cell count
/is not necessary for radiotherapy to prove 
effective, and that factors such as haemolysis 
and *hypersplenism' must be taken into account 
in assessing the patient’s suitability for 
splenic irradiation.
It is suggested by the results of these 
14 treatments with splenic irradiation that 
the stage of the disease may be assessed 
from the response of the haemoglobin to therapy. 
If the disease is in a fairly early stage the 
haemoglobin will rise during treatment, if 
later, there may be a delayed response, and 
later still the haemoglobin may be unaffected 
or may even fall during therapy.
The similarity of response in chronic 
myeloid leukaemia and myelofibrosis to splenic 
irradiation, regardless of the presence of 
absence of splenic erythropoiesis in either 
disease is considered to favour a relationship 
between these diseases. Further, this response 
is also found in the 'intermediate* cases and 
suggests that even in the transition from one 
disorder to another, the disease is fundamentally
251
/unchanged.
Summary
Splenic irradiation is shown to he a 
satisfactory form of therapy, not only in 
chronic myeloid leukaemia but also in 
some cases of myelofibrosis and intermediate * 
cases.
In myelofibrosis careful consideration 
should be given to the need for radiotherapy 
before this is recommended. If cases are 
selected carefully and if the course is 
planned and controlled, the results may be 
entirely satisfactory.
Splenic erythropoiesis is not necessarily 
a contraindication to splenic irradiation and 
good results may be obtained even in the 
presence of splenic erythropoiesis. The 
response of the haemoglobin to radiotherapy 
may give an indication of the stage of 
development of the disease.
THE PROGRESSION
OP
MYELOPRODIPEEATIVI DISEASE
253
It is well known that the average length 
of survival from the onset of symptoms in chronic 
myeloid leukaemia is about three years (Scott, 
1957) and in myelofibrosis rather longer 
(Whitby and Britton, 1957)* In chronic myeloid 
leukaemia the condition of the patient may be 
improved with treatment, which is required 
usually on several occasions during the course 
of the disease, but it is doubtful if the length 
of survival is prolonged (Scott, 1957). In 
myelofibrosis, however, treatment is probably 
required less frequently and when it is required 
it appears on occasions to be life saving.
Thus, two diseases so similar in many
ways seem to run a different course. Nine 
patients with chronic myeloid leukaemia, 
myelofibrosis or intermediate1 disease have 
been under observation for around two years or 
more and the progress of these patients is 
reported.
Chronic myeloid leukaemia
Patient E.W. was observed for 27 months 
during which time she was treated initially
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Pig. 114 The course of chronic myeloid 
leukaemia in patient E.W,
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ffig, 116 The course of myelofibrosis in 
patient J.C,
/Myelofibrosis
Patient J.C. was observed for three and 
a half years and was treated with radiotherapy 
on three occasions. The course of the disease 
as it affected the haemoglobin and white cell 
count is seen in fig.116. The haemoglobin 
level is on the whole less variable than in 
chronic myeloid leukaemia but in the terminal 
stages it falls steadily. The white cell 
count is much lower in comparison to chronic 
myeloid leukaemia though the fluctuation is 
exaggerated on the graph by the different 
scale. There is, however, some similarity 
though this pattern is much less undulant.
Patient M.C. was under observation for 
over ten years. She was diagnosed originally 
as ‘refractory macrocytic anaemia* and treated 
with ‘Anahaemin* with apparently some response 
(fig.117). Later vitamin B was substituted 
without benefit and iron therapy produced 
temporary improvement. Over her last 18 months, 
the haemoglobin level fell steadily until she 
died. Again, the course is seen to be less
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Fig. 117 The course of myelofibrosis in 
patient M.C.
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Fig. '118 The course of myelofibrosis in
patient J.G.
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/fluctuant than that of chronic myeloid
leukaemia.
Patient J.G. was observed for over three 
years with little significant change in the 
haemoglobin or white cell count over this 
period (fig.118).
Patient S.H. also was observed for over 
three years and again there is no significant 
change in the blood levels during this time 
(fig.119).
Thus, whereas the course of chronic myeloid 
leukaemia is punctuated by periods of marked 
alteration in the haemoglobin and white cell 
levels which usually necessitates therapy, the
course of myelofibrosis appears to follow a 
less undulant pattern. Only one case of 
myelofibrosis had a pattern like that of chronic 
myeloid leukaemia and even in this case the 
haematological variations were less well marked. 
intermediate1 cases
Patient M.B. had a course similar to 
chronic myeloid leukaemia; there was a periodic 
fall in the haemoglobin and a rise in the
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/white cell count which necessitated treatment 
(fig.120). Over the three year period, however, 
there was a progressive deterioration in the 
haemoglobin level. Though splenectomy produced 
a temporary improvement, this was not sustained 
even with repeated blood transfusion.
Patient W.M. had a truly ‘intermediate* 
course (fig.121). The initial high white cell 
count responded to splenic irradiation as did. 
the haemoglobin. Although regular transfusion 
of blood was required there was never any great 
change in the haemoglobin level and this was 
in fact improving before death. Latterly, 
however, the white cell count started to rise 
again.
Thus, of the two * intermediate' cases, 
one had a course which closely resembled chronic 
myeloid leukaemia and the other a course 
similar to chronic myeloid leukaemia in some 
ways and to myelofibrosis in others..
Discussion
Prom these results it would appear that 
myelofibrosis runs a course which produces
W.M.
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/less disturbance of the haemoglobin and white 
cell count than does chronic myeloid 
leukaemia. Furthermore, it takes longer to 
reach the terminal phase which usually is 
ushered in by a progressive fall in the 
haemoglobin. Treatment, other than simple 
remedies, is seldom required in the early 
stages and it is not uncommon to see cases 
such as J.G. and S.H. progress uneventfully 
for several years. Patient M.C. is, of 
course, remarkable and survived almost 
eleven years. In the terminal phase the 
haemoglobin fell steadily but it is noteworthy 
that this took place over a period of one and 
a half years. In patient J.C. the haemoglobin 
fell for about ten months before death 
occurred.
In chronic myeloid leukaemia the course 
is much more fluctuant with repeated alterations 
in the haemoglobin level and white cell count 
related to deterioration and therapy. As 
a result of this pattern it is obvious 
that the haemoglobin and white cell counts
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/are not reliable in determining when a 
terminal stage is reached. In the two patients 
who died the fall in haemoglobin took place 
over a short two month period in contrast 
to the longer periods seen in the cases of 
myelofibrosis.
Thus, myelofibrosis appears to be a much 
less disturbing disease more likely to run 
a longer course and less liable to require 
any major form of therapy than chronic 
myeloid leukaemia. When haematologieal 
deterioration occurs in myelofibrosis the 
disease is likely to be entering a terminal 
phase but this is not necessarily so in 
chronic myeloid leukaemia.
RADIOISOTOPE STUDIES
Radioisotope studies were repeated in 
four patients with myelofibrosis, one with 
chronic myeloid leukaemia and two with 
'intermediate* disease. The results are 
seen in table 43*
Chronic myeloid leukaemia
In the one patient on whom the studies
/were repeated there appears to be no obvious 
change in the pattern of production and 
destruction of red cells.
Myelofibrosis
Patient R.C. shows no significant change 
except for the rise of iron utilisation to 
the obviously fallacious figure of 132 per 
cent. The patient was much more anaemic at 
this time and the great increase in iron 
utilisation is probably partly related 
to marrow turnover and to iron deficiency.
In patient M.C. the iron utilisation had 
fallen to the very low figure of 16 per cent 
which indicates severely deficient erythropoiesis. 
There .was no significant change in haemolysis 
at this time and so the increased transfusion 
requirement is probably the result of hypoplasia. 
This pattern is seen also in patient J.C.
The only test to be repeated on patient J.G-. 
was the red cell survival and this showed 
an increased rate of haemolysis. This patient, 
however, was well and no treatment was required 
thus suggesting that erythropoiesis was able
/to keep pace with the increased rate of 
haemolysis.
'Intermediate' disease
Patient W.McA's transfusion requirements 
remained the same over one and a half years. 
His red cell production capacity, as judged 
by iron uptake and iron utilisation, 
appeared to have improved and there was less 
haemolysis. His death shortly after these 
studies were carried out was due to cerebral 
haemorrhage and was not caused by any change 
in his haematological state, as is so common 
in these patients.
Patient M.B. had the iron uptake only 
repeated and this showed loss of splenic 
erythropoiesis. This however must have played 
only a small part in the production of 
anaemia as her requirements for transfusion 
were so great that excessive haemolysis must 
have been present.
Comment
While one patient showed actual 
improvement in the haematological status
/and two showed no change there was evidence 
of deterioration in four patients. Of these 
four patients three had myelofibrosis and one 
had ’intermediate1 disease. There are obviously 
two main causes for the development of severe 
anaemia; firstly, the rate of haemolysis may 
increase and the limited red cell production 
be unable to compensate; secondly, erythropoiesis 
may decrease until there is insufficient 
erythropoietic tissue to maintain a steady 
haemoglobin at even a lower level. It appears 
that each of these may play a part in any 
patient and that either may be the dominant 
factor.
Summary
The progression of the disease was 
studied in nine patients with chronic myeloid 
leukaemia, myelofibrosis or intermediate 
disease.
Myelofibrosis appears to cause less 
disturbance of the haematological state than 
chronic myeloid leukaemia.
When severe haematological deterioration 
occurs in myelofibrosis it is likely to be 
terminal but in some patients years may pass 
before this occurs. In chronic myeloid 
leukaemia frequent treatment is usually 
required for haematological deterioration.
The development of anaemia may be due to 
hypoplasia or excessive haemolysis and either 
may be the dominant factor.
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S U M  M A R Y  0 ff
S E C T  I  0 1  V
The general aspects of treatment of 
myeloproliferative disease are reviewed 
briefly. Some patients require no therapy 
for long periods and others respond 
satisfactorily to simple measures. Only 
in polycythaemia vera, however, does treatment 
appear to affect the survival time.
Splenectomy is shown to be an effective 
form of therapy in some cases of 
myelofibrosis and the radioisotope studies 
are of help in determining the patients*
suitability for this procedure.
Irradiation of the spleen is found 
similarly to affect chronic myeloid leukaemia 
and myelofibrosis. The presence of splenic 
erythropoiesis is not necessarily a 
contraindication provided that the dosage is 
then adjusted suitably. The nature of the 
response to radiotherapy may provide a guide 
to the stage of progress of the disease.
The radioisotope studies have helped to 
define the mechanism of the anaemia in these 
disorders and thus to place treatment on
/a more logical basis.
The progression of myelofibrosis and of 
chronic myeloid leukaemia has been studied. 
Chronic myeloid leukaemia appears to run a 
more undulant course which is of shorter 
duration than that of myelofibrosis.. When 
haematological deterioration occurs in 
myelofibrosis this usually is an indication 
that the disease is approaching its 
terminal phase.
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S E C T I O N  VI
. T H E  P A T H O G E N E S I S  O F
Y E L 0 P E 0 L I F E 1 A T I V E
D I S E A S E
A CONCEPT
OP
MYELOPROLIFERATIVE DISEASE
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The myeloproliferative disorders are 
regarded by some workers as a group of diseases 
with a superficial resemblance but without 
any aetiological relationship; other workers, 
however, regard them as a group of closely 
related diseases.
The suggestion of relationship of some of 
these disorders was put forward by Vaughan 
and Harrison (1939) and has been supported 
by Heller et al (1947) and Rosenthal (1950). 
Dameshek (1951) publicised this view and 
extended the range of speculation to include 
the whole group of myeloproliferative disorders 
and has since been supported by Robson (1953) f
Hutt et al (1953) and Goldberg and Seaton (1959).
Other workers, however, oppose this view 
and regard the diseases as unrelated thus 
favouring the suggestion of Donhauser (1908) 
that a primary interference in the bone marrow 
leads to secondary and compensatory extramedullary 
erythropoiesis in the spleen and other organs. 
Wyatt and Sommers (1950) compared myelofibrosis 
and hepatic cirrhosis; they felt that there
270
/were many causes for these conditions and 
concluded that both disorders were 
morphological entities without aetiological 
unity. Wintrobe (1951) felt that there was
no sound basis for assuming myelosclerosis 
to be a variant of chronic leukaemia. More 
recently Leonard et al (1957) gave their 
opinion that the group of disorders were not 
simply facets of a single disease and felt 
that if 'transition* forms occurred at all 
commonly then the constant patterns which they 
found would not have been expected..
In the present study, clinical and 
haematological assessments have been made of 
each of the diseases constituting the 
myeloproliferative group and the mechanism 
of blood production and destruction has been 
studied by radioactive isotopes, further 
points have been investigated and the 
indications for, and effect of, treatment 
have been studied.
The onset and the signs and symptoms 
of chronic myeloid leukaemia and myelofibrosis
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/have been shown to be similar and while some 
points of resemblance are found on examination 
of the blood and bone marrow it is on 
histological grounds that the two disorders 
are conclusively differentiated. The mechanisms 
of blood production and destruction have 
been studied and the same patterns were found 
in each disease. These points are considered 
to favour a relationship between the two 
diseases and the occurrence of two 'intermediate' 
cases provides further evidence for this view. 
Polycythaemia vera, megakaryocytic 
thrombocythaemia and Di Guglielmo's disease 
have all been studied in the same way and
the results discussed. Again the evidence 
appears to favour a close aetiological 
relationship of the whole group of 
myeloproliferative disorders and the four 
'transition' cases provide strong support for 
this.
The treatment of myeloproliferative 
disease has been reviewed briefly and the 
main problems of the roles of splenic
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/irradiation and splenectomy in the treatment 
of myelofibrosis and other myeloproliferative 
states have been investigated. The use of 
radioactive iron and radioactive chromium 
in assessing the mechanisms and sites of 
blood production and destruction seems to 
place these forms of therapy on a more 
logical basis and it has been shown that 
with these methods satisfactory results may 
be obtained. Further, the effects of treatment 
have been observed and the results appear to 
strengthen the case for relationship between 
these diseases.
Thus the evidence gained by this study 
suggests that although each component 
disease is a separate morphological entity, 
the myeloproliferative group of disorders 
are closely related and the not uncommon 
occurrence of 'transition' forms appears to 
provide the final evidence for this 
aetiological relationship.
The primitive mesenchymal cell is 
considered to be multipotential and thus
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Fig. 123 A concept of myeloproliferative 
disease.
/is capable of differentiating into osteoblast 
fibroblast or any of the precursors of the 
cells of the blood (fig.122). Thus, if the 
myeloproliferative disorders are produced 
by an abnormality in development this may lead 
to involvement of any of the succeeding cell 
types or a combination of these (fig.123). 
Thus, chronic myeloid leukaemia, Di Guglielmo* 
disease and megakaryocytic thrombocythaemia 
may be circumscribed types of abnormality 
occurring at a late stage in development 
and consequently affecting one major cell 
type only. Polycythaemia vera may be caused 
by abnormality at a rather earlier stage 
of differentiation and thus may involve all 
three cellular components of the blood. 
Myelofibrosis and myelosclerosis could be 
the results of developmental abnormality at 
a very early phase of differentiation and 
could involve all the succeeding phases 
resulting in osteosclerosis, fibrosis and 
leucopoietic,erythropoietic or megakaryocytic 
proliferation in the bone marrow. Transition
/forms are then easily explained by a 
variation in the predominant cell type 
involved or by the progression of abnormality 
to an earlier phase of differentiation thus 
involving other cell types.
The results of the work composing this 
thesis substantiate this concept that the 
myeloproliferative disorders are variable 
expressions of abnormal development of the 
primitive mesenchymal cell.
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A P P E N D  I X
CASE SUMMARIES
The case summaries are presented in 
order to provide an overall picture of 
each case without the detail as described in 
various chapters.
Chronic myeloid leukaemia
Patient E.W., a female, aged 69 years, 
was first seen in June 1957 because of 
intermittent symptoms of anaemia during the 
previous few years. She also complained of 
abdominal discomfort and loss of weights 
The main findings on examination were of pallor, 
hepatomegaly, splenomegaly and a few palpable 
nodes in the axillae. The diagnosis of chronic 
myeloid leukaemia was made on investigation 
of the blood and marrow..
Blood transfusion was required on several 
occasions and she was then treated with splenic 
irradiation. She had a good response to this 
and remained well for a little over a year 
before she required further blood transfusion 
and radiotherapy. The response was less 
satisfactory than on the first occasion and within
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/a few months busulphan had to be given.
Despite this, however, deterioration continued 
and she developed bronchopneumonia and then 
congestive cardiac failure. Further treatment 
was of no avail and she died in September 1959.
Patient J.L., a male, aged 33 years, 
attended hospital first in April 1958 because 
of tiredness, dyspnoea, sweating and marked 
weight loss despite a good appetite. His first 
attendance was at an Endocrine Glinic to which 
he was referred because of the above history, 
but the suspected diagnosis was not confirmed. 
Abdominal examination revealed hepatomegaly and 
splenomegaly and a few nodes were found in the 
axillae. The diagnosis of chronic myeloid 
leukaemia was made on blood and bone marrow 
examination. He was very anaemic but responded 
well to splenic irradiation and blood transfusion.. 
His one complication was of priapism which was 
treated with anticoagulant drugs.
Following irradiation his spleen shrank 
to the costal margin, the blood picture returned 
to normal and the patientfs general condition
/was greatly improved. This satisfactory 
state of affairs continued for almost two 
years though latterly the white cell count 
was beginning to rise again. He has as yet 
required no further treatment and remains 
symptom free.
Patient C.L., a female, aged 47 years, 
first attended the urological unit of the 
Western Infirmary in June 1957 because of 
increased frequency of micturition and 
dysuria. The cause of this was a urethral 
caruncle but the patient also complained of 
weight loss of four stone in four months.
Abdominal examination revealed splenomegaly 
and marked bruising was noted on the legs.
The diagnosis of chronic myeloid leukaemia 
was made on blood and bone marrow examination.
The patient was treated by splenic irradiation 
with considerable benefit. The improvement 
however, lasted only for a few months and 
she required treatment on two more occasions 
before she died in July 1959*
Patient A.R., a female, aged 59 years, 
first attended hospital in January 1956 because 
of abdominal pain, dyspnoea on exertion and 
spontaneous bruising. Examination revealed 
multiple ecchymoses and gross splenomegaly was 
present.
She. was treated by splenic irradiation with 
marked symptomatic improvement but there was no 
alteration in the level of the white cell count 
until the completion of the course and the spleen 
did not change in size.
She remained relatively well for a further 
one and a half years before being readmitted 
with the same symptoms as before. Bo abnormality 
was found on investigation of the clotting 
mechanism but following iliac crest trephine 
biopsy there was considerable haemorrhage.
A few days later in October 1957, she died 
following a cerebral vascular accident.
Patient M.M., a female, aged 51 years, 
had had symptoms of abdominal discomfort and 
dyspnoea on exertion for only a few weeks when 
she first attended in February 1959.
Examination revealed hepatomegaly, splenomegaly,
/widespread large palpable nodes and a right 
sided pleural effusion. The diagnosis of chronic 
myeloid leukaemia was made on blood and bone 
marrow examination. X-ray of chest showed a 
right sided pleural effusion and marked 
leukaemic infiltration of the pulmonary 
parenchyma. The patient developed 
bronchopneumonia but despite antibiotic 
therapy she died.
Myelofibrosis
Patient J.C., a female, aged 42 years, 
presented first in March 1956 with swelling 
of the abdomen of one year’s duration. She 
also complained of weight loss and spontaneous 
bruising. Examination revealed gross 
splenomegaly and the diagnosis of myelofibrosis 
was established by iliac crest trephine biopsy.
She was treated by splenic irradiation and 
had a satisfactory response which lasted, 
however, for a few months only before a further 
course was required* A few months later she 
developed gout in her right foot.
Thereafter followed gradual deterioration
/and another course of splenic irradiation in 
1958 had little effect except to lower the 
white cell count.
In 1959 she developed congestive cardiac 
failure and died in September of that year.
Patient T.Q.t a female, aged 56 years, 
was first seen in December 1958. Her complaint 
were of the symptoms of anaemia, nose bleeds 
and right sided abdominal discomfort. 
Examination revealed congestive cardiac failure 
pallor, hepatomegaly and gross splenomegaly.
She was very anaemic due to an increased rate 
of haemolysis and required frequent blood 
transfusion. Radioisotope studies demonstrated 
that the spleen was the site of sequestration 
and destruction of red cells; although there 
was some splenic erythropoiesis there was also 
some continuing marrow activity*
On these grounds splenectomy was performed 
after the cardiac failure was cleared; there 
was a very satisfactory result. The patient 
has remained well since, has required no 
further therapy and is still at work.
Patient M.C., a female aged 62 years, 
first presented at hospital in June 194-9 
because of abdominal swelling which proved to 
be due to gross splenomegaly. She was 
investigated and found to have a mild macrocytic 
anaemia which was treated with thyroid extract.
She became more anaemic in the next few months 
and was then changed to 1Anahaemin1 to which 
she had a 12 per cent reticulocyte response.
She remained fairly well for the next three 
years and although marrow puncture was
attempted on several occasions the result 
was always a * dry tap *.
In 1952 a bone marrow trephine biopsy 
was carried out and the diagnosis established 
as myelofibrosis. She was not seen again until 
1956 when she attended because of tiredness.
Again there was very mild anaemia and the 
'Anahaemin1 was stopped and ’Cytamen1 substituted. 
She became more anaemic over the next few months 
and this was found to be due to iron deficiency 
which responded well to parenteral iron therapy.
In 1959 she again became anaemic and
/developed a urinary tract infection and 
septicaemia. With antibiotic therapy she 
recovered but the anaemia was found to be 
due to splenic sequestration of red cells 
and increased haemolysis. Splenectomy was 
therefore carried out but the patient 
unfortunately died in a sudden post operative 
collapse after a technically satisfactory 
operation.
Patient S.H., a female, aged 64 years, 
presented first in March 1957 with 
intermittent claudication due to true 
peripheral vascular disease. She was found 
to have splenomegaly and the diagnosis of 
myelofibrosis was established by iliac crest 
trephine. This diagnosis, however, was 
incidental as she has required no treatment 
for myelofibrosis, though her vascular 
condition has necessitated her being in hospital
for most of the past four years. It is o;f 
interest that she did not trouble about the 
symptdms of mild anaemia and weight loss which 
had been present for around three years and
/that her first attendance was only because 
her intermittent claudication severely 
limited her activity. This underlines the 
insidious onset of myelofibrosis.
Patient A.S., a female, aged 49 years, 
first attended in May 1959 because of weight 
loss and abdominal discomfort of about six 
months duration. A few small lymph nodes 
were palpable in the right axilla and 
there was hepatomegaly and marked splenomegaly. 
The diagnosis of myelofibrosis was 
established by iliac crest trephine.
The only treatment required was for 
iron deficiency anaemia and this produced a 
satisfactory response. The patient has 
remained well since.
Patient J.G., a male, aged 62 years, 
was first seen in May 1957 when he complained 
of the symptoms of mild anaemia for the 
previous few weeks. Examination revealed 
hepatomegaly and marked splenomegaly.
The diagnosis of myelofibrosis was 
established by iliac crest trephine.
/ The patient required no specific therapy 
and remained well for a further three years.
Oral iron therapy was then administered hut 
in view of his satisfactory general state no 
major therapy was undertaken although 
radiochromium studies indicated that the 
spleen was sequestering and destroying red cells.
Patient B.C., a female, aged 58 years, 
was seen first in April 1959 because of weight 
loss and angina of effort of three years 
duration. Examination revealed hypertension, 
anaemia and gross splenomegaly.. Investigations 
showed that no treatment was necessary other 
than for iron deficiency. Following this 
treatment she remained well for a further 
fifteen months when she required a blood 
transfusion and further iron therapy. She 
has remained well since.
Patient l.G-.B., a female, aged 63 years, 
first complained of right sided abdominal
discomfort and weight loss of 1 year*s 
duration in June 1959. She then was pale, 
had an easily palpable liver and spleen
/and was in cardiac failure secondary to
myocardial infarction. Megaloblasts
were found in the peripheral blood but
there was no real response to vitamin B-, ^12
except a) to correct the serum level 
and b) to eliminate megaloblasts from the 
blood. The diagnosis of myelofibrosis was 
established by iliac crest trephine.
She required blood transfusion and 
despite leucopenia was treated with splenic
irradiation. There was a satisfactory response 
to this treatment and she remained well for 
a further six months before succumbipg to her 
second myocardial infarction. This patient 
had radiological defects in the skull possibly 
secondary to myelofibrosis but unfortunately 
no autopsy was obtained.
Patient W.P., a male, aged 56 years, 
had a three week history of left sided upper 
abdominal pain when he first attended in 
January I960. Examination revealed a few 
small nodes in the axillae and groins. The 
liver and spleen were both markedly enlarged.
/The diagnosis of myelofibrosis was established 
by iliac crest trephine.
This patient was found to have a haemolytic 
anaemia with splenic sequestration; the 
marrow and spleen both showed erythropoietic 
activity and so the haemolysis was treated 
by steroid therapy. With this treatment he 
improved greatly and has remained well since.
* Intermediate1 disease
Patient W.M., a male, aged 57 years, 
was first seen in January 1957 because of 
enlargement of the abdomen and symptoms of 
anaemia. He had mild cardiac failure, was 
pale and anaemic and had greatly enlarged 
liver and spleen. Investigation revealed 
some features of chronic myeloid leukaemia 
and some of myelofibrosis and he was 
classified as ’intermediate*.
He was treated with splenic irradiation 
and had a satisfactory response. About six 
months later however his symptoms recurred 
but blood transfusion was sufficient on this
A
occasion to provide improvement. Thereafter
/he remained relatively well for about a year 
when further transfusion was required. He 
died at home a few months later as a result 
of a cerebrovascular accident.
Patient M .B., a female, aged 34 years, 
presented first in March 1956 with abdominal 
swelling and the symptoms of anaemia during 
the previous few months. She was found to 
have hepatomegaly and marked splenomegaly.
Investigation revealed some features of 
chronic myeloid leukaemia and some of 
myelofibrosis. She was, therefore, classified 
as ’intermediate* disease.
Treatment with splenic irradiation was 
required on five occasions during the next 
two and a half years. Eventually she 
developed severe haemolysis which necessitated 
frequent blood transfusion. Splenectomy 
was carried out with an apparently successful 
result in that the blood picture improved 
remarkably and blood transfusion requirements 
were greatly reduced. Wound infection and 
abscess formation occurred, probably partly
/due to hypogammaglobulinaemia, and the 
patient died about two months after operation. 
Polycythaemia Vera
Patient A.McA.., a male, aged 70 years, 
first attended for examination in April 1958.
He had a 15 year history of dyspepsia due to 
proved duodenal ulcer and had had melaena and 
haematemesis on two previous occasions. 
Furthermore he had a history of jaundice in 1914. 
He was admitted to the wards because of recent 
melaena and symptoms of anaemia. Liver and 
spleen were both palpable as had been noted 
on the occasion of his last melaena in 1954.
He also had gouty arthritis of his hands.
He was found to be rather anaemic but 
with elevated platelet and white cell counts.
Investigation confirmed the presence of 
a duodenal ulcer, there was no upset of liver 
function and the diagnosis of polycythaemia 
vera was established on later examination 
of the bone marrow.
Treatment with radiophosphorus was 
delayed until his bleeding had settled and his
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/blood values had risen to above normal. He 
had a good response to this therapy and has 
remained well since.
Patient M.S., a female, aged 56 years, 
first attended hospital in 1951 when she was
found to have a mild hydronephrosis. At that 
time plethora was noted. In 1953 she again 
attended because of abdominal pain. She was 
then found to have a dusky red complexion, 
splenomegaly was noted and the haemoglobin 
was recorded as 140 per cent. Treatment was 
by radiotherapy and thereafter repeated 
venesections until July 1958. She defaulted 
for a year and was then found to be in a 
mental hospital. By this time she was again 
polycythaemic and the diagnosis was confirmed 
by marrow histology and was treated by 
venesection and then radiophosphorus with a 
satisfactory response. She has remained well 
since and has also improved mentally.
Patient F.N., a female, aged 55 years, 
was first seen in August 1959 because of
/chest pain, breathlessness, cough and spit. 
She was seen to be plethoric but cyanotic and
was found t© have hypertension but no 
splenomegaly. The diagnosis of polycythaemia 
vera was confirmed on blood and marrow 
examination.
She was treated with radiophosphorus 
and improved haematologieally and 
symptomatically for three months.. Thereafter 
although she remained symptom free her 
polycythaemia returned.
Patient J.G., a male, aged 61 years, 
was diagnosed as having polycythaemia vera 
in 1936 and was treated by phenylhydrazine 
and blood-letting. In 1958 he developed 
severe gouty arthritis of the hands and 
feet. His haemoglobin thereafter remained 
around normal but the white cell count was 
constantly elevated to about 40,000 per 
e.mnu Marrow examination was typical of 
polycythaemia vera.
In 1959 his haemoglobin rose again to 
high levels and he was then treated with
/radiophosphorus with s©me haematological 
improvement.
Patient J.O., a male, aged 50 years, 
first attended an Orthopaedic department 
because of bone pain. He was noted to be 
plethoric and had a palpable spleen. Blood 
and marrow examination confirmed the 
diagnosis of polycythaemia vera.
Treatment was with radiophosphorus and 
he responded satisfactorily.
Pi G-uglielmofs disease
Patient G-.McF., a male, aged 77 years, 
was admitted for investigation of a 
normochromic anaemia in September, 1958.
His complaints were of the symptoms of anaemia 
of about four months duration. There were 
no physical findings of significance.
Further examination of the blood revealed 
the presence of occasional nucleated red cells 
and marrow examination showed irregular areas 
of hyperplasia. Erythropoiesis was 
predominantly megaloblastic and many 
multinucleated well haemoglobinised red cells
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/were seen. The diagnosis of hi G-uglielmo’s
disease was thus made..
Vitamin B^2 and folic acid studies
revealed nothing to account for
megaloblastic erythropoiesis and the 
administration of these substances produced 
no benefit. Further treatment with blood 
transfusion and Prednisolone was of no avail 
and the patient*s condition steadily deteriorated 
until he died in November 195b.
Me gakaryo cytic thrombocythaemia
Patient J.D., a female, aged 67 years, 
was admitted first to another hospital in 
August 1957 because of spontaneous bruising. 
Physical examination revealed also 
hepatomegaly and splenomegaly. She was found 
to have elevated white cell and platelet 
counts and investigation of the clotting system 
gave evidence of haemorrhagic megakaryocytic 
thrombocythaemia.
During the next two years despite several 
haematemeses and episodes of melaena, she 
gradually became polycythaemic. The 
treatment of choice appeared to be
294
/radiophosphorus; this was given and the 
response was very satisfactory. The pEfcient 
has remained well since and has had no further 
haemorrhagic episodes. 
transition1 myeloproliferative disease
Patient J.N., a male, aged 54 years, was 
first seen in November 1959 when he 
complained of joint pains. He was found to 
have splenomegaly and a few palpable axillary 
nodes.
Investigations of the blood and marrow 
suggested a diagnosis of polycythaemia vera 
but further study using radioisotopes suggested 
that the patient was in fact in a state of 
transition from polycythaemia vera to 
myelofibrosis.
No treatment was required for his 
haematological state and he has since 
remained well.
Patient J.McG-.« a male, aged 74 years, 
first attended hospital in March 1959 because 
of the symptoms of anaemia and a bleeding 
tendency. Physical examination revealed
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/marked pallor and hepatomegaly but no 
splenomegaly.
White cell count was usually within normal 
limits but platelet counts were persistently 
over half a million per c.mm. Marrow 
examination revealed marked megakaryocytic 
proliferation and gross myeloid hyperplasia.
Further investigation suggested that 
the disease was in a state of transition between 
megakaryocytic thrombocythaemia and chronic 
myeloid leukaemia.
The patient was treated with repeated 
blood transfusion and was given radiophosphorus 
on two occasions. While there was considerable 
haematological response the patients' general 
condition deteriorated steadily over the next 
few months and he died in October 1959.
Patient J.McI)., a female, aged 64 years, 
first attended another hospital in 1956 
because of weakness and lassitude. She was 
found to have hepatomegaly and splenomegaly 
and blood examination revealed no diagnostic 
features. Marrow histology, however, showed
/30 - 50 per cent of the cells to be 
myeloblasts. In 1959 she was very anaemic 
and had hepatomegaly. There was also an 
abdominal mass which appeared to come from 
the pelvis and the spleen was palpable just 
below the costal margin i.e. much less large 
than in 1956.
Investigation showed that the abdominal 
mass was in fact an ectopic spleen. In view 
of the evidence of hypersplenism at that 
time splenectomy was performed. Following 
operation the white cell count rose to 
leukaemic levels and had to be controlled 
with 'Busulphan*. Otherwise the patient was 
much improved and has since required no 
further therapy.
The investigations suggest that this 
case was in a state of transition probably 
from polycythaemia vera to myeloid leukaemia.
Patient A.McG., a female, aged 74 years, 
first presented in 1946 with swelling of the 
legs, thrombophlebitis and bleeding after 
dental extraction. Ko definite diagnosis
2 91
/was made. In 1950 she was found to have 
polycythaemia vera with splenomegaly and was 
treated by repeated venesection. In 1956 
she developed gouty arthritis and by 1959 
was anaemic and had thromboeythaemia. The 
marrow appearances were those of polycythaemia 
vera with exaggerated proliferation of the 
megakaryocytes.
Further investigation suggested that 
the patient was in a state of transition 
between spent polycythaemia vera and 
megakaryocytic thromboeythaemia.
Her gout was controlled by probenecid 
and the only other treatment required was the 
administration of iron. With this treatment 
she has remained well.
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